

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094671 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/US2004/012788

(22) International Filing Date: 22 April 2004 (22.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/464,586 22 April 2003 (22.04.2003) US  
60/464,588 22 April 2003 (22.04.2003) US

(71) Applicants (*for all designated States except US*): COLEY PHARMACEUTICAL GmbH [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). COLEY PHARMACEUTICAL GROUP, INC. [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): VOLLMER, Jörg [DE/DE]; Kohlrauschweg 24, D-40591 Duesseldorf (DE).

JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerknauhof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).


(74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

*[Continued on next page]*

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



WO 2004/094671 A2

(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

- 1 -

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT  
OF TLR LIGANDS**

**Background of the Invention**

5 Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and  
10 humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15 The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high  
20 throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

**Summary of the Invention**

The invention provides in its broadest sense screening methods and tools for  
25 identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

In one aspect, the invention provides a screening method for identifying TLR agonists.  
30 The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

- 2 -

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.

In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive

- 3 -

reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which 5 is known to signal through TLR7 and TLR8. Accordingly, the screening method can be performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does 10 not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, 15 carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a 20 RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. 25 In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- $\alpha$  secretion 30 and TNF- $\alpha$  secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

- 4 -

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and 5 subunits of NF- $\kappa$ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other 10 embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that 15 uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but 20 not limited to  $^3$ H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- $\alpha$ . Preferably, in this latter embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji 25 cell and the TLR signaling is indicated by IL-6 or IFN- $\alpha$ 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the 30 cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a

- 5 -

polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- $\alpha$ , etc.), and other detectable protein sequences known to those of skill in the art. Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- $\kappa$ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- $\alpha$ 1 gene, an IFN- $\alpha$ 4 gene, an IFN- $\beta$  gene, an IFN- $\gamma$  gene, a TNF- $\alpha$  gene, a TNF- $\beta$  gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

- 6 -

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell 5 surface marker, and a unique distinguishable coding sequence conjugated thereto. In these embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not 10 endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

15 In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine, 20 porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

In still another aspect, the invention provides kits including the cells lines (e.g., the 25 RPMI 8226 cell line), the reporter constructs and/or expression constructs described above, and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and, 30 importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

- 7 -

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

- 8 -

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw  
5 materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the  
10 test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

15 In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

20 In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another  
25 embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the  
30 reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

- 9 -

factors (e.g., NF- $\kappa$ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- $\kappa$ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter  
5 construct under the control of an interferon-stimulated response element (ISRE); an IFN- $\alpha$  promoter; an IFN- $\beta$  promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In  
10 another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

15 In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

20 In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a  
25 pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

30 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

15 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT TTT-3' (SEQ ID NO:143).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

20 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

25 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC\_G TTT TAC\_GGC GCC\_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

- 11 -

Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure  
5 to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

10 Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

15 Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The EC<sub>50</sub> for CpG nucleic acid is 19 nM and the EC<sub>50</sub> for non-CpG nucleic acid is 263 nM.

20 Fig. 7 is a bar graph showing NF-κB activation in RPMI 8226 transfected transiently with a NF-κB-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF-α. NF-κB activation is measured by luciferase activity.

25 Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

30 Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

- 12 -

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- $\alpha$ 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

Fig. 18A is a bar graph showing the induction of NF- $\kappa$ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 19 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 21 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

It is to be understood that the Figures are not required for enablement of the invention.

#### Brief Description of Sequences

- 13 -

SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP\_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM\_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP\_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM\_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM\_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM\_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM\_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP\_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP\_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP\_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP\_612567).

SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM\_021297).

30 SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- 14 -

- SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).  
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).  
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).  
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).  
5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).  
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).  
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).  
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).  
10 SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM\_016562).  
SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).  
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).  
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP\_057646).  
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).  
15 SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).  
SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant  
(NM\_133211).  
SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).  
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).  
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).  
20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).  
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP\_573474).  
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).  
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).  
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).  
25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM\_138636).  
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM\_016610).  
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).  
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).  
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).  
30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP\_619542).  
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP\_057694).  
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).  
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM\_133212).

- 15 -

SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).  
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP\_573475).  
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).  
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).  
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).  
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).  
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).  
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).  
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).  
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).  
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).  
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).  
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).  
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).  
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM\_031178).  
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).  
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).  
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).  
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP\_112455).  
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).  
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).  
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).  
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM\_006068).  
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).  
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP\_006059).  
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).  
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).  
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM\_011604).  
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).  
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).  
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).  
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP\_035734).  
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

- 16 -

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p65 subunit.

5 SEQ ID NO:92 is the nucleotide sequence of an example of an NF- $\kappa$ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10 SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15 SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20 SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25 SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30 SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

- 17 -

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- $\alpha$  response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- $\beta$ .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- $\alpha$ .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- $\beta$ .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

- 18 -

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5 SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

10 SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.

15 SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

20 SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

, SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25 SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.

SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.

SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.

SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.

SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.

30 SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.

SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.

SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.

- 19 -

SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

#### Detailed Description of the Invention

5       In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

Thus, the invention is based in part on the discovery that cell lines expressing  
10 endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based  
15 on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand  
20 indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The  
25 invention allows for the tailoring of TLR ligands for particular patients or disorders.

The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example; the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines  
30 RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered  
5 that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution  
10 and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product  
15 materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

20 Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

25 The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as  
30 immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR

- 21 -

agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary cell such as a PBMC.

10 Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

5'-TCGTCGTTTGTCTGTTTGTCTGTT-3'	(SEQ ID NO:1)
5'-TCGTCGTTTGACGTTTGTCTGTT-3'	(SEQ ID NO:139)
15 5'-TCGTCGTTTGTCTGTTTGTCTGTT-3'	(SEQ ID NO:140)
5'-TCGTCGTTTCGTCGTTCGTCGTT-3'	(SEQ ID NO:141)
5'-TCGTCGTTTCGTCGTTTGTCTGTT-3'	(SEQ ID NO:142)
5'-TCGTCGTTTCGGTCGTTT-3'	(SEQ ID NO:143)
5'-TCGTCGTTTCGTGCGTTT-3'	(SEQ ID NO:144)
20 5'-TCGTCGTTTCGGCGGCCGCG-3'	(SEQ ID NO:145)
5'-TCGTC_GTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

25 Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- $\alpha$  and IFN- $\beta$ ), TNF- $\alpha$  and some interleukins (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some 30 species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

- 22 -

An “immunoinhibitory compound” as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a 5 cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 10 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and 15 chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these 20 cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular 25 response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell 30 surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the EC<sub>50</sub> value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5        Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the  
10      immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the  
15      readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immunoinhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or  
20      immunoinhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test  
25      assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compounds is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory  
30      response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

- 24 -

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

- 5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound
- 10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound
- 15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference

20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

- 25 The breadth of response by the cell line to immunomodulatory compounds, and its facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell
- 30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

- 25 -

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate  
5 cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two  
10 contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the  
15 comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-  
20 test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be  
25 assayed under defined conditions in a number of independent measurements and found to yield a result expressed as  $100 \pm 5$  units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance  
30 observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable

- 26 -

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such comparison is useful for quality control assessment of the test lot of material, also referred to herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity. Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity. In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.

- 27 -

In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at 5 which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by  $EC50 \pm 1$  log concentration, e.g.,  $1 \times 10^{-7}$  M –  $1 \times 10^{-5}$  M, where EC50 is  $1 \times 10^{-6}$  M. In another embodiment the standard curve spans a broader range of concentrations defined by  $EC50 \pm 2$  log concentration, e.g.,  $1 \times 10^{-8}$  M –  $1 \times 10^{-4}$  M, where EC50 is  $1 \times 10^{-6}$  M. In yet another embodiment the standard curve spans a narrower 10 range of concentrations defined by  $EC50 \pm 0.5$  log concentration, e.g.,  $3.16 \times 10^{-7}$  M –  $3.16 \times 10^{-6}$  M, where EC50 is  $1 \times 10^{-6}$  M. The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference 15 composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done 20 by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include  $EC50 \pm 3$  log concentration or  $EC50 \pm 4$  log concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

25 The methods of the invention can be adapted to be automated or at least partially automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery 30 devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and 5 analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

#### Cell lines

The screening methods may use experimental cells. As used herein, an experimental 10 cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell 15 may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable 20 cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or 25 TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- $\alpha$ 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL- 30 8, IL-10, IP-10 and TNF- $\alpha$ . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.

- 29 -

The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5 The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell 10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1 15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20 A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express 25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

30 A cell that artificially expresses an expression or reporter construct is preferably stably transfected.

RPMI

- 30 -

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and

5 production of IL-12p40 mRNA. (Takeshita et al. (2000), Eur. J. Immunol. 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has

10 also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other

15 aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- $\alpha$ .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that

20 RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

25

#### Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6;

30 Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

- 31 -

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A. et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol* 10 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et a. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

15 Reference and Test Compounds

A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as 20 amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

25 Some specific examples of small molecules include the imidazoquinolines. As used herein, an imidazoquinolines include imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640; 30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-c]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-c]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5       The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

A reference compound, as used herein, is a compound having a known activity in the  
10 presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater  
15 extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and  
20 the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may  
25 be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhancer may be due to its ability to stimulate TLR signaling independently of the positive reference compound.

30       A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

- 33 -

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall 5 refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

10 In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass 15 or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR 20 ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration 25 can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one- 30 and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

- 34 -

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG 5 oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of 10 contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a 15 composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist 20 compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

Unlike a reference composition, a test composition is not characterized at all, or is 25 only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition 30 previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of

a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

Immunostimulatory and Immunoinhibitory Nucleic Acids

5        Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types  
10      A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as  
15      described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units  
20      will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,  
25      individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other  
30      covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

- 36 -

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);  
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed  
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTGTGCGTTTGTGCGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTGACGTTTGTGCGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTGTGCGTTTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTCGTCGTTCGTCGTT-3' (SEQ ID NO:141).

25 In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTCGTCGTTTGTGCGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTTCGGTCGTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by  
5'-TCGTC\_GTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146).

The oligonucleotides described by SEQ ID NOS: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- $\alpha$ . Type B nucleic acids are described in U.S. Patents  
10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- $\alpha$  but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,  
15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- $\alpha$ . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are  
20 hereby incorporated by reference herein.

- In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other  
25 immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.  
30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTGTZGTTTGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

- 38 -

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZGZTTZTTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

5 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZGTTGZTZTZTGTGZG-3' (SEQ ID NO:149), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a 15 nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

20 Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In Applied Antisense Oligonucleotide Technology, Krieg and Stein, eds., pp. 335-352; Kimura Y et al. 25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat. 30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immunoinhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

- 39 -

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- $\kappa$ B DNA binding but prevented CpG-induced NF- $\kappa$ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I $\kappa$ B $\alpha$ , and I $\kappa$ B $\beta$  degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACAGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCGGGGAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX<sub>n</sub>GCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

- 40 -

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8  
5 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine  
10 (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably  
15 synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other  
20 than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid  
25 backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a  $\beta$ -D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known  
30 to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

- 41 -

Methods 7:331-417. An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is 5 composed of natural DNA or RNA.

- For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:
- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
  - 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
  - c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
  - d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
  - 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to 20 degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endo-nuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

25 A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate, NR<sup>1</sup>R<sup>2</sup>-phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-(C<sub>1</sub>-C<sub>21</sub>)-O-alkyl ester, phosphate-[(C<sub>6</sub>-C<sub>12</sub>)aryl-(C<sub>1</sub>-C<sub>21</sub>)-O-alkyl]ester, (C<sub>1</sub>-C<sub>8</sub>)alkylphosphonate and/or (C<sub>6</sub>-C<sub>12</sub>)arylphosphonate bridges, (C<sub>7</sub>-C<sub>12</sub>)- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in 30 WO 95/01363), wherein (C<sub>6</sub>-C<sub>12</sub>)aryl, (C<sub>6</sub>-C<sub>20</sub>)aryl and (C<sub>6</sub>-C<sub>14</sub>)aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where R<sup>1</sup> and R<sup>2</sup> are, independently of each other, hydrogen, (C<sub>1</sub>-C<sub>18</sub>)-alkyl, (C<sub>6</sub>-C<sub>20</sub>)-aryl, (C<sub>6</sub>-C<sub>14</sub>)-aryl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably hydrogen,

- 42 -

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl and/or methoxyethyl, or R<sup>1</sup> and R<sup>2</sup> form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazone, 10 dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a β-D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer 15 (as described, for example, in Stinchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such 20 as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A β-ribose unit or a β-D-2'-deoxyribose unit can be replaced by a modified sugar unit, 25 wherein the modified sugar unit is for example selected from β-D-ribose, α-D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose, β-D-xylo-furanose, α-arabinofuranose, 30 2,4-dideoxy-β-D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

- 43 -

In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence N<sub>1</sub> YZ N<sub>2</sub>, wherein N<sub>1</sub> and N<sub>2</sub> are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a) N<sub>1</sub> and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide, (b) Z and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide, or (c) N<sub>1</sub> and Y are linked by a phosphodiester or

phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide and Z and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively 5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids of the invention are cleavable to fragments with reduced or no immunostimulatory activity relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide 10 an "off switch" which alters the pharmacokinetics of the nucleic acid so as to reduce the duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular value in tissues and in clinical applications in which it is desirable to avoid injury related to chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially 15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft nucleic acids generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower 20 effective concentrations and have lower effective doses than conventional fully stabilized immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase with increasing "dose" of phosphodiester or phosphodiester-like internucleotide linkages involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a 25 given nucleic acid sequence with five internal YZ dinucleotides, an nucleic acid with five internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more immunostimulatory than an nucleic acid with four internal phosphodiester or phosphodiester-like YG internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages, 30 which in turn is more immunostimulatory than an nucleic acid with two internal phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with one internal phosphodiester or phosphodiester-like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or

- 45 -

phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5 The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the  
10 inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at  
15 the 3' end.

A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage  
20 is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNase H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are  
25 susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNase H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the  
30 phosphodiester-like internucleotide linkage is diasteromerically pure Rp phosphorothioate. It is believed that diasteromerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNase H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

- 46 -

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

- 5 As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an Rp conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the R<sub>p</sub>, but not  
10 the S<sub>p</sub> stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the S<sub>p</sub> but not the R<sub>p</sub> stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the R<sub>p</sub> and S<sub>p</sub> stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.  
15 First, the enhanced activity of the Rp stereoisomer compared to the Sp for stimulating immune cells at early time points indicates that the Rp may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the Rp PS-nucleic acids compared to the Sp results in a much shorter duration of signaling, so that the Sp PS-nucleic acids appear to be more biologically  
20 active when tested at later time points.

A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in Rp was slightly more active, while the congener containing an Sp linkage was nearly inactive for inducing spleen cell proliferation.

- 25 Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

- 30 A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

- 47 -

- 4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N<sup>2</sup>-dimethylguanine,
- 5 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N4-alkylcytosine, e.g., N4-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N4-alkyldeoxycytidine, e.g., N4-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and
- 10 diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases.
- This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N4-substituted cytosines (e.g., N4-ethyl-cytosine), 5-aza-cytosine, 2-mercaptop-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C<sub>2</sub>-C<sub>6</sub>)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N2-substituted guanines (e.g., N2-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N6-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the  $\beta$ -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

#### TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

- 49 -

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive  
5 reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the  
10 functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

15 To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten currently known human TLRs are available from public databases such as GenBank. Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.  
20

25 Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677 (SEQ ID NO: 57), respectively.  
30

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

- 50 -

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as  
5 GenBank accession numbers NM\_003265 (coding region spanning nucleotides 102-2816)  
(SEQ ID NO: 7) and NP\_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid  
sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers  
AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117  
(SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as  
GenBank accession numbers NM\_003263 and NP\_003254, respectively. Nucleic acid and  
amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession  
numbers NM\_030682 and NP\_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a  
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally  
occurring TLR). An example is a chimeric TLR having an extracellular domain and the  
cytoplasmic domain derived from TLRs from different species. Such chimeric TLR  
polypeptides can include, for example, a human TLR extracellular domain and a murine TLR  
cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can  
20 include chimerae created with different TLR splice variants or allotypes.

#### TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity.  
TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.  
25 TLR signaling can be measured in a number of ways including but not limited to interaction  
between a TLR and a protein or factor (such as an adaptor protein), interaction between  
downstream proteins or factors (such as an adaptor protein) with each other, activation of  
nuclear factors such as transcription factors or transcription complexes, up- or down-  
regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the  
30 signaling cascade, expression, production and/or secretion of cytokines and/or chemokines,  
changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the  
like. Those of ordinary skill in the art are familiar with assays for measuring these latter

- 51 -

events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the 5 signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by another interaction between the adapter protein and a 10 kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- $\kappa$ B. The first kinase is a mitogen-activated 15 kinase kinase kinase (MAPKKK) known as NIK, for NF- $\kappa$ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase  $\alpha$  (IKK  $\alpha$ ) and I kappa B kinase  $\beta$  (IKK  $\beta$ ), that together form a heterodimer of IKK $\alpha$ :IKK $\beta$ , which phosphorylates I kappa B. NF- $\kappa$ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 20 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter 25 construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

30 Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

- 52 -

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- $\kappa$ B promoter. The gene under the control of the NF- $\kappa$ B promoter can be a gene which naturally includes an NF- $\kappa$ B promoter or it can be a gene in a construct in which an NF- $\kappa$ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- $\kappa$ B promoter include but are not limited to IL-8, IL-12 p40, NF- $\kappa$ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- $\gamma$ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.

- 53 -

TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

TLR signaling activity can be measured by changes in gene expression. The  
5 expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- $\alpha$ , TNF- $\alpha$ , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

#### Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR 20 signaling activity. These reporter constructs are intended to substitute for the "native" readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is 25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to 30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

- 54 -

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited  
5 by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se,  
10 decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and  
15 it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an  
20 IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- $\kappa$ B Binding site:

Consensus p50 subunit  
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit  
5' GGRNNTTCC 3' (SEQ ID NO:91)

Example of p65 subunit binding site  
5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

35 CREB Binding site:  
5' AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

**AP-1 Binding site:**

5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)  
 5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

5 ISRE :

5'- TGCAGAAGTGAAACTGAGG-3' (SEQ ID NO:96)  
 5'- AGAACGAAACA-3' (SEQ ID NO:97)  
 5'- GAGAAGTGAAAGTGG-3' (SEQ ID NO:98)  
 5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)  
 10 5'- ATGAAACTGAAAGTA-3' (SEQ ID NO:100)  
 5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)  
 5'- AGAAATGGAAAGT-3' (SEQ ID NO:102)

SRE

15 5'- TCACCCCCAC-3' (SEQ ID NO:103)  
 5'- CTCACCCCCAC-3' (SEQ ID NO:104)  
 5'- GCCACCCTAC-3' (SEQ ID NO:105)

NFAT:

20 5'- TATGAAACAGTTTCC -3' (SEQ ID NO:106)  
 5'- AGGAAACTC -3' (SEQ ID NO:107)  
 5'- ARGARATTCC -3' (SEQ ID NO:108)  
 5'- CCAGTTGAGCCAGAGA -3' (SEQ ID NO:109)

25 GAS:

5'- CTTTCAGTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

p53 Binding Site :

30 p53 Consensus site:  
 5'- RRRCWWGYYY -3' (SEQ ID NO:111)

Examples of p53 binding sites:

35 5'- AGGCATGCCT -3' (SEQ ID NO:112)  
 5'- GGGCTTGCCTC -3' (SEQ ID NO:113)  
 5'- GGGCTTGCTT -3' (SEQ ID NO:114)  
 5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)  
 5'- GGACATGCCGGCATGTCC -3' (SEQ ID NO:116)  
 5'- GTAGCATTAGCCCAGACATGTCC -3' (SEQ ID NO:117)

40 TARE (TNF- $\alpha$  response element):

e.g. from the COL1A1 promoter

5'GAGGTATGCAGACAAGAGTCAGAGTTCCCTTGAA 3' (SEQ ID  
 NO:118)

45 SRF

5'- CCWWWWWWGG -3' (SEQ ID NO:119)  
 5'- CCAAATAAGGC -3' (SEQ ID NO:120)

- 56 -

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- $\alpha$ 4 gene, the IFN- $\beta$  gene, the TNF- $\alpha$  gene, the TNF- $\beta$  gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') – 10 620 to +50 promoter region of IFN- $\alpha$ 4 or the upstream (5') – 140 to +9 promoter region of IFN- $\alpha$ 1 can be used. In one embodiment, the IFN- $\alpha$ 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- $\alpha$ 4.

The promoter can also be the upstream (5') – 280 to +20 promoter region of IFN- $\beta$ .

15 The promoter can also be the upstream (5') – 397 to +5 promoter region of RANTES. In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') – 397 to +5 promoter region of RANTES.

20 The promoter can also be the upstream truncated (-250 to +30) and full length (-860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') – 250 to +30 promoter region of human IL-12 p40. In another embodiment, the 25 full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') – 751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated – 250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control 30 of the upstream (5') – 250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

- 57 -

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to +7 (Accession No M22111, SEQ ID NO:129).

5 The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

10 The promoter can also be derived from the -615 to +30 promoter region of human TNF- $\alpha$ .

The promoter can also be derived from a promoter region of human TNF- $\beta$ .

15 The promoter can also be derived from the -875 to +97 promoter region of human IP-10.

The promoter can also be derived from the -219 to +114 promoter region of human CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

20 The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

25 The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- $\kappa$ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box upstream of a luciferase reporter gene.

30 The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- $\alpha$ ), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or 5 functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

The expression construct coding sequence is preferably a TLR coding sequence 10 derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the 15 expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter 20 region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

25 Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would 30 result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited

- 59 -

to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,

- 5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.
- 10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

15 In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

- 20 As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

25 A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

- 30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,

- 61 -

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled 5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTEN™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as 10 LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred 15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

### Examples

#### **Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector**

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of 25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found 30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF- $\kappa$ B binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF- $\kappa$ B driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

- 62 -

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test material compared to activity of the reference material falls within predetermined limits.

**Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells**

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- $\kappa$ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

**20 Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)**

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGCCACCATGAGACAGACTTGCCTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM\_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP\_003256 (SEQ ID NO:8).

- 63 -

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

#### **Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts**

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. The resulting expression vectors mentioned above were transfected into

10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a "gain of function" assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- $\kappa$ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*

15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- $\kappa$ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- $\alpha$ 4-driven luciferase reporter 20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

25 **Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application

PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv

30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

- 64 -

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

**Example 6. Reconstitution of TLR8 Signaling**

5 Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
10 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

**Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts**

Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
20 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

25 To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- $\kappa$ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates ( $2 \times 10^6$  cells/plate) with 16  $\mu$ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cöln, Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- $\kappa$ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

- 65 -

- 293-hTLR9-luc: expressing human TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
293-mTLR9-luc: expressing murine TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
293-hTLR9: expressing human TLR9  
293-mTLR9: expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF- $\kappa$ B-luciferase reporter plasmid (NF- $\kappa$ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2 $\mu$ M, TCGTCGTTTGTGCGTTTGTCGTT, SEQ ID NO:1), GpC-ODN (2 $\mu$ M,

10 TGCTGCTTTGTGCTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF- $\kappa$ B activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the 15 NF- $\kappa$ B-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2 $\mu$ M, SEQ ID NO:1), GpC-ODN 20 (2 $\mu$ M, SEQ ID NO:154), Me-CpG-ODN (2 $\mu$ M; TZGTZGTTTGTZGTTTGTCGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF- $\kappa$ B activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific 25 manner.

#### Example 8. Method of Making IFN- $\alpha$ 4 Reporter Vector

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors 30 pNF- $\kappa$ B-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF- $\kappa$ B or AP1, respectively. Other reporter vectors can be constructed following standard

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase,  $\beta$ -galactosidase ( $\beta$ -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5 IFN- $\alpha$ 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the –620 to +50 promoter region of IFN- $\alpha$ 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –620 to +50 promoter region of IFN- $\alpha$ 4. The sequence of the –620 to +50 promoter region of IFN- $\alpha$ 4 is provided as  
10 SEQ ID NO:121.

#### **Example 9. Method of Making IFN- $\alpha$ 1 Reporter Vector**

IFN- $\alpha$ 1 is a late type 1 IFN. Sequence-specific PCR products for the –140 to +9 promoter region of IFN- $\alpha$ 1 were derived from genomic DNA of human 293 cells and cloned  
15 into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –140 to +9 promoter region of IFN- $\alpha$ 1. A sequence of the –140 to +9 promoter region of IFN- $\alpha$ 1 is provided as SEQ ID NO:122.

#### **Example 10. Method of Making IFN- $\beta$ Reporter Vector**

20 IFN- $\beta$  is an immediate-early type 1 IFN. The –280 to +20 promoter region of IFN- $\beta$  was derived from the pUC $\beta$ 26 vector (Algarté M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –280 to +20 promoter region of IFN- $\beta$ . A sequence of the –280 to +20 promoter region of IFN- $\beta$  is provided as SEQ ID NO:123.

#### **Example 11. Method of Making Human IL-6 Reporter Vectors**

Reporter constructs are made using the –285 to +7 promoter region derived from  
30 human IL-6 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108–116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xba*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of

- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to + 7 (GenBank Accession No M22111) as shown below as SEQ ID NO:129.

#### **Example 12. Method of Making Human IL-8 Reporter Vectors**

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *KpnI-XhoI* insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

20

#### **Example 13. Method of Making Human IL-12 p40 Reporter Vectors**

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108-116.) In one reporter construct the truncated IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

- 68 -

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO: 5 126.

#### **Example 14. Method of Making RANTES Reporter Vector**

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- $\kappa$ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter plasmid by restriction with *Bgl*II and *Sal*II, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125) revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

#### **Example 15. RT-PCR Analysis of Cell Lines for TLR Expression**

25 TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

30 A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor

- 69 -

leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell 5 leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, 10 with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen 15 potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligoribonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate 20 TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

#### **Example 16. Screening of Various Cell Lines for Responses to TLR Ligands**

Except where otherwise indicated, the following general methods were used.

25 Cells were plated at  $5 \times 10^5$ /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

30 TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T\*C\*C\*A\*G\*G\*A\*C\*T\*T\*C\*T\*C\*T\*C\*A\*G\*G\*T\*T (SEQ ID NO: 2);

- 70 -

T\*C\*G\*T\*C\*G\*T\*T\*T\*G\*T\*C\*G\*T\*T\*T\*G\*T\*C\*G\*T\*T (SEQ ID NO: 1);

T\*G\*C\*T\*G\*C\*T\*T\*T\*G\*T\*G\*C\*T\*T\*T\*G\*T\*G\*C\*T\*T (SEQ ID NO: 154);

T\*C\*G\*T\*C\*G\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\*C\*G (SEQ ID NO: 158);

G\*G\*G\_G\_A\_C\_G\_A\_C\_G\_T\_C\_G\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 159);

5 T\*G\*C\*T\*G\*C\*T\*T\*T\*C\*G\*G\*C\*G\*G\*C\*C\*G (SEQ ID NO: 160);

G\*G\*G\_G\_A\_G\_C\_A\_G\_C\_T\_G\_C\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 161).

\* phosphorothioate linkage; \_ phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as described above and then stained with different monoclonal antibody combinations specific for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a NF- $\kappa$ B reporter construct (Stratagene) and a  $\beta$ -galactosidase reporter control plasmid (Invitrogen) using electroporation. For NF- $\kappa$ B analysis, a 5x NF- $\kappa$ B-Luciferase Vector (Stratagene) was used. The amount of DNA transfected as well as cell concentration was varied. Stimulation was performed 24h after transfection. Cells were stimulated with the indicated amounts of ODN, R-848, LPS, TNF- $\alpha$ , or IL-1  $\beta$  for the indicated incubation times. Cell extracts were prepared by lysing the cells in 100  $\mu$ l reporter lysis buffer (Promega) using the freeze-thaw method. All data were normalized for  $\beta$ -galactosidase expression.

20 Stimulation indices were calculated in reference to luciferase activity of medium without addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14 and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.

25 Fig. 16 shows IFN- $\alpha$ 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848. In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-regulation of cell surface markers such as CD80, as shown in Fig. 17.

30 **Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound**

Inhibition of CpG mediated chemokine production was determined using RPMI 8226 cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

**Equivalents**

5       The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described  
10      herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

      All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

- 72 -

**Claims**

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising
  - contacting an RPMI 8226 cell that expresses a TLR with a test compound and
  - 5 measuring a test level of TLR signaling activity,
    - wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and
    - 10 wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.
2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising
  - 15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,
    - wherein a test level that is positive is indicative of an immunostimulatory compound, and
    - 20 wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell.
3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.
  - 25
4. The method of claim 3, wherein the reference compound is a positive reference compound
  - 30
5. The method of claim 4, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

- 73 -

6. The method of claim 3, wherein the reference compound is a negative reference compound.

7. The method of claim 6, wherein the negative reference compound is  
5 medium alone.

8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

10

9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

15

10. The method of claim 1 or 2, wherein the test compound is a nucleic acid.

11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

20

12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

25

13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.

30

15. The method of claim 1 or 2, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

17. The method of claim 1 or 2, wherein the test compound is derived from a molecular library.

5 18. The method of claim 1, wherein the cell is transfected with a nucleic acid.

19. The method of claim 18, wherein the nucleic acid encodes a TLR or a reporter construct.

10 20. The method of claim 2, wherein the cell is transfected with a nucleic acid.

15 21. The method of claim 20, wherein the nucleic acid encodes a TLR or a reporter construct.

22. The method of claim 19 or 21, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

20 23. The method of claim 22, wherein the TLR is a human TLR.

24. The method of claim 19 or 21, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

25 25. The method of claim 19 or 21, wherein the reporter construct comprises a TLR responsive promoter.

30 26. The method of claim 25, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an

- 75 -

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a  
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a  
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.  
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected  
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- $\alpha$  secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected  
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8  
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured  
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular phosphorylation.

- 76 -

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

36. The method of claim 1, wherein the TLR signaling activity is measured by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- $\alpha$  expression.

37. The method of claim 35, wherein TLR signaling activity is measured by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.

- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising  
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR  
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct  
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive  
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter  
comprises a nucleic acid sequence selected from the group consisting of an NF- $\kappa$ B binding  
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3  
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding  
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected  
from the group consisting of a luciferase sequence, a  $\beta$ -galactosidase sequence, a green  
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol  
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide or fragment thereof.

25 49. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,  
TLR7, TLR8, TLR9 and TLR10.

30 50. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)  
signaling activity, comprising

- 78 -

contacting a cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5           wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

10           52.         The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.

53.         The method of claim 52, wherein the reference compound is a positive reference compound.

15           54.         The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

20           55.         The method of claim 54, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

56.         The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

25           57.         The method of claim 52, wherein the reference compound is negative reference compound.

30           58.         The method of claim 57, wherein the negative reference compound is medium alone.

59.         The method of claim 51, wherein the test compound is a nucleic acid.

- 79 -

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

15 64. The method of claim 51, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

20 66. The method of claim 51, wherein the test compound is derived from a molecular library.

25 67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

30 68. The method of claim 51, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

69. The method of claim 51, wherein the TLR is a human TLR.

- 80 -

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from  
5 the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is  
10 measured by luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a  
15 TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is  
a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a  
TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a  
20 TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a  
TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter  
comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B  
25 binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an  
IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF  
binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a  
30 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6  
promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter  
region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an  
IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter

- 81 -

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

10 78. The method of claim 70, wherein the cell is stably transfected with the reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

15 80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- $\alpha$  secretion, IL-10 secretion and IP-10 secretion.

20 81. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

25 83. The method of claim 82, wherein phosphorylation is total cellular phosphorylation.

84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

30 85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

88. The method of claim 51, wherein the TLR signaling activity is  
10 measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

15 90. The method of claim 51, wherein the TLR signaling activity is measured by cell surface marker expression.

20 91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR cell surface expression.

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

94. The method of claim 93, wherein the antibody secretion is IgM  
30 secretion.

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

- 83 -

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5 .       wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

      wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10           96.       The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

15           97.       The method of claim 96, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

98.       The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20           99.       The method of claim 95, wherein the test compound is a nucleic acid.

100.       The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a 25 poly-G motif.

101.       The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30           102.       The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

- 84 -

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an 5 amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

10 106. The method of claim 95, wherein the test compound is derived from a molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.

15 108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

20 109. The method of claim 108, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

25 111. The method of claim 108, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

30 112. The method of claim 111, wherein the TLR signaling activity is selected from the group consisting of luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

- 85 -

113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter  
5 comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

10 115. The method of claim 113, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

20 116. The method of claim 113, wherein the TLR responsive promoter is selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25

117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

30 118. The method of claim 95, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

- 86 -

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- $\alpha$  secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

10 121. The method of claim 95, wherein the TLR signaling activity is measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

20 124. The method of claim 95, wherein the TLR signaling activity is measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

127. The method of claim 95, wherein the TLR signaling activity is measured by microarray techniques.

30 128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

15

133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:

30 measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

- 89 -

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- $\kappa$ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10 148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\alpha$  promoter.

149. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\beta$  promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20 151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25 153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

154. The method of claim 137, wherein the known TLR ligand is a TLR9  
30 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3  
ligand.

- 90 -

156. The method of claim 137, wherein the known TLR ligand is a TLR7  
ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8  
ligand.

158. The method of claim 137, wherein the known TLR ligand is an  
immunostimulatory nucleic acid.

10 159. The method of claim 137, wherein the known TLR ligand is a CpG  
nucleic acid.

15 160. The method of claim 137, wherein the known TLR ligand is an  
immunoinhibitory nucleic acid.

161. A method for quality assessment of a test lot of a pharmaceutical  
product containing a known TLR9 ligand, comprising:  
measuring a reference activity of a reference lot of a pharmaceutical product  
comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid  
molecule;  
measuring a test activity of a test lot of a pharmaceutical product comprising  
the known TLR9 ligand;  
comparing the test activity to the reference activity; and  
rejecting the test lot if the test activity falls outside of a predetermined range of  
variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an  
oligonucleotide comprising a base sequence TCGTCGTTTGTGCGTTTGTGTT (SEQ ID  
30 NO:1).

- 91 -

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTGACGTTTGTGCGTT-3' (SEQ ID NO:139).

5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTGTCGTTTTTCGA-3' (SEQ ID NO:140).

10 165. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

15 166. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTGTCGTT-3' (SEQ ID NO:142).

167. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGTCGTTT-3' (SEQ ID NO:143).

20 168. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

25 169. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

30 170. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTC\_GTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.

10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

15 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.

173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

25 wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.

174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10 contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a 15 RAMOS cell and a Raji cell, and the TLR is TLR7.

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference 20 level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25 wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

176. A screening method for identifying an enhancer of a Toll-like receptor 30 (TLR) agonist, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

- 94 -

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR  
5 agonist.

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

10 178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.

15 180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is  
TLR3.


181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a  
20 THP-1 cell, and the TLR is TLR9.

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

25 183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.

1/15

**Fig. 1****SUBSTITUTE SHEET (RULE 26)**

2/15




Fig. 2

SUBSTITUTE SHEET (RULE 26)

3/15




Fig. 3

4/15




Fig. 4

5/15




Fig. 5

6/15




Fig. 6

7/15




Fig. 7

8/15




Fig. 8

9/15




Fig. 9

10/15




Fig. 10




Fig. 11

11/15






Fig. 12

12/15



**Fig. 13**



**Fig. 14**

13/15




Fig. 15




Fig. 16




Fig. 17  
SUBSTITUTE SHEET (RULE 26)

14/15




Fig. 18A







Fig. 18B

**Fig. 19****Fig. 20****Fig. 21**  
SUBSTITUTE SHEET (RULE 26)

## SEQUENCE LISTING

<110> COLEY PHARMACEUTICAL GmbH  
COLEY PHARMACEUTICAL GROUP INC.

<120> METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR  
LIGANDS

<130> C1041.70024WO00

<140> not yet assigned  
<141> 2004-04-22

<150> US 60/464,586  
<151> 2003-04-22

<150> US 60/464,588  
<151> 2003-04-22

<160> 161

<170> PatentIn version 3.2

<210> 1  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1  
tcgtcgttt gtcgtttgt cgtt

24

<210> 2  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2  
tccaggactt ctctcagggtt

20

<210> 3  
<211> 2600  
<212> DNA  
<213> Homo sapiens

<400> 3  
ggatccaaag gagacctata gtgactccca ggagcttta gtgaccaagt gaaggtaacct

60

gtggggctca ttgtgccat tgctttca ctgcttcaa ctggtagttg tgggttgaag

120

cactggacaa tgccacatac tttgtggatg gtgtgggtct tgggggtcat catcagcctc

180

tccaaggaag aatcctccaa tcaggcttct ctgtcttg accgcaatgg tatctgcaag

240

ggcagctcgatctttaaa	ctccattccc	tcagggctca	cagaagctgt	aaaaagecctt	300
gacctgtcca	acaacaggat	cacctacatt	agcaacagtg	acctacagag	360
ctccaggctc	tggtgctgac	atccaatgga	attaacacaa	tagaggaaga	420
tccctggca	gtcttgaaca	tttagactta	tcctataatt	acttatctaa	480
tcctggttca	agcccctttc	ttctttaaca	ttctttaact	tactggaaa	540
accctagggg	aaacatctct	tttttctcat	ctcacaaaat	tgcaaatcct	600
aatatggaca	ctttcactaa	gattcaaaga	aaagattttg	ctggacttac	660
gaacttgaga	ttgatgcttc	agatctacag	agctatgagc	caaaaagttt	720
cagaacgtaa	gtcatctgat	ccttcatatg	aagcagcata	tttactgct	780
gttagatgtta	caagttccgt	ggaatgtttg	gaactgcgag	atactgattt	840
cattttcag	aactatccac	tggtaaaaca	aattcattga	ttaaaaagtt	900
aatgtgaaaa	tcacccgatga	aagtttgtt	caggttatga	aactttgaa	960
ggattgttag	aatttagagtt	tgatgactgt	acccttaatg	gagttggtaa	1020
tctgataatg	acagagttat	agatccaggt	aaagtggaaa	cgttaacaat	1080
catattccaa	gttttactt	atttatgat	ctgagcactt	tatattcaact	1140
gttaaaaagaa	tcacagttaga	aaacagtaaa	gttttctgg	ttcctgttt	1200
catttaaaat	cattagaata	cttggatctc	agtggaaatt	tgatggttga	1260
aaaaattcag	cctgtgagga	tgcctggccc	tctctacaaa	ctttaatttt	1320
catttggcat	cattggaaaa	aaccggagag	actttgctca	ctctgaaaaa	1380
attgatgatca	gtaagaatag	tttcattct	atgcctgaaa	cttgcgttg	1440
atgaaatatt	tgaacttattc	cagcacacga	atacacagtg	taacaggctg	1500
acactggaaa	tttttagatgt	tagcaacaac	aatctcaatt	tatttcttt	1560
caactcaaag	aactttatat	ttccagaaat	aagttgatga	ctctaccaga	1620
ttacccatgt	tactagtatt	gaaaatcagt	aggaatgcaa	taactacgtt	1680
caacttgact	catttcacac	actgaagact	ttggaagctg	gtggcaataa	1740
tcctgtgaat	tccttcctt	cactcaggag	cagcaagcac	tggccaaagt	1800
tggccagcaa	attacctgtg	tgactctcca	tcccatgtgc	gtggccagca	1860
gtccgcctct	cggtgtcgga	atgtcacagg	acagcactgg	tgtctggcat	1920
ctgttcctgc	tgatcctgct	cacgggggtc	ctgtgccacc	gtttccatgg	1980
atgaaaatga	tgtgggcctg	gctccaggcc	aaaaggaagc	ccaggaaagc	2040
aacatctgt	atgatgcatt	tgtttcttac	agtgagcggg	atgcctactg	2100

cttatggtcc aggagctgga gaactcaat ccccccttca agttgtgtct tcataagcg	2160
gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac	2220
aaaactgtct ttgtgctttc tgaaaacttt gtgaagagtg agtggtgcaa gtatgaactg	2280
gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattcttctg	2340
gagccattg agaaaaaaagc cattccccag cgcttctgca agctgcggaa gataatgaac	2400
accaagacct acctggagtg gcccatggac gaggctcagc gggaggatt ttgggtaaat	2460
ctgagagctg cgataaaagtc ctaggttccc atattaaga ccagtcttg tctagttggg	2520
atcttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg	2580
gatgtaccgt catttgagga	2600

<210> 4  
<211> 784  
<212> PRT  
<213> Homo sapiens

<400> 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser			
1	5	10	15

Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg			
20	25	30	

Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser			
35	40	45	

Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile			
50	55	60	

Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala			
65	70	75	80

Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe			
85	90	95	

Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu			
100	105	110	

Ser Asn Leu Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe			
115	120	125	

Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu			
130	135	140	

Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp			
145	150	155	160

Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu			
165	170	175	

Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys			
180	185	190	

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys  
195 200 205

Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val  
210 215 220

Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser  
225 230 235 240

Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe  
245 250 255

Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu  
260 265 270

Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr  
275 280 285

Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile  
290 295 300

Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro  
305 310 315 320

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu  
325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser  
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp  
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala  
385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr  
405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys  
420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile  
435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val  
450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys  
465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser  
485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr  
500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

515	520	525
Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe		
530	535	540
Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala		
545	550	555
Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln		
565	570	575
Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser		
580	585	590
Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Thr Gly Val Leu		
595	600	605
Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp		
610	615	620
Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys		
625	630	635
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu		
645	650	655
Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu		
660	665	670
Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn		
675	680	685
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser		
690	695	700
Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser		
705	710	715
His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu		
725	730	735
Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu		
740	745	750
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu		
755	760	765
Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser		
770	775	780

<210> 5  
<211> 2824  
<212> DNA  
<213> murine

<400> 5	
gccccccatg gccatatggg caccggggag cggcggctgg aggactccta ggctcctggg	60
caggcggtca catggcagaa gatgtgtccg caatcatagt ttctgatgggt gaagggttggaa	120
cggcagtctc tgcgacctag aagtggaaaa gatgtcggttc aaggaggtgc ggactgtttc	180

cttctgacca ggatcttgtt tctgagtgtt ggggcttcac ttctctgtt ttcgttcatc	240
tctggagcat ccgaatttca tcaccggtaaaaacaact taccgaaacc tcagacaaag	300
cgtcaaatct cagaggatgc tacgagctct ttggcttcc tggatcttgg tggccataac	360
agtccctttc agcaaacgct gttctgtca ggagtctctg tcatgtgatg cttctgggt	420
gtgtgatggc cgctccaggc ctccaccc tattccctcc ggactcacag cagccatgaa	480
aagccttgac ctgtcttca acaagatcac ctacattggc catggtgacc tccgagcgtg	540
tgcgAACCTC caggttctga ttttgaagtc cagcagaatc aatacaatag agggagacgc	600
cttttattct ctgggcagtc ttgaacattt ggatttgtct gataatcacc tatctagttt	660
atcttcctcc tggttcgggc cccttcctc tttgaaatac ttAAacttaa tggaaatcc	720
ttaccagaca ctggggtaa catcgctttt tcccaatctc acAAatttac aaaccctcag	780
gataggaaat gttagagactt tcagttagat aaggagaata gatttgctg ggctgacttc	840
tctcaatgaa cttgaaatta aggcatTAAG tctccggaat tatcagtccc aaagtctaaa	900
gtcgatccgc gacatccatc acctgactct tcacttaagc gagtctgtt tcctgtggaa	960
gattttgca gatattctga gttctgtgag atatTTAGAA ctaagagata ctaacttggc	1020
caggttccag ttttccaccac tgccccgtaga tgaagtcagc tcaccgtga agaagctggc	1080
attccgaggc tcggTTCTCA ctgatgaaag cttaacgag ctccctgaagc tggcgttta	1140
catcttgaa ctgtcggagg tagagttcga cgactgtacc ctcaatggc tcggcgattt	1200
caaccctcg gagtcagacg tagtgagcga gctgggtaaa gtagaaacag tcactatccg	1260
gaggttgcatttcccccagt tctatTTGTT ttatgacctg agtactgtct attccctct	1320
ggagaaggtg aagcgaatca cagtagagaa cagcaaggc ttccTGGTTC cctgctcgTT	1380
ctcccagcat ttaaaatcat tagaattctt agacctcagc gaaaatctga tggTTGAAGA	1440
atatTTGAAG aactcagcct gtaaggggagc ctggcTTCTC ctacAAACCT tagTTTGTAG	1500
ccagaatcat ttgagatcaa tgcaaaaaac aggagagatt ttgctgactc tgaaaaacct	1560
gacctccctt gacatcagca ggaacacttt tcacccgtatg cccgacagct gtcagtggcc	1620
agaaaaagatg cgcttcctga atttgcctcag tacagggatc cgggtggtaa aacgtgcatt	1680
tcctcagacg ctggagggtgt tggatgttag taacaacaat cttgactcat tttctttgtt	1740
cttgccctgg ctgcaagagc tctatTTTC cagaaataag ctgAAAACAC tcccaGATGC	1800
ttcgttGTTc cctgtgttgc tggcatgaa aatcagagag aatgcagtaa gtactttctc	1860
taaagaccaa cttggTTCTT ttcccaaact ggagactctg gaagcaggcg acaaccactt	1920
tgtttgctcc tgcaactcc tatttttac tatggagacg ccagctctgg ctcaaATCCt	1980
ggTTGACTGG ccagacagct acctgtgtga ctctccgcct cgcctgcacg gccacaggct	2040
tcaggatgcc cggccctccg tcttggaaatg tcaccaggtt gcactgggtt ctggagtctg	2100

ctgtgccctt ctccctgttga tcttgctcgt aggtgccctg tgccaccatt tccacgggct 2160  
 gtggtaacctg agaatgatgt gggcgtggct ccaggccaag aggaagccca agaaagctcc 2220  
 ctgcaggggac gttgctatg atgccttgt ttcctacagt gagcaggatt cccattgggt 2280  
 ggagaacctc atggtccagc agctggagaa ctctgaccgg cccttaagc tgtgtctcca 2340  
 caagcgggac ttctgtccgg gcaaattggat cattgacaac atcatcgatt ccatecgaaaa 2400  
 gagccacaaa actgtgttcg tgctttctga gaacttcgta cggagcggagt ggtgcaagta 2460  
 cgaactggac ttotcccact tcaggctctt tgacgagaac aacgacgcgg ccattcctgt 2520  
 tttgctggag cccattgaga ggaaagccat tccccagcgc ttctgcaaac tgcgcaagat 2580  
 aatgaacacc aagacctacc tggagtggcc cttggatgaa ggccagcagg aagtgtttt 2640  
 ggtaaatctg agaactgcaa taaagtccctt ggttctccac ccagttccctg acttccttaa 2700  
 ctaaggtctt tgtgacaccaa actgtaacaa agtttataag taacatagaa ttgtattatt 2760  
 gaggatatta actatgggtt ttgtcttgaa tactgttata taaatatgtg acatcaggct 2820  
 ttag 2824

<210> 6  
 <211> 784  
 <212> PRT  
 <213> murine

<400> 6

Met Leu Arg Ala Leu Trp Leu Phe Trp Ile Leu Val Ala Ile Thr Val  
 1 5 10 15

Leu Phe Ser Lys Arg Cys Ser Ala Gln Glu Ser Leu Ser Cys Asp Ala  
 20 25 30

Ser Gly Val Cys Asp Gly Arg Ser Arg Ser Phe Thr Ser Ile Pro Ser  
 35 40 45

Gly Leu Thr Ala Ala Met Lys Ser Leu Asp Leu Ser Phe Asn Lys Ile  
 50 55 60

Thr Tyr Ile Gly His Gly Asp Leu Arg Ala Cys Ala Asn Leu Gln Val  
 65 70 75 80

Leu Ile Leu Lys Ser Ser Arg Ile Asn Thr Ile Glu Gly Asp Ala Phe  
 85 90 95

Tyr Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Asp Asn His Leu  
 100 105 110

Ser Ser Leu Ser Ser Ser Trp Phe Gly Pro Leu Ser Ser Leu Lys Tyr  
 115 120 125

Leu Asn Leu Met Gly Asn Pro Tyr Gln Thr Leu Gly Val Thr Ser Leu  
 130 135 140

Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu  
 145 150 155 160  
 Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu  
 165 170 175  
 Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln  
 180 185 190  
 Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser  
 195 200 205  
 Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val  
 210 215 220  
 Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser  
 225 230 235 240  
 Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe  
 245 250 255  
 Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu  
 260 265 270  
 Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser  
 290 295 300  
 Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu  
 325 330 335  
 Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg  
 385 390 395 400  
 Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile  
 435 440 445  
 Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

465	470	475	480
Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys	Thr Leu Pro Asp Ala Ser		
485	490	495	
Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser			
500	505	510	
Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu			
515	520	525	
Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe			
530	535	540	
Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp			
545	550	555	560
Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln			
565	570	575	
Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser			
580	585	590	
Gly Val Cys Cys Ala Leu Leu Leu Leu Ile Leu Leu Val Gly Ala Leu			
595	600	605	
Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp			
610	615	620	
Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys			
625	630	635	640
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu			
645	650	655	
Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu			
660	665	670	
Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn			
675	680	685	
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser			
690	695	700	
Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser			
705	710	715	720
His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu			
725	730	735	
Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu			
740	745	750	
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu			
755	760	765	
Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser			
770	775	780	

<210> 7  
<211> 3029  
<212> DNA

<213> Homo sapiens  
 <400> 7  
 gcggccgcgt cgacgaaatg tctggattt gactaaagaa aaaagggaaag gctagcagtc 60  
 atccaacaga atcatgagac agactttgcc ttgtatctac ttttgggggg gccttttgcc 120  
 ctttggatg ctgtgtgcat cctccaccac caagtgcact gttagccatg aagttgctga 180  
 ctgcagccac ctgaagttga ctcaggtaacc cgatgatcta cccacaaaaca taacagtgtt 240  
 gaaccttacc cataatcaac tcagaagatt accagccgcc aacttcacaa ggtatagcca 300  
 gctaactagc ttggatgttag gatccaacac catctcaaaa ctggagccag aattgtgcca 360  
 gaaacttccc atgttaaaag ttttgaacct ccagcacaat gagctatctc aactttctga 420  
 taaaaccttt gccttctgca cgaatttgc ac tgaactccat ctcatgtcca actcaatcca 480  
 gaaaattaaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca 540  
 taatggcttgc tcatctacaa aattaggaac tcaggttcag ctggaaaatc tccaagagct 600  
 tctattatca aacaataaaa ttcaagcgct aaaaagtgaa gaactggata tctttgccaa 660  
 ttcatcttta aaaaaatttag agttgtcatc gaatcaaatt aaagagttt ctccagggtg 720  
 ttttacgcga attggaagat tatttgcct ctttctgaac aatgtccagc tgggtcccag 780  
 ctttacagag aagctatgtt tggaatttgc aaacacaagc attcggaaatc tgtctctgag 840  
 taacagccag ctgtccacca ccagcaatac aactttcttggactaaatggacaaatct 900  
 cactatgctc gatcttcctt acaacaactt aaatgtggtt ggtaacgatt cctttgcttgg 960  
 gcttccacaa ctggatatt tcttcctaga gtataataat atacagcatt tttttctca 1020  
 ctctttgcac gggctttca atgtgaggtt cctgaatttggaaacggctttttaactaaaca 1080  
 aagtatttcc ttgcctcac tccccaaatggat tgatgatttt tctttcagt ggctaaaatgg 1140  
 tttggagcac cttaacatgg aagataatga tattccaggc ataaaaagca atatgttcac 1200  
 aggattgata aacctgaaat acttaagtct atccaactcc tttacaagtt tgcaactttt 1260  
 gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaaccac 1320  
 gaataaaaatc tcaaaaaatag agagtgtatgc tttctttggg tttggccacc tagaagtact 1380  
 tgacctgggc cttaatgaaa ttggcaaga actcacaggc caggaatggaa gaggtctaga 1440  
 aaatattttc gaaatctatc ttccctacaa caagtacctg cagctgacta ggaactcctt 1500  
 tgccttggtc ccaaggccttc aacgactgat gctccgaagg gtggccctta aaaaatgtgg 1560  
 tagctctcct tcaccattcc agcctcttgc taacttgacc attctggatc taagcaacaa 1620  
 caacatagcc aacataaaatg atgacatgtt ggagggtctt gagaacttag aaattctcga 1680  
 tttgcagcat aacaacttag cacggctctg gaaacacgca aaccctgggtg gtcccatat 1740  
 ttccctaaag ggtctgtctc acctccacat ccttaacttg gagtccaacg gctttgacga 1800

gatcccagtt gaggtcttca aggatttatt tgaactaaag atcatcgatt taggattgaa	1860
taatttaaac acacttccag catctgtctt taataatcag gtgtctcaa agtcattgaa	1920
ccttcagaag aatctcataa catccgttga gaagaagggtt ttccggccag ctttcaggaa	1980
cctgactgag ttagatatgc gctttaatcc ctttgattgc acgtgtgaaa gtattgcctg	2040
gtttgttaat tggattaacg agaccatac caacatccct gagctgtcaa gccactacct	2100
ttgcaacact ccacctcact atcatgggtt cccagtgaga ctttttgata catcatcttg	2160
caaagacagt gccccctttg aactctttt catgatcaat accagtatcc tggtgatttt	2220
tatcttatt gtacttctca tccactttga gggctggagg atatctttt attggaatgt	2280
ttcagtagat cgagttcttg gtttcaaaga aatagacaga cagacagaac agtttgaata	2340
tgcagcatat ataattcatg cctataaaaga taaggattgg gtctggaaac atttctttc	2400
aatggaaaag gaagaccaat ctctcaaatt ttgtctggaa gaaagggact ttgaggcggg	2460
tgttttgaa ctagaagcaa ttgttaacag catcaaaaaga agcagaaaaa ttattttgt	2520
tataacacac catctattaa aagaccatt atgcaaaaga ttcaaggtagc atcatgcagt	2580
tcaacaagct attgaacaaa atctggattc cattatattg gtttccctt aggagattcc	2640
agattataaa ctgaaccatg cactctgtt gcgaagagga atgtttaat ctcactgcatt	2700
cttgaactgg ccagttcaga aagaacggat aggtgcctt cgtcataaat tgcaagtagc	2760
acttggatcc aaaaactctg tacattaaat ttattnaat attcaattag caaaggagaa	2820
actttctcaa tttaaaaagt tctatggcaa atttaagttt tccataaagg tgttataatt	2880
tgtttattca tatttgtaaa tgattatatt ctatcacaat tacatcttt ctagaaaaat	2940
gtgtctccctt atttcaggcc tattttgac aattgactta attttaccca aaataaaaaca	3000
tataagcacg caaaaaaaaaa aaaaaaaaaa	3029

<210> 8  
<211> 904  
<212> PRT  
<213> Homo sapiens

<400> 8

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro  
1               5                           10                           15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His  
20               25                           30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp  
35               40                           45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg  
50               55                           60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

65                    70                    75                    80  
 Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln  
 85                    90                    95  
  
 Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser  
 100                  105                  110  
  
 Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu  
 115                  120                  125  
  
 His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro Phe Val  
 130                  135                  140  
  
 Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His Asn Gly Leu Ser  
 145                  150                  155                  160  
  
 Ser Thr Lys Leu Gly Thr Gln Val Gln Leu Glu Asn Leu Gln Glu Leu  
 165                  170                  175  
  
 Leu Leu Ser Asn Asn Lys Ile Gln Ala Leu Lys Ser Glu Glu Leu Asp  
 180                  185                  190  
  
 Ile Phe Ala Asn Ser Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln  
 195                  200                  205  
  
 Ile Lys Glu Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe  
 210                  215                  220  
  
 Gly Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys  
 225                  230                  235                  240  
  
 Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu Ser  
 245                  250                  255  
  
 Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Thr Phe Leu Gly Leu Lys  
 260                  265                  270  
  
 Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr Asn Asn Leu Asn Val  
 275                  280                  285  
  
 Val Gly Asn Asp Ser Phe Ala Trp Leu Pro Gln Leu Glu Tyr Phe Phe  
 290                  295                  300  
  
 Leu Glu Tyr Asn Asn Ile Gln His Leu Phe Ser His Ser Leu His Gly  
 305                  310                  315                  320  
  
 Leu Phe Asn Val Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln  
 325                  330                  335  
  
 Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln  
 340                  345                  350  
  
 Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro  
 355                  360                  365  
  
 Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu  
 370                  375                  380  
  
 Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr  
 385                  390                  395                  400  
  
 Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys

405	410	415
Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His		
420	425	430
Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr		
435	440	445
Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser		
450	455	460
Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro		
465	470	475
480		
Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp		
485	490	495
Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp		
500	505	510
Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly		
515	520	525
Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg		
530	535	540
Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly		
545	550	555
560		
Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu		
565	570	575
Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp		
580	585	590
Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn		
595	600	605
Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser		
610	615	620
Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu		
625	630	635
640		
Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp		
645	650	655
Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser		
660	665	670
Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val		
675	680	685
Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu		
690	695	700
Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val		
705	710	715
720		
Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val		
725	730	735
Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu		

740	745	750
Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp		
755	760	765
Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu		
770	775	780
Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu		
785	790	795
Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val		
805	810	815
Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val		
820	825	830
His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile		
835	840	845
Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu		
850	855	860
Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro		
865	870	875
Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala		
885	890	895
Leu Gly Ser Lys Asn Ser Val His		
900		

<210> 9  
 <211> 3310  
 <212> DNA  
 <213> murine

<400> 9		
tagaatatga tacagggatt gcaccataa tctgggctga atcatgaaag ggtgttcctc	60	
ttatctaattg tactcctttg gggactttt gtccctatgg attcttctgg tgtcttccac	120	
aaaccaatgc actgtgagat acaacgtgc tgactgcgc catttgaagc taacacacat	180	
acctgatgat ctccctcta acataacagt gttaatctt actcacaacc aactcagaag	240	
attaccacct accaacttta caagatacag ccaacttgct atcttggatg caggattaa	300	
ctccatttca aaactggagc cagaactgtg ccaaatactc ctttgttga aagtattgaa	360	
cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtttct gcacgaacct	420	
gacagaactc gatctaattgt ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa	480	
ccagaagaat ctaatcaaatt tagatttgc tcataatggt ttatcatcta caaagttggg	540	
aacgggggtc caactggaga acctccaaga actgcttta gcaaaaaata aaatccttgc	600	
gttgcgaagt gaagaacttg agtttcttgg caattttctt ttacgaaagt tggacttgc	660	
atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattcgc	720	

cctccctttg aacaacgccc aactgaaccc ccacccata gagaagctt gctggaaact	780
ttcaaacaca agcatccaga atctctctc ggotaacaac cagctgcgtt ccaccagcga	840
gagcactttc tctggctga agtggacaaa tctcacccag ctcgatctt cctacaacaa	900
cctccatgtat gtcggcaacg gttccttctc ctatctccca agcctgaggat atctgtctc	960
ggagtacaac aatatacagc gtctgtcccc tcgcttttat tatggactct ccaacctgag	1020
gtacctgagt ttgaagcgag catttactaa gcaaagtgtt tcacttgctt cacatccaa	1080
cattgacgat tttcccttc aatggtaaa atatttggaa tatctcaaca tggatgacaa	1140
taatattcca agtacccaaa gcaataacctt cacgggattt gtgagtctga agtacctaag	1200
tctttccaaa actttcacaa gtttgcacaa tttaacaaat gaaacatttgc tgtaacttgc	1260
tcattctccc ttgctactc tcaacttaac gaaaaatcac atctcaaaaa tagcaaatgg	1320
tactttctct tggttaggccc aactcaggat acttgatctc ggccttaatg aaattgaaca	1380
aaaactcagc ggccaggaat ggagaggctt gagaatata tttgagatct acctatccta	1440
taacaaatac ctccaactgt ctaccagttc cttgcattt gtccccagcc ttcaaagact	1500
gtatgcaggaggaggcc ttaaaaatgt ggatatctcc ccttcaccc tccgcctct	1560
tcgtaacttg accattctgg acttaagcaa caacaacata gccaacataa atgaggactt	1620
gctggagggt cttgagaatc tagaaatcctt ggattttcag cacaataact tagccaggct	1680
ctggaaacgc gcaaaccggc gtggccgt taatttcctt aagggctgt ctcacccat	1740
catcttgaat ttagagtcca acggcttaga tgaaatccca gtcgggttt tcaagaactt	1800
attcgaacta aagagcatca atctaggact gaataactt aacaaactt aaccattcat	1860
ttttgatgac cagacatctc taaggtcaactt gaaacctccag aagaacctca taacatctgt	1920
tgagaaggat gtttcgggc cgccctttca aaacctgaac agtttagata tgcgcttcaa	1980
tccgttcgac tgcacgtgtt aaagtatttc ctgggtttttt aactggatca accagaccca	2040
cactaatatc tttgagctgt ccactcaactt cctctgttac actccacatc attattatgg	2100
cttccccctt aagcttttcg atacatcatc ctgtttttttt aacccatccatc ttgaacttcc	2160
cttcataatc agcaccagta tgctccgtt ttttatactt gtggactgc tcattcacat	2220
cgagggctgg aggtatctttt tttactggaa tgtttcaatgtt catcgatcc ttgggttcaa	2280
ggaaatagac acacaggctg agcagtttga atatacagcc tacataattt atgcccataa	2340
agacagagac tgggtctggg aacatttctc cccaatggaa gaacaagacc aatctctcaa	2400
attttgccta gaagaaaggg actttgaagc aggcgttccctt ggacttgaag caattgtttaa	2460
tagcatcaaa agaagccgaa aaatcattttt cgttatcaca caccattttt taaaagaccc	2520
tctgtgcaga agattcaagg tacatcacgc agttcagccaa gctattgagc aaaatctgga	2580
ttcaattata ctgatttttc tccagaatat tccagattt aaactaaacc atgcactctg	2640

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg 2700  
 gataaatgcc tttcatcata aattgcaagt agcacttgaa tctcgaaatt cagcacatta 2760  
 aactcatttga aagatttgaa gtcggtaaag ggatagatcc aatttataaaa ggtccatcat 2820  
 gaatctaagt tttacttcaa agttttgtat. atttatttat atgtatacat gatgatatta 2880  
 catcacaatc caatctcagt tttgaaatat ttccggcttat ttcatggaca tctggtttat 2940  
 tcactccaaa taaacacatg ggcagttaaa aacatcctct attaatacat tacccattaa 3000  
 ttcttgaggt gtatcacagc tttaaagggt tttaaataattt tttatataaaa taagactgag 3060  
 agtttataaa atgtaatttt tttaaactcg agtcttactg tgttagctcg aaaggcctgg 3120  
 aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc 3180  
 agagtgttgc tttaaggc atgtagcacc acacccagct atgtacgtgt gggattttat 3240  
 aatgctcatt ttgagacgt ttatagaata aaagataatt gctttatgg tataaggcta 3300  
 cttgaggtaa 3310

<210> 10  
 <211> 905  
 <212> PRT  
 <213> murine

<400> 10

Met Lys Gly Cys Ser Ser Tyr Leu Met Tyr Ser Phe Gly Gly Leu Leu  
1 5 10 15

Ser Leu Trp Ile Leu Leu Val Ser Ser Thr Asn Gln Cys Thr Val Arg  
20 25 30

Tyr Asn Val Ala Asp Cys Ser His Leu Lys Leu Thr His Ile Pro Asp  
35 40 45

Asp Leu Pro Ser Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu  
50 55 60

Arg Arg Leu Pro Pro Thr Asn Phe Thr Arg Tyr Ser Gln Leu Ala Ile  
65 70 75 80

Leu Asp Ala Gly Phe Asn Ser Ile Ser Lys Leu Glu Pro Glu Leu Cys  
85 90 95

Gln Ile Leu Pro Leu Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu  
100 105 110

Ser Gln Ile Ser Asp Gln Thr Phe Val Phe Cys Thr Asn Leu Thr Glu  
115 120 125

Leu Asp Leu Met Ser Asn Ser Ile His Lys Ile Lys Ser Asn Pro Phe  
130 135 140

Lys Asn Gln Lys Asn Leu Ile Lys Leu Asp Leu Ser His Asn Gly Leu  
145 150 155 160

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu  
165 170 175

Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu  
180 185 190

Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn  
195 200 205

Pro Ile Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu  
210 215 220

Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu  
225 230 235 240

Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu  
245 250 255

Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu  
260 265 270

Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His  
275 280 285

Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu  
290 295 300

Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr  
305 310 315 320

Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys  
325 330 335

Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe  
340 345 350

Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile  
355 360 365

Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr  
370 375 380

Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu  
385 390 395 400

Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr  
405 410 415

Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly  
420 425 430

Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu  
435 440 445

Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu  
450 455 460

Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val  
465 470 475 480

Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

	485	490	495
Asp Ile Ser Pro Ser Pro Phe Arg Pro Leu Arg Asn Leu Thr Ile Leu			
	500	505	510
Asp Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Glu Asp Leu Leu Glu			
	515	520	525
Gly Leu Glu Asn Leu Glu Ile Leu Asp Phe Gln His Asn Asn Leu Ala			
	530	535	540
Arg Leu Trp Lys Arg Ala Asn Pro Gly Gly Pro Val Asn Phe Leu Lys			
	545	550	555
			560
Gly Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Leu Asp			
	565	570	575
Glu Ile Pro Val Gly Val Phe Lys Asn Leu Phe Glu Leu Lys Ser Ile			
	580	585	590
Asn Leu Gly Leu Asn Asn Leu Asn Lys Leu Glu Pro Phe Ile Phe Asp			
	595	600	605
Asp Gln Thr Ser Leu Arg Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr			
	610	615	620
Ser Val Glu Lys Asp Val Phe Gly Pro Pro Phe Gln Asn Leu Asn Ser			
	625	630	635
			640
Leu Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ser			
	645	650	655
Trp Phe Val Asn Trp Ile Asn Gln Thr His Thr Asn Ile Phe Glu Leu			
	660	665	670
Ser Thr His Tyr Leu Cys Asn Thr Pro His His Tyr Tyr Gly Phe Pro			
	675	680	685
Leu Lys Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu			
	690	695	700
Leu Leu Phe Ile Ile Ser Thr Ser Met Leu Leu Val Phe Ile Leu Val			
	705	710	715
			720
Val Leu Leu Ile His Ile Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn			
	725	730	735
Val Ser Val His Arg Ile Leu Gly Phe Lys Glu Ile Asp Thr Gln Ala			
	740	745	750
Glu Gln Phe Glu Tyr Thr Ala Tyr Ile Ile His Ala His Lys Asp Arg			
	755	760	765
Asp Trp Val Trp Glu His Phe Ser Pro Met Glu Glu Gln Asp Gln Ser			
	770	775	780
Leu Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Leu Gly			
	785	790	795
			800
Leu Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe			
	805	810	815
Val Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Arg Arg Phe Lys			

820	825	830
Val His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile		
835	840	845
Ile Leu Ile Phe Leu Gln Asn Ile Pro Asp Tyr Lys Leu Asn His Ala		
850	855	860
Leu Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp		
865	870	875
Pro Val Gln Lys Glu Arg Ile Asn Ala Phe His His Lys Leu Gln Val		
885	890	895
Ala Leu Gly Ser Arg Asn Ser Ala His		
900	905	

<210> 11  
 <211> 3811  
 <212> DNA  
 <213> Homo sapiens

<400> 11 acaggccac tgctgctcac agaagcagtg aggatgatgc caggatgatg tctgcctcgc gcctggctgg gactctgatc ccagccatgg ccttcctctc ctgcgtgaga ccagaaaagct gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaaccaga gctttcagac tccggagcct cagcccttca ccccgattcc attgcttctt gctaaatgct gccgttttat cacggaggtg gttcctaata ttacttatca atgcattggag ctgaatttct acaatccc cgacaaccc tccttcctcaa ccaagaacct ggacctgagc ttatcccc tgaggcattt aggcagctat agcttcttca gtttcccaga actgcagggtg ctggatttat ccagggtgtga aatccagaca attgaagatg gggcatatca gagcctaagc cacctctcta ccttaatatt gacaggaaac cccatccaga gtttagccct gggagccctt tctggactat caagtttaca gaagctggtg gctgtggaga caaatctagc atctctagag aacttcccc ttggacatct caaaactttt aaagaactta atgtggctca caatcttatac caatcttca aattacctga gtatttttct aatctgacca atcttagagca cttggacctt tccagcaaca agattcaaag tatttattgc acagacttgc gggttctaca tcaaattcccc ctactcaatc tctctttaga cctgtccctg aaccctatga actttatcca accaggtgca tttaaagaaa ttaggcattca taagctgact ttaagaaata atttttagatg tttaaatgta atgaaaactt gtattcaagg tctggctgg ttagaagtcc atcgtttgg tctggagaa tttagaaatg aaggaaactt gggaaagttt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg aagaattccg attagcatac ttagactact acctcgatga tattattgac ttatttaatt gtttgacaaa tttttcttca tttccctgg tgagtgtgac tattgaaagg gtaaaagact tttcttataa ttccggatgg caacatttag aattagttaa ctgtaaattt ggacagttc	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200
--	---

ccacattgaa actcaaatct ctcaaaaaggc ttactttcac ttccaacaaa ggtgggaatg	1260
cttttcaga agttgatcta ccaagccttg agtttctaga tctcagtata aatggcttga	1320
gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc	1380
ttagcattcaa tggtgttatt accatgagtt caaacttctt gggcttagaa caactagaac	1440
atctggattt ccagcattcc aatttggaaac aaatgagtga gtttcagta ttcttatcac	1500
tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca	1560
tcttcattgg cttgtccagt ctcgaagtct tggaaatggc tggcaattct ttccaggaaa	1620
acttcattcc agatatcttc acagagctga gaaacttgac cttcctggac ctctctcagt	1680
gtcaactgga gcagttgtct ccaacacgat ttaactcact ctccagttt caggtactaa	1740
atatgagcca caacaacttc tttcattgg atacgtttcc ttataagtgt ctgaactccc	1800
tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc	1860
attttccaag tagtcttagct ttcttaatc ttactcagaa tgactttgct tgtacttgc	1920
aacaccagag ttcctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac	1980
gaatggaatg tgcaacaccc tcagataagc agggcatgcc tgtgctgagt ttgaatatca	2040
cctgtcagat gaataagacc atcattggtg tgtcggtcct cagtgctgtt gtatgtatcg	2100
ttgttagcgt tctggtctat aagttctatt ttcacctgat gttcttgct ggctgcataa	2160
agtatggtag aggtgaaaac atctatgatg cctttgttat ctactcaagc caggatgagg	2220
actgggtaag gaatgagcta gtaaaagaatt tagaagaagg ggtgcctcca tttcagctct	2280
gccttcacta cagagacttt attcccggtg tggccattgc tgccaaatc atccatgaag	2340
gtttccataa aagccgaaag gtgattgttg tgggtccccca gcacttcatc cagagccgct	2400
ggtgatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta	2460
tcatcttcat tgcctgcag aagggtggaga agaccctgct caggcagcag gtggagctgt	2520
accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggcggcaca	2580
tcttcggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa	2640
cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa	2700
cctcctgagg catttcttgc ccagctgggt caaacacttg ttcaagttaat aagtattaaa	2760
tgctgccaca tgcaggcct tatgctaagg gtgagtaatt ccatggtgca ctatgtatgc	2820
agggctgcta atctcaagga gcttccagtg cagagggaaat aaatgctaga ctaaaataca	2880
gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca	2940
tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc	3000
ttttcctgag tctttgaat ggaaattgta ttatgttata gccatcataa aaccattttg	3060

gtagtttga ctgaactggg tgttcacttt ttccttttg attgaataca atttaaattc 3120  
 tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc catttaagt 3180  
 ctgtctcctt acagaggta aagtctaatg gctaattcct aaggaaacct gattaacaca 3240  
 tgctcacaac catcctggtc attctcgAAC atgttctatt ttttaactaa tcaccctga 3300  
 tatatTTTA ttttatata tccagtttc attttttac gtctgccta taagctaata 3360  
 tcataaataa ggttgtttaa gacgtgctc aaatatccat attaaccact attttcaag 3420  
 gaagtatgga aaagtacact ctgtcacttt gtcaactcgat gtcattccaa agttattgcc 3480  
 tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag gggcactct 3540  
 tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttggctataggc 3600  
 atgaaggaag tgggattacc tcaggaagtc acctttctt gattccagaa acatatgggc 3660  
 tgataaaaccc ggggtgacct catgaaatga gttcagcag atgtttattt tttcagaac 3720  
 aagtgatgtt tgatggacct atgaatctat ttagggagac acagatggct gggatccctc 3780  
 ccctgtaccc ttctcactga caggagaact a 3811

<210> 12  
 <211> 2845  
 <212> DNA  
 <213> Homo sapiens

<400> 12  
 cctctcaccc tttAGCCAG aactgcttg aatacaccaa ttgctgtggg gggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca 120  
 ttcacagggc cactgctgt cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgccgcctggc tggactctg atcccagcca tggccttcct ctcctgcgtg agaccagaaa 240  
 gctgggagcc ctgcgtggag gtgtgaaatc cagacaatttgg aagatgggc atatcagagc 300  
 ctaagccacc tctctacctt aatattgaca gaaacccca tccagagttt agccctggaa 360  
 gcctttctg gactatcaag ttacagaag ctggggctg tggagacaaa tctagcatct 420  
 ctagagaact tccccattgg acatctcaa actttgaaag aacttaatgt ggctcacaat 480  
 cttatccaaat ctttcaaatt acctgagttat ttttctaattc tgaccaatct agagcacttg 540  
 gacctttcca gaaacaagat tcaaagtatt tattgcacag acttgcgggt tctacatcaa 600  
 atgcccctac tcaatctc tttAGACCTG tccctgaacc ctatgaactt tatccaaacca 660  
 ggtgcattta aagaaatttgg gttcataag ctgactttaa gaaataattt tgatagttt 720  
 aatgtaatga aaacttggat tcaaggtctg gctggtttag aagtccatcg tttggttctg 780  
 ggagaatttta gaaatgaagg aaacttggaa aagttgaca aatctgctct agagggcctg 840

tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	900
attgacttat ttaattgttt gacaatgtt tcttcatttt ccctggtag ttgtactatt	960
gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1020
aaatttggac agtttcccac attgaaactc aaatctctca aaaggcttac tttcaattcc	1080
aacaaaggtg ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc	1140
agtagaaatg gtttgagttt caaagggtgc tggtctcaaa gtgattttgg gacaaccagc	1200
ctaaagtatt tagatctgag cttcaatgggt gtttattacca tgagttcaaa cttcttggc	1260
ttagaacaac tagaacatct ggattccag cattccaatt tgaaacaaat gagtgagttt	1320
tcaagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1380
gttgcattca atggcatctt caatggcttgc tccagtcgt aagtcttgaa aatggctggc	1440
aattcttcc aggaaaactt cttccagat atcttcacag agctgagaaa ctgaccttc	1500
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcattaa ctcactctcc	1560
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1620
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaa	1680
aaacaggaac tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac	1740
tttgcttgta cttgtgaaca ccagagtttc ctgcaatggta tcaaggacca gaggcagctc	1800
ttgggttgaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttgggtgtgtc ggtcctcagt	1920
gtgctttagt tatctgttgt agcagttctg gtctataagt tctattttca cctgatgctt	1980
cttgcggct gcataaaagta tggtagaggt gaaaacatct atgatgcctt tggtatctac	2040
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaattttaga agaaggggtg	2100
cctccatttc agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc	2160
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgggt gtcccagcac	2220
ttcatccaga gccgctggtg tatcttgaa tatgagattt ctcagacctg gcagttctg	2280
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2340
cagcaggtgg agctgtaccg cttctcagc aggaacactt acctggagtg ggaggacagt	2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2460
tggaaatccag aaggaacagt gggtagacca tgcaattggc aggaagcaac atctatctga	2520
agaggaaaaaa taaaaacctc ctgaggcatt tcttgccag ctgggtccaa cacttggta	2580
gttaataagt attaaatgct gccacatgtc aggcctttagt ctaagggtga gtaattccat	2640
ggtgacttag atatgcaggg ctgctaatttca caaggagctt ccagtgcaga gggataaaat	2700
gcttagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2760

atgacaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca 2820  
aaaaaaaaaaa aaaaaaaaaaa aaaaaa 2845

<210> 13  
<211> 3767  
<212> DNA  
<213> Homo sapiens

<400> 13  
cctctcaccc tttagcccg aactgcgg aatacaccaa ttgtgtgg gcccgcgag 60  
gaagagaaga caccagtgcc tcagaaactg ctcggcaga cggtgatagc gagccacgca 120  
ttcacaggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
cgccgcgtggc tgggactctg atcccagcca tggccttcct ctccctgcgtg agaccagaaa 240  
gctgggagcc ctgcgtggag acttggccct aaaccacaca gaagagctgg catgaaaccc 300  
agagcttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360  
gctgcgttt tatcacggag gtgtgaaatc cagacaattt aagatgggc atatcagagc 420  
ctaagccacc tctctaccc aatattgaca ggaaacccca tccagagttt agccctggg 480  
gcctttctg gactatcaag tttacagaag ctggcggctg tggagacaaa tctagcatct 540  
ctagagaact tccccattgg acatctaaa actttgaaag aacttaatgt ggctcacaat 600  
cttatccaat ctttcaaatt acctgagttt ttttctaattc tgaccaatct agagcacttg 660  
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcgggt tctacatcaa 720  
atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaacct tatccaacca 780  
ggtcatttta aagaaatttgc gtttcataag ctgactttaa gaaataattt tgatagttt 840  
aatgtaatga aaacttgtat tcaaggctg gctggtttag aagtccatcg tttggttctg 900  
ggagaatttta gaaatgaagg aaacttggaa aagttgaca aatctgcctt agagggcctg 960  
tgcaatttga ccattgaaga attccgatta gcatacttag actactacctt cgatgatatt 1020  
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctggtagt tgtgactatt 1080  
gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt 1140  
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcaattcc 1200  
aacaaagggtg ggaatgcttt ttcaagaagttt gatctaccaa gccttgagtt tctagatctc 1260  
agttagaaatg gcttgagttt caaagggtgc tggatctcaaa gtgattttgg gacaaccagc 1320  
ctaaaggattt tagatctgag cttcaatggt gttattacca tgagttcaaa cttctggc 1380  
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt 1440  
tcagtattcc tatcaactcag aaacctcatt taccttgaca tttctcatac tcacaccaga 1500

gttgcttca atggcatctt caatggcttg tccagtcctcg aagtctgaa aatggctggc	1560
aattttcc agaaaaactt cttccagat atctcacag agctgagaaa cttgacccttc	1620
ctggacctct ctcagtgtca actggagcag ttgtctccaa cagcattaa ctcactctcc	1680
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gttccttat	1740
aagtgtctga actccctcca gggttcttgat tacagtctca atcacataat gacttccaaa	1800
aaacaggaac tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac	1860
tttgcttgta cttgtgaaca ccagagttc ctgcaatgga tcaaggacca gaggcagctc	1920
ttgggttggaa gtgaacgaat ggaatgtgca acacccatcg ataaggcagg catgcctgtg	1980
ctgagtttga atatcacctg tcagatgaat aagaccatca ttgggtgtgc ggtcctcagt	2040
gtgctttag tatctgttgt agcagttctg gtctataagt tctattttca cctgatgctt	2100
cttgctggct gcataaaagta tggttagaggt gaaaacatct atgatgcctt tgttatctac	2160
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaattttaga agaaggggtg	2220
cctccatttc agctctgcct tcactacaga gactttatcc ccgggtgtggc cattgctgcc	2280
aacatcatcc atgaagggtt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2340
ttcatccaga gccgctggtg tatctttgaa tatgagattt ctcagacctg gcagttctg	2400
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2460
cagcaggtgg agctgtaccg ctttcagc aggaacactt acctggagtg ggaggacagt	2520
gtcctggggc ggcacatctt ctggagacga ctcagaaaaag ccctgctgga tggtaaatca	2580
tggaatccag aaggaacagt gggtaacagga tgcaattggc aggaagcaac atctatctga	2640
agaggaaaaaa taaaaacctc ctgaggcatt tottgccccag ctgggtccaa cacttgttca	2700
gttaataagt attaaatgct gccacatgtc aggcctttagt ctaagggtga gtaattccat	2760
ggtgacttag atatgcaggg ctgctaatttca caaggagctt ccagtgcaga gggataaaat	2820
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2880
atgacaaaga aagtcatctt aactcttacc tcatcaagtt gaataaagac agagaaaaca	2940
gaaagagaca ttgttctttt cctgagtctt ttgaatggaa attgtattat gttatagcca	3000
tcataaaacc attttggtag ttttgaactga actgggtgtt cacttttcc ttttgattt	3060
aatacaattt aaattctact tgatgactgc agtcgtcaag gggctcctga tgcaagatgc	3120
cccttcatt ttaagtctgt ctccttacag aggttaaaagt ctgtggcta attcctaagg	3180
aaacctgatt aacacatgtt cacaaccatc ctggtcattt tcgagcatgt tctattttt	3240
aactaatcac ccctgatata ttttatttt tatatatcca gttttcattt ttttacgtct	3300
tgcctataag ctaatatcat aaataagggtt gtttaagacg tgcttcaaattt atccatatta	3360
accactattt ttcaaggaag tatggaaaag tacactctgt cactttgtca ctcgatgtca	3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataattgt	3480
ttaaaggggg cactcttta aacgggaaga aaattccgc ttctggct tatcatggac	3540
aatttggct agagggcagga aggaagtggg atgacctcg gaggtcacct tttttgatt	3600
ccagaaaacat atgggctgat aaaccgggg tgacctcatg aaatgagttg cagcagaagt	3660
ttatTTTTT cagaacaagt gatgttgat ggacctctga atctcttag ggagacacag	3720
atggctggga tccctcccct gtacccttct cactgccagg agaacta	3767

<210> 14  
<211> 3814  
<212> DNA  
<213> Homo sapiens

<400> 14	
cctctcaccc tttagccag aactgcttg aatacaccaa ttgctgtgg gcggctcgag	60
gaagagaaga caccagtgcc tcagaaactg ctgggtcaga cggtgatagc gagccacgca	120
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcctggc tgggactctg atcccagcca tggcttcct ctctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag gtggttccta atattactta tcaatgcatt gagctgaatt	300
tctacaaaat ccccgacaac ctcccccttca accaaagaa cctggacctg agcttaatc	360
ccctgaggca tttaggcagc tatagcttct tcagttccc agaactgcag gtgctggatt	420
tatccaggtg tggaaatccag acaatttgaag atggggcata tcagagcata agccacctct	480
ctaccttaat attgacagga aacccatcc agattttgc cctggagcc ttttctggac	540
tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc	600
ccattggaca tctcaaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt	660
tcaaattacc tgagtatttt tctaattctga ccaatctaga gcacttggac cttccagca	720
acaagattca aagtattttat tgcacagact tgcgggtct acatcaaatg cccctactca	780
atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccaggc gcattaaag	840
aaatttaggt tcataagctg actttttaagaa ataattttga tagtttaat gtaatgaaaa	900
cttgtattca aggtctggct ggtttagaag tccatcgat ggttctggga gaatttagaa	960
atgaaggaaa ctggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgcacca	1020
ttgaagaatt ccgatttagca tacttagact actacccatcgat gatattattt gacttattta	1080
attgtttgac aaatgtttct tcattttccc tggtgagtgt gactattgaa agggtaaaag	1140
acttttctta taatttcgga tggcaacatt tagaatttagt taactgtaaa tttggacagt	1200
ttcccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaaac aaaggtggga	1260

atgcttttc agaagtttatc caacaaagcc tttagtttctt agatctcagt agaaatggct 1320  
tgagttcaa aggttgctgt tctcaaagtgc attttggac aaccaggcta aagtatttag 1380  
atctgagctt caatgggtgtt attaccatga gttcaaactt cttgggctta gaacaactag 1440  
aacatctgga tttccagcat tccaaatttgc aacaaatgag tgagtttca gtattcctat 1500  
cactcagaaa cctcatttac cttgacattt ctctactca caccagagtt gctttcaatg 1560  
gcatttcaa tggcttgc tggcttgc tggcttgc tggcttgc 1620  
aaaacttcc tccagatatac ttcacagagc tgagaaactt gaccttcctg gacctctctc 1680  
agtgtcaact ggagcagttt ttcacaaacat catttaactc actctccagt cttcaggtagc 1740  
taaatatgag ccacaacaac ttctttcat tggatacggtt tccttataag tgtctgaact 1800  
ccctccagggt tcttgattac agtctcaatc acataatgac ttccaaaaaa caggaactac 1860  
agcattttcc aagtagtcta gctttctt aaatctactca gaatgacttt gcttgactt 1920  
gtgaacacca gagtttcctg caatggatca aggaccagag gcagcttgc gtggaaatgg 1980  
aacgaatgga atgtgcaaca cttcagata agcagggcat gcctgtgctg agtttgaata 2040  
tcacctgtca gatgaataag accatcattt gttgtcggt cttcaggtagt cttgttagt 2100  
ctgttgtagc agttctggtc tataagttctt atttcacct gatgcttctt gctggctgca 2160  
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg 2220  
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcagc 2280  
tctgccttca ctacagagac ttatcccgtt gttgtggccat tgctgccaac atcatccatg 2340  
aaggtttcca taaaagccga aagggttattt gttgtgggttccagcacttc atccagagcc 2400  
gctgggttat ctttgaatat gagattgctc agacctggca gtttctgagc agtcgtgctg 2460  
gtatcatctt cattgtcctg cagaagggttgg agaagaccct gctcaggcag caggtggagc 2520  
tgtaccgcct ttcagcagg aacacttacc tggagtggga ggacagtgtc ctggggcgcc 2580  
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag 2640  
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa 2700  
aaaccccttg aggcatatttct tgcccagctg ggtccaaacac ttgttcagtt aataagtatt 2760  
aaatgtgcc acatgtcagg ctttatgctt aggggtgagta attccatggt gcactagata 2820  
tgccaggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat 2880  
acagagtctt ccagggtggc atttcaacca actcagtcaa ggaacccatg acaaagaaag 2940  
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattt 3000  
ttctttccct gagtcttttgc aatggaaattt gtattatgtt atagccatca taaaaccatt 3060  
ttggtagttt tgactgaact ggggtttcac tttttccctt ttgattgaat acaatttaaa 3120  
ttctacttgc tgactgcgtt cgtcaagggg cttcctgtatgc aagatgcccc ttccattttta 3180

agtctgtctc	tttacagagg	ttaaaagtcta	gtggctaatt	cctaaggaaa	cctgattaac	3240
acatgctcac	aaccatcctg	gtcattctcg	agcatgttct	attttttaac	taatcacccc	3300
tgatataattt	ttatTTTtat	atatccagtt	ttcatttttt	tacgtcttc	ctataagcta	3360
atatcataaa	taaggTTgtt	taagacgtgc	ttcaaataatc	catattaacc	actatTTtc	3420
aaggaagtat	ggaaaagtac	actctgtcac	tttgtcaactc	gatgtcattc	caaagttatt	3480
gcctactaag	taatgactgt	catgaaagca	gcattgaaat	aatttgttta	aagggggcac	3540
tcttttaaac	gggaagaaaa	tttccgcttc	ctggctttat	catggacaat	ttgggctaga	3600
ggcaggaagg	aagtgggatg	acctcaggag	gtcacctttt	cttgattcca	gaaacatatg	3660
ggctgataaa	cccgGGGTGA	cctcatgaaa	tgagttgcag	cagaagtta	ttttttcag	3720
aacaagtgtat	gtttgatgga	cctctgaatc	tcttaggga	gacacagatg	gctgggatcc	3780
ctccccctgtat	cccttctcac	tgcaggaga	acta			3814

<210> 15  
<211> 3934  
<212> DNA  
<213> Homo spaiens

<400> 15						
cctctcaccc	tttagccag	aactgctttg	aatacaccaa	ttgctgtggg	gcggctcgag	60
gaagagaaga	caccagtgcc	tcagaaactg	ctcggtcaga	cggtgatagc	gagccacgca	120
ttcacagggc	cactgctgct	cacagaagca	gtgaggatga	tgccaggatg	atgtctgcct	180
cgcgcctggc	tgggactctg	atcccagcca	tggccttcct	ctcctgcgtg	agaccagaaa	240
gctgggagcc	ctgcgtggag	acttggccct	aaaccacaca	gaagagctgg	catgaaaccc	300
agagctttca	gactccggag	cctcagccct	tcaccccgat	tccattgctt	cttgctaaat	360
gctgccgtt	tatcacggag	gtggttccta	atattactta	tcaatgcatg	gagctgaatt	420
tctacaaaat	ccccgacaac	ctccccttct	caaccaagaa	cctggacctg	agcttaatc	480
ccctgaggca	tttaggcagc	tatagcttct	tcagttccc	agaactgcag	gtgctggatt	540
tatccaggtg	tgaaatccag	acaattgaag	atggggcata	tcagagccta	agccacctct	600
ctaccttaat	attgacagga	aaccccattcc	agagtttagc	cctgggagcc	ttttctggac	660
tatcaagttt	acagaagctg	gtggctgtgg	agacaaatct	agcatctcta	gagaacttcc	720
ccattggaca	tctcaaaaact	ttgaaagaac	ttaatgtggc	tcacaatctt	atccaatctt	780
tcaaattacc	tgagtatttt	tctaatctga	ccaatctaga	gcacttggac	ctttccagca	840
acaagattca	aagtatttt	tgcacagact	tgccgggttct	acatcaaatg	ccccctactca	900
atctctcttt	agacctgtcc	ctgaacccta	tgaactttat	ccaaccaggt	gcatttaaag	960

aaatttaggct tcataagctg actttaagaa ataattttga tagtttaaat gtaatgaaaa	1020
cttgttattca aggtctggct ggtttagaaag tccatcgaaa ggttctggaa gaatttagaa	1080
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca	1140
ttgaagaatt ccgatttagca tacttagact actacacctga tgatattatt gacttattta	1200
attgtttgac aaatgtttct tcattttccc tggtagtgt gactattgaa aggtaaaag	1260
acttttccta taatttcgga tggcaacatt tagaatttagt taactgtaaa tttggacagt	1320
ttccccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggaa	1380
atgctttttc agaagttgat ctaccaagcc tttagtttct agatctcagt agaaatggct	1440
tgagtttcaa aggttgcgt tctcaaagtg attttggac aaccagccta aagtatttag	1500
atctgagctt caatgggtttt attaccatga gtcacaaactt cttggctta gaacaactag	1560
aacatctgga tttccagcat tccaaatttga aacaaatgag tgagtttca gtattcctat	1620
cactcagaaaa cctcatttac cttgacattt ctcatactca caccagagtt gctttcaatg	1680
gcacatctcaa tggcttgcgtt agtctcgaag tcttggaaat ggctggcaat tctttccagg	1740
aaaacttcct tccagatatc ttcacagagc tgagaaactt gacccctctg gacccctctc	1800
agtgtcaact ggagcagttt tctccaaacag catttaactc actctccagt cttcaggtac	1860
taaatatgag ccacaacaac ttctttcat tggatacgat tcttataag tgtctgaact	1920
ccctccaggt tcttgattac agtctcaatc acataatgac ttccaaaaaaaa caggaactac	1980
agcattttcc aagtagtcta gctttctaa atcttactca gaatgacttt gcttgcattt	2040
gtgaacacca gagtttctg caatggatca aggaccagag gcagctttg gtggaaagttt	2100
aacgaatgga atgtgcacaaca cttcagata agcagggcat gcctgtgtc agtttgaata	2160
tcacctgtca gatgaataag accatcattt gtgtgtcggt ctcagtgatc ctgttagtat	2220
ctgtgttagc agttctggtc tataagttct atttcacct gatgcttctt gctggctgca	2280
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg	2340
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcago	2400
tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg	2460
aagggttcca taaaagccga aaggtgattt ttgtgggtgc ccagcacttc atccagagcc	2520
gctgggttat ctttgaatat gagattgctc agacctggca gtttctgagc agtcgtgtc	2580
gtatcatctt cattgtcctg cagaaggtgg agaagaccct gtcaggcag caggtggagc	2640
tgtaccgcct tctcagcagg aacacttacc tggagtggaa ggacagtgtc ctggggcggc	2700
acatcttctg gagacgactc agaaaaagccc tgctggatgg taaatcatgg aatccagaag	2760
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataaa	2820
aaacccctctg aggcattttct tgcccagctg ggtccaaacac ttgttcagtt aataagtatt	2880

aatgctgcc acatgtcagg ccttatgcta agggtgagta attccatgg gcactagata	2940
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat	3000
acagagtctt ccaggtggc atttcaacca actcagtcaa ggaaccatg acaaagaaag	3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg	3120
ttctttcct gagtctttt aatggaaatt gtattatgtt atagccatca taaaaccatt	3180
ttggtagtt tgactgaact ggggttcac ttttcctt ttgattgaat acaattaaa	3240
ttctacttga tgactgcagt cgtcaagggg ctccgtatgc aagatgcccc ttccatTTA	3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac	3360
acatgctcac aaccatcctg gtcattctcg agcatgttct atttttAAC taatCACCCC	3420
tgatatatTT ttatTTTAT atatccagtt ttcatTTTT tacgtcttgc ctataagcta	3480
atATCATAAA taaggTTGTT taagacgtgc ttCAAATATC catATTAACC actATTTTC	3540
aaggaagtat gggAAAGTAC actctgtcac tttgtcactc gatgtcatTC caaAGTTATT	3600
gcctactaag taatgactgt catgaaAGCA gcattGAAT aATTGTTA aAGGGGGCAC	3660
tctttAAAC gggAAAGAAA tttccgcttc ctggTCTTAT catggacaAT ttgggCTAGA	3720
ggcaggaagg aagtgggatg acctcaggag gtcacCTTT cttgattCCA gaaACATATG	3780
ggctgataAA cccggggTGA CCTCATGAAA tgagttgcag cagaAGTTA tttttTCAG	3840
aacaagtGAT gtttgatGGA CCTCTGAATC TCTTAGGGA gacacAGATG gctgggatCC	3900
ctcccctgtA ccTTCTCAC tgccaggAGA actA	3934

&lt;210&gt; 16

&lt;211&gt; 839

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Met	Met	Ser	Ala	Ser	Arg	Leu	Ala	Gly	Thr	Leu	Ile	Pro	Ala	Met	Ala
1						5			10					15	

Phe	Leu	Ser	Cys	Val	Arg	Pro	Glu	Ser	Trp	Glu	Pro	Cys	Val	Glu	Val
									20	25			30		

Val	Pro	Asn	Ile	Thr	Tyr	Gln	Cys	Met	Glu	Leu	Asn	Phe	Tyr	Lys	Ile
								35	40			45			

Pro	Asp	Asn	Leu	Pro	Phe	Ser	Thr	Lys	Asn	Leu	Asp	Leu	Ser	Phe	Asn
								50	55		60				

Pro	Leu	Arg	His	Leu	Gly	Ser	Tyr	Ser	Phe	Phe	Ser	Phe	Pro	Glu	Leu
									65	70		75		80	

Gln	Val	Leu	Asp	Leu	Ser	Arg	Cys	Glu	Ile	Gln	Thr	Ile	Glu	Asp	Gly
								85	90		95				

Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn  
100 105 110

Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu  
115 120 125

Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe  
130 135 140

Pro Ile Gly His Ile Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn  
145 150 155 160

Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn  
165 170 175

Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys  
180 185 190

Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu  
195 200 205

Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys  
210 215 220

Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu  
225 230 235 240

Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His  
245 250 255

Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe  
260 265 270

Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe  
275 280 285

Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe  
290 295 300

Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile  
305 310 315 320

Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu  
325 330 335

Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser  
340 345 350

Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser  
355 360 365

Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly  
370 375 380

Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser  
385 390 395 400

Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser  
405 410 415

Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

420                    425                    430  
Asn Leu Lys Gln Met Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn  
435                    440                    445

Leu Ile Tyr Leu Asp Ile Ser His Thr His Thr Arg Val Ala Phe Asn  
450                    455                    460

Gly Ile Phe Asn Gly Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly  
465                    470                    475                    480

Asn Ser Phe Gln Glu Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg  
485                    490                    495

Asn Leu Thr Phe Leu Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser  
500                    505                    510

Pro Thr Ala Phe Asn Ser Leu Ser Ser Leu Gln Val Leu Asn Met Ser  
515                    520                    525

His Asn Asn Phe Phe Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn  
530                    535                    540

Ser Leu Gln Val Leu Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys  
545                    550                    555                    560

Lys Gln Glu Leu Gln His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu  
565                    570                    575

Thr Gln Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln  
580                    585                    590

Trp Ile Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu  
595                    600                    605

Cys Ala Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn  
610                    615                    620

Ile Thr Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser  
625                    630                    635                    640

Val Leu Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe  
645                    650                    655

His Leu Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn  
660                    665                    670

Ile Tyr Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val  
675                    680                    685

Arg Asn Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln  
690                    695                    700

Leu Cys Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala  
705                    710                    715                    720

Asn Ile Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val  
725                    730                    735

Val Ser Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu  
740                    745                    750

Ile Ala Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe

755	760	765
Ile Val Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu		
770	775	780
Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser		
785	790	795
Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu		
805	810	815
Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn		
820	825	830
Trp Gln Glu Ala Thr Ser Ile		
835		

<210> 17  
<211> 782  
<212> PRT  
<213> Homo sapiens

<400> 17

Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg		
1	5	10
		15

Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu		
20	25	30

Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser		
35	40	45

Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala		
50	55	60

Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn		
65	70	75
		80

Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys		
85	90	95

Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu		
100	105	110

Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn		
115	120	125

Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met		
130	135	140

Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe		
145	150	155
		160

Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu		
165	170	175

Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly		
180	185	190

Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn		
195	200	205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys  
210 215 220

Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu  
225 230 235 240

Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe  
245 250 255

Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn  
260 265 270

Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe  
275 280 285

Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn  
290 295 300

Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe  
305 310 315 320

Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln  
325 330 335

Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn  
340 345 350

Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu  
355 360 365

His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser  
370 375 380

Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr  
385 390 395 400

His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu  
405 410 415

Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro  
420 425 430

Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln  
435 440 445

Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser  
450 455 460

Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr  
465 470 475 480

Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu  
485 490 495

Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser  
500 505 510

Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys  
515 520 525

Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530                        535                        540  
 Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly  
 545                        550                        555                        560  
  
 Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile  
 565                        570                        575  
  
 Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val  
 580                        585                        590  
  
 Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile  
 595                        600                        605  
  
 Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser  
 610                        615                        620  
  
 Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu  
 625                        630                        635                        640  
  
 Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile  
 645                        650                        655  
  
 Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys  
 660                        665                        670  
  
 Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg  
 675                        680                        685  
  
 Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser  
 690                        695                        700  
  
 Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr  
 705                        710                        715                        720  
  
 Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr  
 725                        730                        735  
  
 Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg  
 740                        745                        750  
  
 Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly  
 755                        760                        765  
  
 Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 770                        775                        780

<210> 18  
 <211> 799  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr  
 1                        5                            10                        15  
  
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr  
 20                        25                        30  
  
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys  
 35                        40                        45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu  
50 55 60

Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly  
65 70 75 80

Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr  
85 90 95

Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu  
100 105 110

Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro  
115 120 125

Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser  
130 135 140

Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln  
145 150 155 160

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
165 170 175

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
180 185 190

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
195 200 205

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
210 215 220

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
225 230 235 240

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
245 250 255

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
260 265 270

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
290 295 300

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
305 310 315 320

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
325 330 335

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
340 345 350

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
355 360 365

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370                   375                   380  
Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe  
385                   390                   395                   400

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
405                   410                   415

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
420                   425                   430

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
435                   440                   445

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
450                   455                   460

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
465                   470                   475                   480

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
485                   490                   495

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
500                   505                   510

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
515                   520                   525

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
530                   535                   540

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
545                   550                   555                   560

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
565                   570                   575

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
580                   585                   590

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
595                   600                   605

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
610                   615                   620

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
625                   630                   635                   640

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
645                   650                   655

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
660                   665                   670

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
675                   680                   685

Lys Ser Arg Lys Val Ile Val Val Ser Gln His Phe Ile Gln Ser  
690                   695                   700

Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu

705	710	715	720
Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys			
725	730	735	

Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn			
740	745	750	

Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp			
755	760	765	

Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu			
770	775	780	

Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile			
785	790	795	

<210> 19

<211> 639

<212> PRT

<213> Homo sapiens

<400> 19

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn			
1	5	10	15

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr			
20	25	30	

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln			
35	40	45	

Gly Ile Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg			
50	55	60	

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu			
65	70	75	80

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr			
85	90	95	

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser			
100	105	110	

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr			
115	120	125	

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln			
130	135	140	

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser			
145	150	155	160

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu			
165	170	175	

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser			
180	185	190	

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe			
195	200	205	

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu  
210 215 220

Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met ,Ser Glu Phe  
225 230 235 240

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
245 250 255

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
260 265 270

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
275 280 285

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
290 295 300

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
305 310 315 320

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
325 330 335

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
340 345 350

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
355 360 365

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
370 375 380

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
385 390 395 400

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
405 410 415

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
420 425 430

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
435 440 445

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
450 455 460

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
465 470 475 480

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
485 490 495

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
500 505 510

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
515 520 525

Lys Ser Arg Lys Val Ile Val Val Ser Gln His Phe Ile Gln Ser

530	535	540
Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu		
545	550	555

Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys	565	570	575
---	-----	-----	-----

Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn	580	585	590
---	-----	-----	-----

Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp	595	600	605
---	-----	-----	-----

Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu	610	615	620
---	-----	-----	-----

Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile	625	630	635
---	-----	-----	-----

<210> 20

<211> 3866

<212> DNA

<213> murine

<400> 20

ctggttgcag aaaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg	60
gcactgttct ttcctgcct gacaccagga agcttgaatc cctgcataaga ggttagttct	120
aatattacct accaatgcat ggatcagaaaa ctcagcaaag tcccgtatga cattccttct	180
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc	240
tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa	300
gacaaggcat ggcattggctt acaccacctc tcaaacttga tactgacagg aaaccctatc	360
cagagttttt ccccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg	420
gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaaa	480
ctcaatgtgg ctcacaattt tatacattcc tgtaagttac ctgcataattt ttccaatctg	540
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac	600
ttacagtttc tacgtaaaaa tccacaagtc aatctcttt tagacatgtc tttgaaccca	660
attgacttca ttcaagacca agccttcag ggaattaagc tccatgaact gactctaaga	720
ggtaattttt atagctaaa tataatgaaa acttgcttc aaaacctggc tggttcacac	780
gtccatcggt tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc	840
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat	900
gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg	960
gcaggtgtat ctataaaata tctagaagat gttcctaaac atttcaaatg gcaatcctta	1020
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt	1080

ttgactttaa ctagaacaa agggtctatc agttttaaaa aagtggccct accaagtctc	1140
agctatctag atcttagtag aaatgcactg agcttagtg gttgctgttc ttattctgat	1200
ttggacaacaa acagcctgag acacttagac ctcagcttca atgggccat cattatgagt	1260
gccaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa	1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tacttacct tgacatctct	1380
tatactaaca ccaaaattga ctgcgttgtt atatttcttg gcttgaccag tctcaacaca	1440
ttaaaaatgg ctggcaattc tttcaaagac aacaccctt caaatgtctt tgcaaacaca	1500
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatatc ttgggggta	1560
tttgacaccc tccatagact tcaatttatta aatatgagtc acaacaatct attgttttg	1620
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc	1680
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt	1740
actaacaatt ctgttgcttg tatatgtgaa catcagaaat tcctgcagt ggtcaaggaa	1800
cagaagcagt tcttggtgaa tgttgacaa atgacatgtg caacacctgt agagatgaat	1860
acctcccttag ttttgattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtgg tcagtgtgat ttttgatcc actgttagcat ttctgatata ccacttctat	1980
tttccacctga tacttattgc tggctgtaaa aagtacagca gaggagaag catctatgat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgccccg cttcacctc tgccttcaact acagagactt tattcctggt	2160
gtagccatttgc tgccaaacat catccaggaa ggcttccaca agagccggaa gtttattgt	2220
gtatgtcta gacactttat tcagagccgt tgggttatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaagggttag	2340
aagtccctgc tgaggcagca ggtggatttgc tatcgcttc ttgcagaaa cacctacctg	2400
gaatgggagg acaatccctt ggggaggcac atcttcttggaa gaagacttaa aaatgcccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctgggccc taaacccagt ctgtttgcaa ttaataaaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gaccttaccg ggcagaagga agtagcactg acacccctt ttccagggt	2700
atgaattacc taactcgaaa aaagaaacat aatccagaat cttaacctt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcactg ggccttttga	2820
atacaagcca tgcgtatgttc tttgtttcag ttgtttttaga agagtattga tagttcaac	2880
tgaactgaac gtttcttac ttccctttt ttctactgaa tgcaatatta aatagcttt	2940
tttgagaggt cttcattcca attcatctt ccattttatg tcattttctt ttcttttttg	3000

ttttatct~~a~~ attctataag aaatatgatt gatacacgct cacagatgc ctggccaatc 3060  
 ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120  
 ttatcgaaaa tcatacccttg actataaact aatatacataa ataagatgt tacaggtatg 3180  
 ctaagaaggc ccatatttga ctataatttt ttaagaaaagt atataaaata tactttgtca 3240  
 tattgtcaact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtcagt 3300  
 gttaaaaata atttgggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt 3360  
 gcagggacacaa aatcatgat ttcatacattt attcttgatt tttccggaaag ttcacatagc 3420  
 tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga 3480  
 acttgagaac attttggggaa ggaagaaaagg tctaacatec ttttccttca tcattctcat 3540  
 ttctggacat gccttgttag atggatcaat gttgggagta cacatttctg ctttcacctt 3600  
 atttcagtca gcatgaacac tgaatataata atgtcatttc acagtgtgtg tgtgttgtgt 3660  
 atgtacatat atgaacacctgt acatgtgtt aagtttaaag agaaaatagt gtacagagca 3720  
 ggtgtatatt tgtgataggg cttaaatag ttgagctaat tcagaaaagt atggaggttt 3780  
 ctggtaaac caaacaaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa  
3866

<210> 21  
 <211> 2520  
 <212> DNA  
 <213> murine

<400> 21  
 atgatgcctc cctggctcct ggctaggact ctgatcatgg cactgttctt ctcctgcctg 60  
 acaccaggaa gttgaatcc ctgcataagag gtagttccta atattaccta ccaatgcatg 120  
 gatcagaaac tcagcaaagt ccctgtatgac attccttctt caaccaagaa catagatctg 180  
 agcttcaacc cttgaagat cttaaaaagc tatacattctt ccaattttc agaacttcag 240  
 tggctggatt tatccaggtg tgaaattgaa acaattgaag acaaggcatg gcatggctt 300  
 caccacctct caaacttgat actgacagga aaccctatcc agagttttc cccaggaagt 360  
 ttctctggac taacaagttt agagaatctg gtggctgtgg agacaaaatt ggcctctcta 420  
 gaaagttcc ctattggaca gttataacc tttaaagaaac tcaatgtggc tcacaatttt 480  
 atacattcct gtaagttacc tgcataatttt tccaaatctga cgaacctagt acatgtggat 540  
 ctttcttata actatattca aactattact gtcaacgact tacagttct acgtaaaaat 600  
 ccacaagtca atctctcttt agacatatct ttgaacccaa ttgacttcat tcaagaccaa 660  
 gccttcagg gaattaagct ccatgaactg actctaagag gtaattttaa tagctcaaat 720

ataataaaa cttgccttca aaacctggct ggtttacaca tccatcggtt gatctggga	780
gaatttaaag atgaaaggaa tctggaaatt tttgaaccct ctatcatgga aggactatgt	840
gatgtgacca ttgatgagtt caggttaaca tatacaaatg attttcaga tgatattgtt	900
aagttccatt gcttggcga tgtttctgca atgtctctgg caggtgtatc tataaaatat	960
ctagaagatg ttcctaaaca tttcaaattgg caatccttat caatcattag atgtcaactt	1020
aagcagtttc caactctgga tctaccctt cttaaaagtt tgacttaac tatgaacaaa	1080
gggtctatca gtttaaaaaa agtggcccta ccaagtctca gctatctaga tcttagtaga	1140
aatgeactga gctttagtgg ttgctgttct tattctgatt tgggaacaaa cagcctgaga	1200
cacttagacc tcagcttcaa tgggccatc attatgagtg ccaatttcat gggcttagaa	1260
gagctgcagc acctggattt tcagcactt actttaaaaa gggtcacaga attctcagcg	1320
ttcttatccc ttgaaaagct actttacctt gacatcttctt atactaacac caaaattgac	1380
ttcgatgta tatttcttgg cttgaccagt ctcaacacat taaaaatggc tggcaattct	1440
ttcaaaagaca acaccctttc aaatgtctt gcaaacacaa caaacttgac attcctggat	1500
ctttctaaat gtcaatttgg acaaataatct tggggggat ttgacaccctt ccataagact	1560
caattattaa atatgagtca caacaatcta ttgttttgg attcatcccc ttataaccag	1620
ctgtattccc tcagcactt tgattgcagt ttcaatcgca tagagacatc taaaggaata	1680
ctgcaacatt ttccaaagag tctagccttc ttcaatctt ctaacaattt tggcttgt	1740
atatgtaac atcagaaatt cctgcagtgg gtcaaggacc agaaggcagtt cttggtaat	1800
gttgaacaaa tgacatgtgc aacacctgta gagatgaata cttccttagt gttggatttt	1860
aataattcta cctgttatat gtacaagaca atcatcagtg tgtcagtggt cagtgtgatt	1920
gtggtatcca ctgtagcatt tctgatatac cacttctatt ttcacctgat acttattgt	1980
ggctgtaaaa agtacagcag aggagaaggc atctatgatg catttgcgtt ctactcgagt	2040
cagaatgagg actgggtgag aaatgagctg gtaaagaatt tagaagaagg agtccccgc	2100
ttcacctct gccttacta cagagacttt attcctggtg tagccattgc tgccaatatc	2160
atccaggaag gcttccacaa gagccgaaag gttattgtgg tagtgcctag acactttatt	2220
cagagccgtt ggtgtatctt tgaatatgag attgctaaa catggcagtt tctgagcagc	2280
cactctggca tcatcttcat tgccttgag aagggtgaga agtccctgct gaggcagcag	2340
gtgaaattgt atcgcccttct tagcagaaac acctacctgg aatgggagga caatcctctg	2400
gggaggcaca tcttctggag aagacttaaa aatgccctat tggatggaaa agcctcgaat	2460
cctgagcaaa cagcagagga agaacaagaa acggcaactt ggacctgagg agaaccgcgg	2520

<212> DNA  
<213> murine

<400> 22  
ctgggttcag aaaatgccag gatgatgcct ccctggctcc tggcttaggac tctgatcatg 60  
gcactgttct ttcctgcct gacaccagga agottgaatc cctgcataaga ggttagttct 120  
aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct 180  
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagctc 240  
tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa 300  
gacaaggcat ggcatggctt acaccacctc tcaaacttga tactgacagg aaaccctatc 360  
cagagttttt ccccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa 480  
ctcaatgtgg ctcacaattt tatacattcc tgtaagttac ctgcatattt ttccaatctg 540  
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac 600  
ttacagtttc tacgtgaaaa tccacaagtc aatctctttagacatgtc tttgaaccca 660  
attgacttca ttcaagacca agccttcag ggaattaagc tccatgaact gactctaaga 720  
ggtaattttt atagctcaaa tataatgaaa acttgccttc aaaacctggc tggtttacac 780  
gtccatcggt tgatctggg agaattttaa gatgaaagga atctggaaat ttttgaaccc 840  
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat 900  
gattttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg 960  
gcaggtgtat ctataaaata tctagaagat gttcctaaac atttcaaatg gcaatcctta 1020  
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt 1080  
ttgactttaa ctatgaacaa agggtctatc agttttaaaa aagtggccct accaagtctc 1140  
agctatctag atcttagtag aaatgcactg agotttagtg gttgctgttc ttattctgat 1200  
ttggaaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt 1260  
gccaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa 1320  
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct 1380  
tatactaaca cccaaattga cttcgatggt atattttttg gcttgaccag tctcaacaca 1440  
ttaaaaatgg ctggcaattc tttcaaagac aacacccttt caaatgtctt tgcaaacaca 1500  
acaaacttga cattcctgga tctttctaaa tgtaattgg aacaaatatac ttggggggta 1560  
tttgacacccc tccatagact tcaatttata aatatgagtc acaacaatct attgttttg 1620  
gattcatccc attataacca gctgttattcc ctcagcactc ttgattgcag tttcaatcgc 1680  
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt 1740

actaacaatt ctgttgcttg tatatgtgaa catcagaaaat tcctgcagt ggtcaaggaa	1800
cagaaggcagt tcttgggtgaa tggtgaacaa atgacatgtg caaacacctgt agagatgaat	1860
accccttag tggtggattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtgg tcagtgtgat tgtggtatcc actgttagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgtat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgccccg ctttcacetc tgccctcact acagagactt tattcctgg	2160
gtagccattg ctgccaacat catccaggaa gggttccaca agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tggtgtatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcaag ccgcctggc atcatcttca ttgtccctga gaagggttag	2340
aagtccctgc tgaggcagca ggtggaaattt tattgccttc tttagcagaaa cacctacctg	2400
gaatgggagg acaatcctct ggggaggcac atcttctgga gaagacttaa aaatgcccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaaa ctctgggccc taaacccagt ctgttgcaa ttaataaaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gacccattccg ggcagaagga agtagcactg acacccttc ttccagggg	2700
atgaattacc taactcgaaa aaagaaacat aatccagaat ctttaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcaactg ggccttttga	2820
atacaagcca tgtcatgttc tgtgtttcag ttgcctttaga agagtattga tagttcaac	2880
tgaactgaac ggtttcttac ttccctttt ttctactgaa tgcaatatta aatagcttt	2940
tttgagaggt ctccattcca atttcatctt ccattttatg tcattttctt ttctttttt	3000
tttttatcta attctataag aaatatgatt gatacacgct cacagatgc ctggccaatc	3060
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag	3120
ttatcgttt tcatgcctt actataaact aatatcataa ataagattgt tacaggtatg	3180
ctaagaaggc ccataatttga ctataatttt ttaagaaagt atataaaata tactttgtca	3240
tattgtcaact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtca	3300
gtaaaaata atttgggtga tagaaatatt tttaatcagg agggaaaagt ggagaggggt	3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt ttccggaaag ttcacatgc	3420
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga	3480
acttgagaac attttgggaa ggaagaaagg tctaacatcc ttcccttca tcattctcat	3540
ttctggacat gccttgtgag atggatcaat gttggagta cacatttctg ctttcacctt	3600
atttcagtca gcatgaacac tgaatataata atgtcatttc acagtgtgtg tttgtgtgt	3660

atgtacatat atgaacctgt acatgtgtt aagttaaag agaaaatagt gtacagagca 3720  
 ggttatatt tgtgataggg ctttaatag ttgagcta atcagaaaatgt atggaggttt 3780  
 cttgtaaac caaacaaaaa gtagaatcat tacaagatct aacaataaaa atttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 23  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1 5 10 15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30

Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45

Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60

Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80

Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95

Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110

Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125

Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140

Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160

Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175

Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190

Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205

Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220

Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg  
245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys  
340 345 350

Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
355 360 365

Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
370 375 380

Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
385 390 395 400

His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
405 410 415

Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
420 425 430

Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
435 440 445

Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
450 455 460

Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
465 470 475 480

Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
485 490 495

Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
500 505 510

Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
515 520 525

Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
530 535 540

Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
545 550 555 560

Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

Ser	Val	Ala	Cys	Ile	Cys	Glu	His	Gln	Lys	Phe	Leu	Gln	Trp	Val	Lys
565						570						575			
580						585						590			
Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr															
595						600						605			
Pro	Val	Glu	Met	Asn	Thr	Ser	Leu	Val	Leu	Asp	Phe	Asn	Asn	Ser	Thr
610						615						620			
Cys	Tyr	Met	Tyr	Lys	Thr	Ile	Ile	Ser	Val	Ser	Val	Val	Ser	Val	Ile
625						630						635			640
Val	Val	Ser	Thr	Val	Ala	Phe	Leu	Ile	Tyr	His	Phe	Tyr	Phe	His	Leu
645						650						655			
Ile	Leu	Ile	Ala	Gly	Cys	Lys	Tyr	Ser	Arg	Gly	Glu	Ser	Ile	Tyr	
660						665						670			
Asp	Ala	Phe	Val	Ile	Tyr	Ser	Ser	Gln	Asn	Glu	Asp	Trp	Val	Arg	Asn
675						680						685			
Glu	Leu	Val	Lys	Asn	Leu	Glu	Glu	Gly	Val	Pro	Arg	Phe	His	Leu	Cys
690						695						700			
Leu	His	Tyr	Arg	Asp	Phe	Ile	Pro	Gly	Val	Ala	Ile	Ala	Ala	Asn	Ile
705						710						715			720
Ile	Gln	Glu	Gly	Phe	His	Lys	Ser	Arg	Lys	Val	Ile	Val	Val	Val	Ser
725						730						735			
Arg	His	Phe	Ile	Gln	Ser	Arg	Trp	Cys	Ile	Phe	Glu	Tyr	Glu	Ile	Ala
740						745						750			
Gln	Thr	Trp	Gln	Phe	Leu	Ser	Ser	Arg	Ser	Gly	Ile	Ile	Phe	Ile	Val
755						760						765			
Leu	Glu	Lys	Val	Glu	Lys	Ser	Leu	Leu	Arg	Gln	Gln	Val	Glu	Leu	Tyr
770						775						780			
Arg	Leu	Leu	Ser	Arg	Asn	Thr	Tyr	Leu	Glu	Trp	Glu	Asp	Asn	Pro	Leu
785						790						795			800
Gly	Arg	His	Ile	Phe	Trp	Arg	Arg	Leu	Lys	Asn	Ala	Leu	Leu	Asp	Gly
805						810						815			
Lys	Ala	Ser	Asn	Pro	Glu	Gln	Thr	Ala	Glu	Glu	Glu	Gln	Glu	Thr	Ala
820						825						830			
Thr	Trp	Thr													
		835													

<210> 24  
<211> 835  
<212> PRT  
<213> murine

<400> 24

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
1 5 10 15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
20 25 30

Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
35 40 45

Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
50 55 60

Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
65 70 75 80

Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
85 90 95

Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
100 105 110

Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
115 120 125

Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
130 135 140

Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
145 150 155 160

Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
165 170 175

Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
180 185 190

Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
195 200 205

Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
210 215 220

Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
225 230 235 240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg  
245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

340	345	350
Ser Leu Thr Leu Thr Met Asn Lys	Gly Ser Ile Ser Phe Lys Lys Val	
355	360	365
Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser		
370	375	380
Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg		
385	390	400
His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe		
405	410	415
Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu		
420	425	430
Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu		
435	440	445
Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile		
450	455	460
Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser		
465	470	475
Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu		
485	490	495
Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly		
500	505	510
Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn		
515	520	525
Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu		
530	535	540
Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile		
545	550	555
Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn		
565	570	575
Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys		
580	585	590
Asp Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr		
595	600	605
Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr		
610	615	620
Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile		
625	630	635
Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu		
645	650	655
Ile Leu Ile Ala Gly Cys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr		
660	665	670
Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn		

675                    680                    685  
 Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys  
 690                    695                    700  
  
 Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile  
 705                    710                    715                    720  
  
 Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser  
 725                    730                    735  
  
 Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala  
 740                    745                    750  
  
 Gln Thr Trp Gln Phe Leu Ser Ser His Ser Gly Ile Ile Phe Ile Val  
 755                    760                    765  
  
 Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr  
 770                    775                    780  
  
 Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu  
 785                    790                    795                    800  
  
 Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly  
 805                    810                    815  
  
 Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala  
 820                    825                    830  
  
 Thr Trp Thr  
 835

<210> 25  
 <211> 3431  
 <212> DNA  
 <213> Homo sapiens

<400> 25  
 ggcttatagg gctcgagcgg ccgccccggc aggtatagaa ttcagcggcc gctgaattct        60  
 agggtttca ggagccccgag cgagggcgcc gctttgcgt ccgggaggag ccaaccgtgg        120  
 cgcaggcggc gcgggggaggc gtcccagagt ctcactctgc cgcccaggct ggactgcagt        180  
 gacacaatct cggctgactg caaccactgc ctccagggtt caagcgattc tcttgctca        240  
 gcctcccaag tagctggat tacagattga tttcatgtt cctggacta ctacaagatt        300  
 catactcctg atgctactga caacgtggct totccacagt caccaaacca gggatgctat        360  
 actggacttc cctactctca tctgctccag cccccctgacc ttatagttgc ccagctttcc        420  
 tggcaattga ctttgcctat caatacacag gathtagcat ccagggaaaga tgtcggagcc        480  
 tcagatgtta attttctaatt tgagaatgtt ggcgctgtcc gaacctggag acagaaaaaac        540  
 aaaaagtccct ttctcctgat tcaccaaaaa ataaaaatact gactaccatc actgtgatga        600  
 gattcctata gtctcaggaa ctgaagtctt taaacaacca gggaccctct gccccttagaa        660  
 taagaacata ctagaagtcc cttctgctag gacaacgagg atcatggag accacctgga        720

ccttcctccta ggagtggtgc tcatggccgg tcctgtgtt ggaattccctt cctgctcctt	780
tgatgccga atagcctttt atcgtttctg caacctcacc caggtccccca aggtctcaa	840
caccactgag aggctcctgc tgagcttcaa ctatatcagg acagtcactg cttcatcctt	900
ccccttctg gaacagctgc agctgctgga gctcgggagc cagtatacc ccttgactat	960
tgacaaggag gccttcagaa acctgccaa ccttagaattt ttggacctgg gaagtagtaa	1020
gatatacttc ttgcattccag atgctttca gggactgttc catctgtttg aacttagact	1080
gtatttctgt ggtctctctg atgctgtattt gaaagatggt tatttcagaa atttaaaggc	1140
tttaactcgc ttggatctat ccaaaaatca gattcgtac ctttacctt atccttcatt	1200
tgggaagttg aattccttaa agtccataga ttttcctcc aaccaaataat tccttgatg	1260
tgaacatgag ctcgagcccc tacaaggaa aacgctctcc ttttttagcc tcgcagctaa	1320
tagcttgat agcagagtct cagtggactg gggaaaatgt atgaacccat tcagaaaacat	1380
ggtgcggag atactagatg tttctggaaa tggctggaca gtggacatca cagggaaactt	1440
tagcaatgcc atcagaaaaa gccaggcctt ctcttgattt cttgcccacc acatcatggg	1500
tgcggggttt ggcttcata acatcaaaga tcctgaccag aacacatttgc ctggcctggc	1560
cagaagttca gtgagacacc tggatcttc acatgggttt gtcttctccc tgaactcacg	1620
agtcttgag acactcaagg atttgaaggt tctgaacctt gcctacaaca agataaataa	1680
gattgcagat gaagcattttt acggacttga caacctccaa gttctcaattt tgtcatataa	1740
ccttcgggg gaacttaca gttcgaattt ctatggacta cctaaaggtag cctacattga	1800
tttgcggaaa aatcacatttca caataattca agaccaaaca ttcaaaattcc tggaaaaattt	1860
acagacccctt gatctccgag acaatgtct tacaaccattt cattttatttca caagcataacc	1920
cgtatcttc ttgagtggca ataaaactagt gactttgcca aagatcaacc ttacagcgaa	1980
cctcatccac ttatcagaaa acaggctaga aaatcttagat attctctact ttcttctacg	2040
ggtacctcat ctccagattt tcattttaaa tcaaaaatcgc ttctcctcct gtatggaga	2100
tcaaaacccctt tcagagaatc ccagctttaga acagcttttc cttggagaaa atatgttgc	2160
acttgcctgg gaaactgagc tctgttggga tttttttagt ggactttctc atcttcaagt	2220
tctgtatgg aatcataactt atcttaatttcc ctttccacca ggagtatttca gcatctgac	2280
tgcatttaagg ggactaagcc tcaactccaa caggctgaca gttcttctc acaatgattt	2340
acctgctaat ttagagatcc tggacatatac caggaaccag ctccctagctc ctaatcctga	2400
tgtatggta tcacttagtg tcttgatattt aactcataac aagttcattt gtgaatgtga	2460
acttagcact tttatcaattt ggcttaatca caccaatgtc actatagctg ggcctcctgc	2520
agacatataat tgggtgtacc ctgactcggtt ctctgggggtt tccctcttctt ctcttccac	2580
ggaagggtgt gatgaagagg aagtctaaaag gtcctaaag ttctcccttt tcattgtatg	2640

cactgtcact ctgactctgt tcctcatgac catcctcaca gtcacaaaagt tccggggctt	2700
ctgttttatac tggttataaga cagcccagag actgggtgttc aaggaccatc cccagggcac	2760
agaacctgat atgtacaaaat atgatgccta tttgtgcttc agcagcaaaag acttcacatg	2820
ggtgtcagaat gctttgctca aacacctgga cactcaatac agtgaccaaa acagattcaa	2880
cctgtgcttt gaagaaaagag actttgtccc aggagaaaaac cgcatcgcca atatccagga	2940
tgcacatctgg aacagtagaa agatcgtttgc tcttgcgac agacacttcc tttagagatgg	3000
ctgggtgcctt gaagccttca gttatgcaca gggcaggtgc ttatctgacc ttaacagtgc	3060
tctcatcatg gtgggtggttg ggcccttgc ccagtaccag ttgatgaaac atcaatccat	3120
cagaggcttt gtacagaaaac agcagtatTTT gaggtggccct gaggatctcc aggtgttgg	3180
ctgggttctt cataaaactct ctcaacagat actaaagaaa gaaaaagaaa agaagaaaaga	3240
caataacatt ccgttgcaaa ctgtagcaac catctcctaa tcaaaggagc aatttccaac	3300
ttatctcaag ccacaaataa ctcttcactt tgtatTTGca ccaagtttac attttgggg	3360
cctctctgga ggtttttttt ttcttttgc tactatgaaa acaacataaa tctctcaatt	3420
ttcgatcaaa a	3431

<210> 26  
 <211> 858  
 <212> PRT  
 <213> Homo sapiens

<400> 26

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
 1 5 10 15

Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
 20 25 30

Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
 35 40 45

Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
 50 55 60

Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Glu Leu Gly Ser Gln  
 65 70 75 80

Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
 85 90 95

Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
 100 105 110

Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
 115 120 125

Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu

130                    135                    140  
Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
145                    150                    155                    160  
Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
165                    170                    175  
Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
180                    185                    190  
Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
195                    200                    205  
Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
210                    215                    220  
Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val  
225                    230                    235                    240  
Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
245                    250                    255  
Ser Ile Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
260                    265                    270  
Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
275                    280                    285  
Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
290                    295                    300  
Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
305                    310                    315                    320  
Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
325                    330                    335  
Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr  
340                    345                    350  
Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
355                    360                    365  
Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
370                    375                    380  
Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
385                    390                    395                    400  
Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
405                    410                    415  
Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
420                    425                    430  
Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
435                    440                    445  
His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
450                    455                    460  
Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu

465	470	475	480
Gly	Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp		
	485	490	495
Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn			
	500	505	510
Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu			
	515	520	525
Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn			
	530	535	540
Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu			
	545	550	560
Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile			
	565	570	575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn			
	580	585	590
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile			
	595	600	605
Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu			
	610	615	620
Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe			
	625	630	640
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr			
	645	650	655
Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys			
	660	665	670
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro			
	675	680	685
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe			
	690	695	700
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser			
	705	710	715
720			
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro			
	725	730	735
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg			
	740	745	750
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys			
	755	760	765
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn			
	770	775	780
Ser Ala Leu Ile Met Val Val Gly Ser Leu Ser Gln Tyr Gln Leu			
	785	790	795
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu			

	805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu			
	820	825	830
Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn			
	835	840	845
Ile Pro Leu Gln Thr Val Ala Thr Ile Ser			
	850	855	
 <b>&lt;210&gt; 27</b>			
<b>&lt;211&gt; 858</b>			
<b>&lt;212&gt; PRT</b>			
<b>&lt;213&gt; Homo sapiens</b>			
 <b>&lt;400&gt; 27</b>			
Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly			
1	5	10	15
Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe			
	20	25	30
Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr			
	35	40	45
Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser			
	50	55	60
Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln			
	65	70	75
			80
Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn			
	85	90	95
Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro			
	100	105	110
Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe			
	115	120	125
Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu			
	130	135	140
Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu			
	145	150	155
			160
Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp			
	165	170	175
Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro			
	180	185	190
Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu			
	195	200	205
Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg			
	210	215	220
Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val			
	225	230	235
			240

Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu  
 465 470 475 480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
 485 490 495  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
 500 505 510  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
 515 520 525  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
 530 535 540  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545 550 555 560  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

	565	570	575
Thr His Asn Lys	Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn		
	580	585	590
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile			
	595	600	605
Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu			
	610	615	620
Ser Thr Glu Gly Cys Asp Glu Glu Val Leu Lys Ser Leu Lys Phe			
	625	630	635
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr			
	645	650	655
Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys			
	660	665	670
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro			
	675	680	685
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe			
	690	695	700
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser			
	705	710	715
720			
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro			
	725	730	735
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg			
	740	745	750
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys			
	755	760	765
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn			
	770	775	780
Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu			
	785	790	795
800			
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu			
	805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu			
	820	825	830
Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Asp Asn Asn			
	835	840	845
Ile Pro Leu Gln Thr Val Ala Thr Ile Ser			
	850	855	

<210> 28  
<211> 365  
<212> PRT  
<213> Homo sapiens

<400> 28

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu  
 1                   5                   10                   15

Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu  
 20                 25                 30

Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu  
 35                 40                 45

Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg  
 50                 55                 60

Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val  
 65                 70                 75                 80

Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr  
 85                 90                 95

Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro  
 100                 105                 110

Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu  
 115                 120                 125

Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser  
 130                 135                 140

Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe  
 145                 150                 155                 160

Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile  
 165                 170                 175

Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly  
 180                 185                 190

Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser  
 195                 200                 205

Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr  
 210                 215                 220

Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp  
 225                 230                 235                 240

Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp  
 245                 250                 255

Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp  
 260                 265                 270

Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser  
 275                 280                 285

Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln  
 290                 295                 300

Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln  
 305                 310                 315                 320

Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

325	330	335
His Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Lys		
340	345	350
Asp Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser		
355	360	365

<210> 29  
<211> 4286  
<212> DNA  
<213> murine

ttgaaatctc acagcccggt tggttgcagt gaccacttc gttgaacata ttcttcctaa	60
tccttagtact ttcaatttgc tctattccct ggtgtctatg catttaaatc gactatgggg	120
ccattttcc ttgaaccacc acagaagaca ttagctctt gggatccttg ttaatttttt	180
ctccttttac atagcaccta cgcttggAAC atatgccaga cacatctgtg agacaccccct	240
tggcgctgca gctcatggat ggatgctgag ttccccacg caccacactt cagcagggtgg	300
gtgtatttct gttcacatt atactccac acggccatgc atgtcaggca tggagcaggc	360
tcataaccca cttaattaag gtgatcatat cagatccttt atcaagatgc atagagtgt	420
cagtgcctgt actatgatct cggatcttg ggagatggc tagatagagt ctgggacaga	480
atacagcaga gaaaccgata tggattttgt ccgatcatca gctaagcttc tggagctag	540
gaatggggct cttggatga acagaagtaa aaatgcctcg tctttatgac tttcaacttc	600
cctcagcagg tctggaatgg gtgaacaaac actgcctgcg tgggtgataa atgccttct	660
tttgcgtctt gttgcgtct tttatggttc tggagggaa cctagaacct agcacatgt	720
agacaagtcc tctagcactg agctatctcc ccagcttggta tgaaatatct gtaaagtact	780
ggtgcccggtg tgtaaaatat gcaccattaa gtgttcaaga agaaaagact gggcatttct	840
gttccaccaa gacaagaaga atctgccagc agaatgtttg cgcagtcatt tgagcaaagg	900
ggtccaaggg acagtaccct ccagtgcgtgg ggacccatgt gccgagcctc aggctgtgat	960
gtgggttgtt, ttttaattct ctctttccct ataggatcat ggcatgtcaa cttgacttgc	1020
tcataggtgt gatcttcatg gccagcccg tttggtaat atctccctgt tttcagacg	1080
gcaggatagc cttttccga ggctgttaacc tcacccagat tccctggatc ctcaatacta	1140
ccactgagag gtcctgctc agcttcaact atatcagtat ggtgggtgcc acatcatttc	1200
cactcctggta gcggctccag ttgctggagc tggggaccca gatatgttaac ttgaccattg	1260
gtccaggggc tttcagaaac ctgccaatc ttaggatctt ggacttgggc caaagccaga	1320
tcgaagtctt gaatcgagat gccttcaag gtcgtccccca tctttggaa cttcggctgt	1380
tttcctgtgg actctccagt gtcgtgttaa gtgacggtaa cttcagaaat ctatattcat	1440

tagctcgctt agacatctatc ggcaaccaga ttcacagcct ccgcctccat tcttcattcc	1500
gggaactgaa ttccctaaggc gacgtaaatt ttgccttcaa ccaaataattc actatatgtg	1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctggcctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaacccttc agaggcgtga	1680
ggctagaaac tcttagatctt tctgaaaatg gctggacggt ggacatcaca aggaacttca	1740
gcaacatcat ccagggaaagc cagattcct ctttgattct taaacaccac atcatgggtc	1800
ctggcttgg cttccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagttcggt gctgcaactg gaccttcgc acggctttat ctttccttg aatcctcgac	1920
tgtttggac actgaaggat ttgaagatgc tgaaccttgc cttcaacaag ataaacaaga	1980
ttggagagaa tgcctttat gggcttgaca gcctccagg tctcaatcta tcctataatc	2040
ttttggggaa actctataat tccaaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaggaa ccacattggg atcattcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctctta aggccattgg ttttattcca agcatacaga	2220
tggctctctt gggaggcaat aagctggtcc atttgccaca catccacttt actgccaact	2280
tcctagagtt atctgaaaac aggctagaaa acctgtccga cctctacttc ctccctgcgag	2340
tccccagct ccagttctc atcttgaatc agaatgcct ttcgtcatgc aaggcagccc	2400
acactccctc ggagaaccca agcttagaac acgtttcct tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tggtggatg ttttcaagg ccttccgc ctccagattc	2520
tttacctgag taataactac cttaatttcc ttccacctgg gatatttaac gacctggttg	2580
cattacggat gcttagtctt agtgcataaca agctgaccgt gctctctccg ggcagttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtcct gaccctgctt	2700
tgtttcttc gttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
ttagcacttt tatctcctgg ctcaacaaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattt catgtaccct aactcaactgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgcggt ccctaaagtt ttccctttc atcctgtgca	2940
cggtcacttt gactctattc ctcgtcatca cccttgttagt cataaagttc cggggatct	3000
gtttcctgtg ctataagacc atccagaagc tgggtgtcaa ggacaaggc tggagttgg	3060
aacctgggtc atatagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgctcaaa cacctggatg ctcactacag ttcccgaac aggctcaggc	3180
tatgctttga agaaagagac ttcatccgg gggaaaacca tatctccaac atccaggcgg	3240
ctgtctgggg cagcaggaag acggtgtgtc tagtgagcag acacttcctg aaggatggtt	3300
ggtgccctgga ggccttcagg tatgcccaga gccggagtct gtctgaccc tc aagagcattc	3360

tcatcggtt ggtgggtggga tcgctgtccc agtatcagct gatgagacat gagaccatca 3420  
 gagggtttct gcaaaaagcaa cagtacttga ggtggcctga agacacctccag gatgttggct 3480  
 ggtttctcga taaaactctcc ggatgcattc taaaggaaga aaaaggaaag aaaagaagca 3540  
 gttccatcca gttgcgaacc atagcaacca tttcttagca ggagcgcctc ctagcagaag 3600  
 tgcaagcatc gtagataact ctccacgctt tatccgcaca gccgctgggg gtcctccct 3660  
 ggagtcattt ttctgacaat gaaaacaaca ccaatctctt gattttcat gtcaacaggg 3720  
 agctttgtct tcactgtttt ccaaattggaa agtaagaggt ccagaaagct gcctctaagg 3780  
 gctctcacct gccattgatg tccttcagg cccaatgaca tggtttccct ccatcctatt 3840  
 gcgtactgtc tgctacccag gtggcaagag caccttggga gaagttacag gcagttcat 3900  
 gctttctgtg ctgttcagtt caaaagcagg tgccttgaga atcctgaatt caagcactct 3960  
 tagaaacatg gacagacaag atgggtccctt ctctggccat aggcatgagg gccagttgt 4020  
 gaggactgct ctcactacac ctaagtgcac aagtgataag aagttggaca gatagacaga 4080  
 tagcagcagt cccattgctg tagccagaat gcacttattt cctgttctga ccctgcaggc 4140  
 ccagcttttg gggaccacag ccatgttctg cacgggacct ctcaacctgg cattcatgcc 4200  
 ctttacgcac tttagcaccgg cctgcccttc tttcttcccc acaactatac aagagctgtt 4260  
 gcaaccactg aaaaaaaaaaaaaaa 4286

<210> 30  
 <211> 859  
 <212> PRT  
 <213> murine

<400> 30

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser  
 1 5 10 15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe  
 20 25 30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr  
 35 40 45

Thr Glu Arg Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala  
 50 55 60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr  
 65 70 75 80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro  
 85 90 95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn  
 100 105 110

Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe  
115 120 125

Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn  
130 135 140

Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser  
145 150 155 160

Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val  
165 170 175

Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu  
180 185 190

Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys  
195 200 205

Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe  
210 215 220

Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr  
225 230 235 240

Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile  
245 250 255

Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe  
260 265 270

Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg  
275 280 285

Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu  
290 295 300

Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu  
305 310 315 320

Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu  
325 330 335

Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu  
340 345 350

Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu  
355 360 365

Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu  
370 375 380

Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile  
385 390 395 400

Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu  
405 410 415

Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser  
420 425 430

Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435                    440                    445  
Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys  
450                    455                    460

Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe  
465                    470                    475                    480

Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp  
485                    490                    495

Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn  
500                    505                    510

Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala  
515                    520                    525

Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro  
530                    535                    540

Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln  
545                    550                    555                    560

Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp  
565                    570                    575

Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile  
580                    585                    590

Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp  
595                    600                    605

Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn  
610                    615                    620

Ile Ser Thr Glu Asp Cys Asp Glu Glu Ala Met Arg Ser Leu Lys  
625                    630                    635                    640

Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val  
645                    650                    655

Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr  
660                    665                    670

Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu  
675                    680                    685

Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp  
690                    695                    700

Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr  
705                    710                    715                    720

Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile  
725                    730                    735

Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser  
740                    745                    750

Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp  
755                    760                    765

Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu

770	775	780
Lys Ser Ile Leu Ile Val Val Val Val Gly Ser		Leu Ser Gln Tyr Gln
785	790	795
Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr		
	805	810
		815
Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys		
	820	825
		830
Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Arg Ser Ser		
	835	840
		845
Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser		
	850	855

<210> 31  
<211> 3373  
<212> DNA  
<213> Homo sapiens

<400> 31	60
agctggctag cgtttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgatt	60
cacctctcat gctctgctct cttcaaccag acctctacat tccattttgg aagaagacta	120
aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatccttt taacataatc	180
ctaatttcca aactccttgg ggctagatgg ttcctaaaaa ctctgccctg tgatgtca	240
ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt	300
cctggaggta ttcccacgaa caccacgaac ctcaccctca ccattaacca cataccagac	360
atctccccag cgtccttca cagactggac catctggtag agatcgattt cagatgcaac	420
tgtgtaccta ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaa	480
cccagaagct ttagtgact cacttattta aaatccctt acctggatgg aaaccagcta	540
ctagagatac cgcaaggcct cccgcctagc ttacagcttc tcagccttga gccaaacaac	600
atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctac	660
ggccaaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc	720
ttcctaaact tgacaaagtt aaaagtgcgc tccctgaaag ataacaatgt cacagccgtc	780
cctactgttt tgccatctac tttaacagaa cstatatctct acaacaacat gattgcaaaa	840
atccaagaag atgattttaa taacctaac acattacaaa ttcttgacat aagtggaaat	900
tgcctcggtt gttataatgc cccatttcct tgcgcgcgt gtaaaaataa ttctccctta	960
cagatccctg taaatgctt tgcgcgcgt acagaattaa aagtttacg tctacacagt	1020
aactctcttc agcatgtgcc cccaaagatgg tttaagaaca tcaacaaact ccaggaactg	1080
gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct gcattttctc	1140
cccaacctca tccaatttggaa tctgtcttc aattttgaac ttccaggctta tcgtgcac	1200

atgaatctat cacaagcatt ttcttcactg aaaagcctga aaattctgcg gatcagagga 1260  
tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320  
gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gtttaaacaa 1380  
tttaaaagac tgaaaagtcat agatcttca gtgaataaaa tatcaccttc aggagattca 1440  
agtgaagttg gcttctgctc aaatgccaga acttctgttag aaagttatga accccaggc 1500  
ctggaacaat tacatttattt cagatatgat aagtatgcaa ggagttgcag attcaaaaac 1560  
aaagaggcct ctttcatgtc tgtaatgaa agctgctaca agtatggca gaccttggat 1620  
ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct ttctttcctc 1680  
aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740  
ccttttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800  
acagcatttg aagagcttca caaactgaa gttctggata taagcagtaa tagccattat 1860  
tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa ggttctgcag 1920  
aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat ggagagttag 1980  
tctcttagaa ctctggaaatt cagagggaaat cacttagatg ttttatggag agaaggtgat 2040  
aacagatact tacaattatt caagaatctg ctaaaatttag aggaattaga catctctaaa 2100  
aattccctaa gtttcttgcc ttctggagtt tttgatggta tgcctccaaa tctaaagaat 2160  
ctctctttgg caaaaaatgg gctcaaatct ttcaagttgga agaaactcca gtgtctaaag 2220  
aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280  
aactgttcca gaagcctcaa gaatctgatt cttaagaata atcaaatcag gagtctgacg 2340  
aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaaatc 2400  
cagatgatcc aaaagaccag cttcccagaa aatgtcctca acaatctgaa gatgttgctt 2460  
ttgcataatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgtctg gtgggttaac 2520  
catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580  
cacaaggggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga tctgactaac 2640  
ctgattctgt tctcaatttc catatctgta tctcttttc tcatggtgat gatgacagca 2700  
agtcacctct atttctggga tgtgtggat atttaccatt tctgttaaggc caagataaaag 2760  
gggtatcagc gtctaataatc accagactgt tgctatgatg cttttattgt gtatgacact 2820  
aaagacccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact ggaagaccca 2880  
agagagaaac attttaattt atgtctcgag gaaagggact ggttaccagg gcagccagtt 2940  
ctggaaaacc tttcccagag catacagctt agcaaaaaga cagtgtttgt gatgacagac 3000  
aagtatgcaa agactgaaaa ttttaagata gcattttact tgcattttcatca gaggctcatg 3060

gataaaaaaag ttgatgtgat tatcttgata tttcttgaga agcctttca gaagtccaag	3120
tccctccagc tccggaaaag gctctgtgg agttctgtcc ttgagtggcc aacaaacccg	3180
caagtcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg	3240
gcctatagtc aggtgttcaa ggaaacggtc tagaatcgaa ttccccggc cgccactgtg	3300
ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt	3360
aagtttaaac cgc	3373

<210> 32  
<211> 3416  
<212> DNA  
<213> Homo sapiens

<400> 32	
tccagatata ggatcactcc atgccatcaa gaaagttgat gctattggc ccatctcaag	60
ctgatcttgg cacctctcat gctctgtct cttcaaccag acctctacat tccattttgg	120
aagaagacta aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt	180
taacataatc ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg	240
tgatgtcaact ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaaggat	300
gacagaaatt cctggaggtt ttcccacgaa caccacgaac ctcaccctca ccattaacca	360
cataccagac atctccccag cgtccttca cagactggac catctggtag agatcgattt	420
cagatgcaac tgtgtaccta ttccactggg gtcaaaaaac aacatgtca tcaagaggct	480
gcagattaaa cccagaagct ttagtggact cacttattta aaatccctt acctggatgg	540
aaaccagcta ctagagatac cgcagggcct cccgccttagc ttacagcttc tcagccttga	600
ggccaacaac atcttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat	660
actctacctg gccaaaaact gttattatcg aaatccttgt tatgttcat attcaataga	720
gaaagatgcc ttccctaaact tgacaaaagtt aaaagtgtct tccctgaaag ataacaatgt	780
cacagccgtc cctactgttt tgccatctac ttaacagaa ctatatctct acaacaacat	840
gattgcaaaa atccaagaag atgatttaa taacctcaac caattacaaa ttcttgacct	900
aagtggaaat tgccctcggtt gttataatgc cccatccct tgcgcgtt gtaaaaataaa	960
ttctccctta cagatccctg taaatgttt tgatgcgtt acagaattaa aagttttacg	1020
tctacacagt aactctttc agcatgtgcc cccaaagatgg tttaagaaca tcaacaaact	1080
ccaggaactg gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct	1140
gcattttctc cccagctca tccaatttggaa tctgtcttc aatttgaac ttcaaggctca	1200
tcgtgcacatct atgaatctat cacaaggatt ttcttcactg aaaagcctga aaattctgcg	1260

gatcagagga tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct	1320
tcaaaaatctt gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat	1380
gtttaaacaa tttaaaagac tgaaagtcat agatcttca gtgaataaaa tatcacccctc	1440
aggagattca agtgaagttg gcttcgtc aaatgccaga acttctgttag aaagttatga	1500
accccaggc tcggaacaat tacattattt cagatatgt aagtatgcaa ggagttgcag	1560
attcaaaaac aaagaggc ttcatgtc tgtaatgaa agctgctaca agtatggca	1620
gaccttggat ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct	1680
ttcttcctc aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag	1740
tgaattccaa ccttttagcag agttgagata tttggacttc tccaacaacc ggcttgatti	1800
actccattca acagcattt aagagcttca caaactggaa gttctggata taagcagtaa	1860
tagccattat ttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa	1920
ggtttgcag aaactgtatga tgaacgacaa tgacatctt tcctccacca gcaggaccat	1980
ggagagttag tctcttagaa ctctggatt cagagggaaat cacttagatg tttatggag	2040
agaagggtat aacagatact tacaattatt caagaatctg ctAAAattAG aggaattAGA	2100
catctctaaa aattccctaa gtttcttgcc ttctggagtt tttgatggta tgcctccaaa	2160
tctaaagaat ctctctttgg ccAAAAATGG gctcaaatct ttcagttgga agaaaactcca	2220
gtgtctaaag aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga	2280
gagattatcc aactgttcca gaagccacaa gaatctgatt cttaagaata atcaaattcag	2340
gagtcgcacg aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc	2400
aaataaaaatc cagatgtatcc AAAAGACCAAG cttcccagaa aatgtccctca acaatctgaa	2460
gatgttgctt ttgcataatcggtttct gtgcacctgt gatgtgtgt ggtttgtctg	2520
gtgggttaac catacgagg tgactattcc ttacctggcc acagatgtga cttgtgtgg	2580
gccaggagca cacaaggggcc aaagtgtat ctccctggat ctgtacacct gtgagttaga	2640
tctgactaac ctgattctgt tctcactttc catabctgtt tctctctttc tcatggat	2700
gatgacagca agtcacccctt atttctggta tgtgtggat atttaccatt tctgttaaggc	2760
caagataaaag ggttatcagc gtctaatatc accagactgt tgctatgtatg cttttattgt	2820
gtatgacact aaagacccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact	2880
ggaagaccca agagagaaac atttaattt atgtctcgag gaaaggact ggttaccagg	2940
gcagccagtt ctggaaaacc ttcccagag catacagctt agcaaaaaga cagtgtttgt	3000
gatgacagac aagtatgcaa agactgaaaa tttaagata gcattttact tgtcccatca	3060
gaggctcatg gatgaaaaag ttgtatgtat tatcttgata tttcttgaga agccctttca	3120
gaagtccaaag ttccctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtgcc	3180

aacaaacccg caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga	3240
caatcatgtg gcctatagtc aggtgttcaa gaaaaacggtc tagcccttct ttgcaaaaca	3300
caactgccta gtttaccaag gagaggcctg gctgtttaaa ttgttttcat atatatcaca	3360
ccaaaagcgt gtttgaaat tcttcaagaa atgagattgc ccataattca ggggag	3416

<210> 33  
<211> 3418  
<212> DNA  
<213> Homo spaiens

<400> 33	
actccagata tggatcaact ccatgccatc aagaaagttg atgctattgg gcccatctca	60
agctgatctt ggcacctctc atgctctgct ctcttcaacc agacacctac attccatttt	120
ggaagaagac taaaaatggt gttccaatg tggacactga agagacaaat tcttacccctt	180
ttaaacataa tcctaatttc caaactcctt gggctagat ggttccctaa aactctgccc	240
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat	300
ttgacagaaa ttccctggagg tattccacg aacaccacga acctcacccct caccattaac	360
cacataccag acatctcccc agcgtccctt cacagactgg accatctggt agagatcgat	420
ttcagatgca actgtgtacc tattccactg gggtaaaaaa acaacatgtg catcaagagg	480
ctgcagatta aacccagaag cttagtggc ctcacttatt taaaatccct ttacctggat	540
ggaaaccagc tactagagat accgcaggc ctccgccta gcttacagct tctcagccct	600
gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa	660
atactctacc tggccaaaaa ctgttattat cgaaatccctt gttatgttc atattcaata	720
gagaaagatg cttccctaaa cttgacaaag taaaaagtgc tctccctgaa agataacaat	780
gtcacagccg tccctactgt tttgcacatct actttaacag aactataatct ctacaacaac	840
atgattgcaa aaatccaaga agatgattt aataacctca accaattaca aattcttgac	900
ctaagtggaa attgcctcg ttgttataat gccccatttc ctgtgcgc gtgtaaaaat	960
aattctcccc tacagatccc tgtaaatgct tttgatgcgc tgacagaatt aaaagttta	1020
cgtctacaca gtaactctct tcagcatgtg ccccaagat ggtttaagaa catcaacaaa	1080
ctccaggaac tggatctgtc cccaaacttc ttggccaaag aaattgggaa tgctaaattt	1140
ctgcattttc tccccagcct catccaattt gatctgtctt tcaattttga acttcaggc	1200
tatcgtgcac ctatgaatct atcacaagca ttttcttcac tgaaaagcct gaaaattctg	1260
cggatcagag gatatgtctt taaagagttt aaaaagcttta acctctgcattacataat	1320
cttcaaaatc ttgaagttct tgatcttggc actaacttta taaaaattgc taacctcagc	1380

atgtttaaac aattttaaaag actgaaagtc atagatctt cagtgaataa aatatccct	1440
tcaggagatt caagtgaagt tggcttctgc tcaaataccca gaacttctgt agaaagttat	1500
gaaccccagg tcctggaca attacattat ttcatatgc ataagtatgc aaggagttgc	1560
agattcaaaa acaaagaggc ttctttcatg tctgttaatg aaagctgcta caagtatgg	1620
cagaccttgg atctaagtaa aaatagtata tttttgtca agtccctctga ttttcagcat	1680
ctttcttcc tcaaatacgct gaatctgtca ggaaatctca ttagccaaac tcttaatggc	1740
agtgaattcc aacctttagc agagctgaga tatttgact tctccaacaa ccggcttgat	1800
ttactccatt caacagcatt tgaagagctt cacaactgg aagttctgga tataagcagt	1860
aatagccatt atttcaatc agaaggaatt actcatatgc taaaactttac caagaaccta	1920
aagttctgc agaaactgat gatgaacgac aatgacatct ctccctccac cagcaggacc	1980
atggagagtg agtctcttag aactctggaa ttcatggaa atcacttaga tgtttatgg	2040
agagaaggtg ataacagata cttacaatta ttcaagaatc tgctaaaatt agaggaatta	2100
gacatctcta aaaattccct aagttcttg cttctggag ttttgatgg tatgcctcca	2160
aatctaaaga atctctcttt ggccaaaaat gggctcaaat ctccatgtt gaagaaactc	2220
cagtgtctaa agaacctgga aactttggac ctcagccaca accaactgac cactgtccct	2280
gagagattat ccaactgttc cagaagcctc aagaatctga ttcttaagaa taatcaaatc	2340
aggagtctga cgaagtattt tctacaagat gccttccagt tgcatatct ggatctcagc	2400
tcaaataaaa tccagatgat cccaaagacc agcttccctg aaaatgtcct caacaatctg	2460
aagatgtgc ttttgcata taatcggtt ctgtcacct gtgtgttgt gtgggttgtc	2520
tgggggtta accatacgga ggtgactatt ctttacctgg ccacagatgt gacttgtgtg	2580
gggcaggag cacacaaggg cccaaagtgtg atctccctgg atctgtacac ctgtgagttt	2640
gatctgacta acctgattet gttctactt tccatatctg tatctcttt tctcatggtg	2700
atgatgacag caagtcaccc ctattctgg gatgtgttgtt atatccatca tttctgttaag	2760
gccaaagataa aggggtatca gcgtctaata tcaccagact gttgtatga tgctttatt	2820
gtgtatgaca ctaaagaccc agctgtgacc gagtgggtt tggctgagct ggtggccaaa	2880
ctggaaagacc caagagagaa acatttaat ttatgtctcg aggaaaggga ctggttacca	2940
ggcagccag ttctggaaaa ctttccctg agcatacagc ttagcaaaaa gacagtgttt	3000
gtgtatgacag acaagtatgc aaagactgaa aattttaaaga tagcattttt cttgtcccat	3060
cagaggctca tggatgaaaa agttgtgtg attatcttgc tattttcttgc gaagccctt	3120
cagaagtcca agttccctcca gctccggaaa aggctctgtg ggagttctgt cttgtgtgg	3180
ccaaacaaacc cgcaagctca cccatacttc tggcagtgtc taaagaacgc cctggccaca	3240
gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt cttgcaaaa	3300

cacaactgcc tagtttacca aggagaggcc tggctgtta aattgtttc atatatatca 3360  
 caccaaaaagc gtgtttgaa attcttcaag aaatgagatt gccccatattt caggggag 3418

<210> 34  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
 20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
 50 55 60

Thr Asn Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
 85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
 100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
 115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

260	265	270
Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala		
275	280	285
Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His		
290	295	300
Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp		
305	310	320
Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu		
325	330	335
His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu		
340	345	350
Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser		
355	360	365
Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu		
370	375	380
Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu		
385	390	400
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met		
405	410	415
Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys		
420	425	430
Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala		
435	440	445
Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His		
450	455	460
Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
465	470	480
Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln		
485	490	495
Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp		
500	505	510
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu		
515	520	525
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu		
530	535	540
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr		
545	550	560
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn		
565	570	575
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr		
580	585	590
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile		

595	600	605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser	Leu Arg Thr Leu	
610	615	620
Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn		
625	630	635
Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp		
645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly		
660	665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys		
675	680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu		
690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn		
705	710	715
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg		
725	730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu		
740	745	750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro		
755	760	765
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg		
770	775	780
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His		
785	790	795
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly		
805	810	815
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr		
820	825	830
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser		
835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		

930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	

<210> 35  
<211> 1049  
<212> PRT  
<213> Homo sapiens

<400> 35

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75
80		
Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe		
85	90	95
Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys		
100	105	110
Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr		
115	120	125
Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140
Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile		
145	150	155
160		
Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile		
165	170	175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

500                    505                    510  
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
515                    520                    525

Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
530                    535                    540

Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
545                    550                    555                    560

Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
565                    570                    575

Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
580                    585                    590

Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
595                    600                    605

Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
610                    615                    620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
625                    630                    635                    640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
645                    650                    655

Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
660                    665                    670

Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
675                    680                    685

Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
690                    695                    700

Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
705                    710                    715                    720

Cys Ser Arg Ser His Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
725                    730                    735

Ser Pro Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu  
740                    745                    750

Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro  
755                    760                    765

Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu His His Asn Arg  
770                    775                    780

Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His  
785                    790                    795                    800

Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly  
805                    810                    815

Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr  
820                    825                    830

Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser

835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		
930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	
<210> 36		
<211> 1049		
<212> PRT		
<213> Homo spaiens		
<400> 36		
Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10 15
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met

405                    410                    415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420                    425                    430  
  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435                    440                    445  
  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450                    455                    460  
  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465                    470                    475                    480  
  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485                    490                    495  
  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500                    505                    510  
  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515                    520                    525  
  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530                    535                    540  
  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545                    550                    555                    560  
  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565                    570                    575  
  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580                    585                    590  
  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595                    600                    605  
  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610                    615                    620  
  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625                    630                    635                    640  
  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
 645                    650                    655  
  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660                    665                    670  
  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675                    680                    685  
  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690                    695                    700  
  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705                    710                    715                    720  
  
 Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725                    730                    735  
  
 Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu

	740	745	750													
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro	
	755				760							765				
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg	
						770			775			780				
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His	
	785				790				795				800			
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly	
	805								810				815			
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr	
	820						825						830			
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser	
	835						840					845				
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe	
	850						855					860				
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly	
	865						870				875			880		
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val	
	885						890					895				
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu	
	900						905					910				
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu	
	915						920					925				
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser	
	930						935					940				
Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Asp	Lys	
	945						950				955			960		
Tyr	Ala	Lys	Thr	Glu	Asn	Phe	Lys	Ile	Ala	Phe	Tyr	Leu	Ser	His	Gln	
	965						970					975				
Arg	Leu	Met	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu	Glu	
	980						985					990				
Lys	Pro	Phe	Gln	Lys	Ser	Lys	Phe	Leu	Gln	Leu	Arg	Lys	Arg	Leu	Cys	
	995						1000					1005				
Gly	Ser	Ser	Val	Leu	Glu	Trp	Pro	Thr	Asn	Pro	Gln	Ala	His	Pro		
	1010						1015					1020				
Tyr	Phe	Trp	Gln	Cys	Leu	Lys	Asn	Ala	Leu	Ala	Thr	Asp	Asn	His		
	1025						1030					1035				
Val	Ala	Tyr	Ser	Gln	Val	Phe	Lys	Glu	Thr	Val						
	1040						1045									

&lt;210&gt; 37

&lt;211&gt; 1049

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
500 505 510

Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
515 520 525

Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
530 535 540

Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
545 550 555 560

Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
565 570 575

Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
580 585 590

Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
595 600 605

Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
610 615 620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
625 630 635 640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp

Ile Ser Lys Asn Ser	645	Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly	650	655
	660		665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys	675	680	685	
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu	690	695	700	
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn	705	710	715	720
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg	725	730	735	
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu	740	745	750	
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro	755	760	765	
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg	770	775	780	
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His	785	790	795	800
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly	805	810	815	
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr	820	825	830	
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser	835	840	845	
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe	850	855	860	
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly	865	870	875	880
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val	885	890	895	
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu	900	905	910	
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu	915	920	925	
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser	930	935	940	
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys	945	950	955	960
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln	965	970	975	
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu				

980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe	Leu Gln Leu Arg Lys	Arg Leu Cys
995	1000	1005
Gly Ser Ser Val Leu Glu Trp	Pro Thr Asn Pro Gln	Ala His Pro
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys	Asn Ala Leu Ala Thr	Asp Asn His
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe	Lys Glu Thr Val	
1040	1045	

<210> 38  
<211> 3243  
<212> DNA  
<213> murine

<400> 38	60
attctcctcc accagacctc ttgattccat tttgaaagaa aactgaaaat ggtgtttcg	120
atgtggacac ggaagagaca aattttgatc tttttaata tgctcttagt ttcttagatc	180
tttgggttcc gatggttcc taaaactcta ctttgtgaag taaaagtaaa tatcccagag	240
gcccatgtga tcgtggactg cacagacaag catttgacag aaatccctga gggcattccc	300
actaacacca ccaatcttac ctttaccatc aaccacatac caagcatctc tccagattcc	360
ttccgttaggc tgaaccatct ggaagaaatc gatttaagat gcaattgtgt acctgttcta	420
ctggggtcca aagccaatgt gtgtaccaag aggctgcaga ttagacctgg aagctttagt	480
ggactctctg acttaaaagc ctttacctg gatggaaacc aacttctgga gataccacag	540
gatctgccat ccagcttaca tcttctgagc cttgaggcta acaacatctt ctccatcacg	600
aaggagaatc taacagaact ggtcaacatt gaaacactct acctgggtca aaactgttat	660
tatcgaaatc cttgcaatgt ttcctattct attaaaaag atgctttcct agttatgaga	720
aatttgaagg ttctctcaact aaaagataac aatgtcacag ctgtccccac cactttgcca	780
cctaatttac tagagctcta tctttataac aatatcatta agaaaatcca agaaaatgat	840
ttaataacc tcaatgagtt gcaagttctt gacctaagt gaaattgccc tcgatgttat	900
aatgtccccat atccgtgtac accgtgtcaa aataattccc ctttacagat ccatgacaat	960
gctttcaatt cattgacaga attaaaagtt ttacgtttac acagtaattc tcttcagcat	1020
gtgcccccaa catggttaa aaacatgaga aaccccccagg aactagacct ctcccaaaac	1080
tacttggcca gagaaaattga ggaggccaaa tttttgcatt ttcttcccaa ctttgtttag	1140
ttggattttt ctttcaatta tgagctgcag gtctaccatg catctataac tttaccacat	1200
tcactctctt cattggaaaa cttgaaaatt ctgcgtgtca aggggtatgt cttaaagag	1260
ctgaaaaact ccagtcttcc ttttgcac aagcttccca ggctggaagt tcttgacctt	

ggcactaact tcataaaaat tgctgaccc aacatattca aacatttga aaacctcaa	1320
ctcatagacc tttcagtcaa taagatatct ctttcagaag agtcaagaga agttggctt	1380
tgtccataatg ctcaaacttc tgttagaccgt catggcccc aggtccttga ggccttacac	1440
tatccat acgatgaata tgcacoggagc tgcaggttca aaaacaaaga gccaccttot	1500
ttcttcgcctt tgaatgcaga ctgccacata tatggcaga ccttagactt aagtagaaat	1560
aacatatttt ttatcaaacc ttctgatttt cagcatctt cattcctcaa atgcctcaac	1620
ttatcaggaa acaccattgg ccaaactctt aatggcagtg aactctggcc gttgagagag	1680
ttgcggtaact tagacttctc caacaaccgg cttgatttac tctactcaac agccttgaa	1740
gagctccaga gtcttgaagt tctggatcta agtagtaaca gccactattt tcaagcagaa	1800
ggaattactc acatgctaaa cttaaccaag aaattacggc ttctggacaa actcatgatg	1860
aatgataatg acatctctac ttcccggcaggc aggaccatgg aaagtgactc tcttcgaatt	1920
ctggagttca gaggcaaccca ttttagatgtt ctatggagag ccggtgataa cagataacttg	1980
gacttcttca agaatttgtt caatttagag gtatttagata tctccagaaa ttccctgaat	2040
tccttcgcctc ctgagggttt tgagggtatg ccgcggaaatc taaagaatct ctccctggcc	2100
aaaaatgggc tcaaatacttt ctttggac agactccagt tactgaagca tttggaaatt	2160
ttggacctca gccataaccca gctgacaaaaa gtacctgaga gattggccaa ctgttccaaa	2220
agtctcacaa cactgattct taagcataat caaatcaggc aattgacaaa atattttcta	2280
gaagatgctt tgcaatttgcg ctatctagac atcagttcaa ataaaatcca ggtcattcag	2340
aagactagct tcccagaaaaa tgcctcaac aatctggaga tgggtttt acatcacaat	2400
cgctttcttt gcaactgtga tgctgtgtgg tttgtctggt gggtaacca tacagatgtt	2460
actattccat acctggccac tgatgtgact tggtaggtc caggagcaca caaaggtaa	2520
agtgtcatat cccttgatct gtatacgtgt gagttagatc tcacaaacct gattctgttc	2580
tcagtttcca tatcatcagt cctcttctt atggtagtta tgacaacaag tcacctctt	2640
ttctggata tgggttacat ttatttttt tgaaagcaa agataaaggg gtatcagcat	2700
ctgcaatcca tggagtcttg ttatgtatgt tttattgtgt atgacactaa aaactcagct	2760
gtgacagaat gggtttgca ggagctggtg gcaaaattgg aagatccaag agaaaaacac	2820
ttcaatttgt gtctagaaga aagagactgg ctaccaggac agccagttct agaaaacctt	2880
tcccagagca tacagctcag caaaaagaca gtgttgtga tgacacagaa atatgctaag	2940
actgagagtt ttaagatggc attttatgg tctcatcaga ggctcctgga tgaaaaagtg	3000
gatgtgatta tcttgatatt ctggaaaag cctcttcaga agtctaagtt tcttcagctc	3060
aggaagagac tctgcaggag ctctgtcctt gaggccctg caaatccaca ggctcaccacca	3120
tacttctggc agtgcctgaa aaatgccctg accacagaca atcatgtggc ttatagtcaa	3180

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat 3240  
cga 3243

<210> 39  
<211> 3747  
<212> DNA  
<213> murine

<400> 39  
gagctcaaag gctctgcgag ttcgggttt ctgttgcctt ctctctgtct cagaggactc 60  
catctataga accactctat gccttcaaga aagatgtcct tggctccctt ctcaggatga 120  
tcctggccta tctctgactc tcttctcctc caccagacct cttgattcca ttttcaaaga 180  
aaactgaaaa tggtgttttc gatgtggaca cgaaagagac aaattttgat ctttttaaat 240  
atgctcttag tttcttagt ctttgggttt cgatggtttc ctaaaactct accttgcgaa 300  
gttaaagtaa atatcccaga ggcccatgtg atcgtggact gcacagacaa gcatttgaca 360  
gaaatccctg agggcattcc cactaacacc accaatctt cccttaccat caaccacata 420  
ccaagcatct ctccagattc cttccgtagg ctgaaccatc tgaaagaaat cgatttaaga 480  
tgcaattgtg tacctgttct actggggtcc aaagccaatg tgtgtaccaa gaggctgcag 540  
attagacctg gaagctttag tggactctct gacttaaaag cccttaccc ggttggaaac 600  
caacttctgg agataaccaca ggatctgcc tccagcttac atcttctgag ctttgaggct 660  
aacaacatct totccatcac gaaggagaat ctaacagaac tggtaacat tgaaacactc 720  
tacctgggtc aaaactgtta ttatcgaaat ctttgcaatg tttccttattc tattgaaaa 780  
gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca 840  
gctgtccccca ccactttgcc acctaatttta ctagagctct atctttataa caatatcatt 900  
aagaaaatcc aagaaaatga ttttaataac ctaatgagt tgcaagttct tgacctaagt 960  
ggaaattgcc ctcgatgtta taatgtccccca tatccgtgtta caccgtgtga aaataattcc 1020  
cccttacaga tccatgacaa tgctttcaat tcattgacag aattaaaagt tttacgttta 1080  
cacagtaatt ctcttcagca tgtgccccca acatggttta aaaacatgag aaacccctcag 1140  
gaactagacc tctccaaaaa ctacttggcc agagaaaattg aggaggccaa atttttgcatt 1200  
tttcttccca accttgggttga gttggatttt tctttcaatt atgagctgca ggtctaccat 1260  
gcatctataa ctttaccaca ttcactctct tcattggaaa acttgaaaat tctgcgtgtc 1320  
aaggggtatg tctttaaaga gctgaaaaac tccagtcttt ctgtattgca caagcttccc 1380  
aggctgaaag ttcttgaccc tggcactaac ttcataaaaa ttgctgaccc caacatattc 1440  
aaacattttg aaaacctcaa actcatagac ctttcagtga ataagatatc tccttcagaa 1500

gagtcaggaa	aagttggctt	ttgtccaat	gctcaaactt	ctgttagaccc	tcatggccc	1560
caggccttg	aggccttaca	ctatccga	taacatataat	atgcacggag	ctgcagggttc	1620
aaaaacaaaag	agccacccccc	tttcttgccc	ttgaatgcag	actgccacat	atatggcag	1680
accttagact	taagttagaaa	taacatataat	tttattaaac	cttctgatTT	tcagcatctt	1740
tcattcctca	aatgcctcaa	cttatcagga	aacaccattt	gccaaactct	taatggcagt	1800
gaactctggc	cgttgagaga	gttgcggcac	tttagacttct	ccaacaaccc	gcttgattta	1860
ctctactcaa	cagccttta	agagctccag	agtcttgaag	ttctggatct	aagtagtaac	1920
agccactatt	ttcaaggcaga	aggaattact	cacatgctaa	actttaccaa	gaaattacgg	1980
cttctggaca	aactcatgat	gaatgataat	gacatctcta	cttcggccag	caggaccatg	2040
gaaagtgact	ctcttcgaat	tctggagttc	agaggcaacc	attttagatgt	tctatggaga	2100
gccggtgata	acagataactt	ggacttcttc	aagaatttgt	tcaattttaga	ggtatttagat	2160
atctccagaa	attccctgaa	ttccttgcct	cctgagggtt	ttgagggtat	gccgccaat	2220
ctaaagaatc	tctccttggc	caaaaatggg	ctcaaatttt	tctttggga	cagactccag	2280
ttactgaagc	atttggaaat	tttggcaccc	agccataacc	agctgacaaa	agtacctgag	2340
agattggcca	actgttccaa	aagtctcaca	acactgattt	ttaagcataa	tcaaattcagg	2400
caattgacaa	aatatttct	agaagatgt	ttgcaattgc	gctatctaga	catcagttca	2460
aataaaatcc	aggtcattca	gaagactagc	ttccccagaaa	atgtcctcaa	caatctggag	2520
atgttggttt	tacatcacaa	tcgctttctt	tgcaactgtg	atgctgtgtg	gtttgtctgg	2580
tgggttaacc	atacagatgt	tactattcca	tacctggcca	ctgatgtgac	ttgtgttaggt	2640
ccaggagcac	acaaagggtca	aagtgtcata	tcccttgatc	tgtatacgtg	tgagtttagat	2700
ctcacaacc	tgattctgtt	ctcagtttcc	atatcatcag	tcctctttct	tatggtagtt	2760
atgacaacaa	gtcacctttt	tttctggat	atgtggtaca	tttattattt	ttgaaagca	2820
aagataaagg	ggtatcagca	tctgcaatcc	atggagtctt	gttatgatgc	ttttattgtg	2880
tatgacacta	aaaactcage	tgtgacagaa	tgggtttgc	aggagctggt	ggcaaaattt	2940
gaagatccaa	gagaaaaaca	cttcaatttgc	tgtctagaag	aaagagactg	gctaccagga	3000
cagccagttc	tagaaaaccc	ttcccagagc	atacagctca	gcaaaaagac	agtgtttgtg	3060
atgacacaga	aatatgctaa	gactgagatgt	tttaagatgg	cattttatTT	gtctcatcag	3120
aggctcctgg	atgaaaaagt	ggatgtgatt	atcttgcata	tcttggaaaa	gcctcttcag	3180
aagtctaagt	ttcttcagct	caggaagaga	ctctgcagga	gctctgtcct	tgagtggcct	3240
gcaaatccac	aggctcaccc	atacttctgg	cagtgcctga	aaaatgcct	gaccacagac	3300
aatcatgtgg	tttatagtca	aatgttcaag	gaaacagtct	agctctctga	agaatgtcac	3360
cacctaggac	atgccttggg	acctgaagtt	ttcataaagg	tttccataaa	tgaaggtctg	3420

aattttcct aacagttgtc atggctcaga ttgggtggaa atcatcaata tatggctaag	3480
aaatthaagaa ggggagactg atagaagata atttcttct tcatagtgccca tgctcagtta	3540
aatatccc ctagctcaa tctgaaaaac tgtgcctagg agacaacaca aggcttgat	3600
ttatctgcat acaattgata agagccacac atctgccctg aagaagtact agtagttta	3660
gtagtagggt aaaaattaca caagcttct ctctctctga tactgaactg taccagagtt	3720
caatgaaata aaagcccaga gaacttc	3747

<210> 40  
<211> 3449  
<212> DNA  
<213> murine

<400> 40	
gcgagtcctcg gtttctgtt gccttctctc tgtctcagag gactccatct atagaaccac	60
tctatgcctt caagaaagat gtccttggct cccttctcag gatgatcctg gcctatctct	120
gactctttc tcctccacca gacctttga ttccatttt aaagaaaact gaaaatggtg	180
ttttcgatgt ggacacggaa gagacaaatt ttgatcttt taaaatgtct cttagttct	240
agagtctttg gtttcgatg gtttcctaaa actctacctt gtgaagttaa agtaaatatc	300
ccagaggccc atgtgatcgt ggactgcaca gacaagcatt tgacagaaat ccctgaggc	360
attcccacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca	420
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgaa ttgtgtacct	480
gttctactgg ggtccaaagc caatgtgtgt accaagaggc tgcagattag acctggaagc	540
tttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata	600
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catcttctcc	660
atcacgaagg agaatctaac agaactggtc aacattgaaa cactctacct gggtaaaaac	720
tgttattatc gaaatccttg caatgtttcc tattctattt gaaaagatgc tttcttagtt	780
atgagaaatt tgaaggttct ctcactaaaa gataacaatg tcacagctgt ccccaccact	840
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa	900
aatgatttta ataacctaa tgagttgcaa gttcttgacc taagtggaaa ttgcctcgaa	960
tgttataatg tcccatatcc gtgtacaccg tgtgaaaata attccccctt acagatccat	1020
gacaatgctt tcaattcatt gacagaatta aaagttttac gtttacacag taattcttt	1080
cagcatgtgc ccccaacatg gttaaaaac atgagaaacc tccaggaact agacctctcc	1140
caaaactact tggccagaga aattgaggag gccaaatttt tgcattttct tcccaacctt	1200
gtttagttgg atttttcttt caattatgag ctgcaggct accatgcatac tataacttta	1260

ccacattcac tctttcatt ggaaaacttg aaaattctgc gtgtcaaggg gtagtgcctt	1320
aaagagctga aaaactccag tctttctgta ttgcacaagg ttcccaggct ggaagttctt	1380
gaccttggca ctaacttcat aaaaattgct gacctaaca tattcaaaca ttttggaaaac	1440
ctcaaactca tagaccttc agtgaataag atatctcctt cagaaggagtc aagagaagtt	1500
ggctttgtc ctaatgctca aacttctgta gaccgtcatg ggccccaggt ccttgaggcc	1560
ttacactatt tccgatacga tgaatatgca cggagctgca ggttcaaaaa caaagagcca	1620
ccttcttct tgcctttgaa tgcagactgc cacatatatg ggcagacctt agacttaagt	1680
agaaaataaca tatttttat taaaccttct gattttcagc atcttcatt cctcaaatgc	1740
ctcaacttat cagggaaacac cattggccaa actcttaatg gcagtgaact ctggccgttg	1800
agagagttgc ggtacttaga cttctccaac aaccggcttg atttactcta ctcaacagcc	1860
tttgaagagc tccagagtct tgaagttctg gatctaagta gtaacagcca ctattttcaa	1920
gcagaaggaa ttactcacat gctaaacttt accaagaaaat tacggcttct ggacaaaactc	1980
atgatgaatg ataatgacat ctctacttcg gccagcagga ccatggaaag tgactcttct	2040
cgaattctgg agttcagagg caaccattta gatgttctat ggagagccgg tgataacaga	2100
tacttggact tcttcaagaa tttgttcaat ttagaggtat tagatatotc cagaaattcc	2160
ctgaattcct tgcctcctgaa ggtttttag ggtatgccgc caaatctaaa gaatctctcc	2220
ttggccaaaa atgggctcaa atctttcttt tgggacagac tccagttact gaagcatttg	2280
gaaattttgg acctcagcca taaccagctg acaaaaagtac ctgagagatt ggccaactgt	2340
tccaaaagtc tcacaacact gattcttaag cataatcaaa tcaggcaatt gacaaaat	2400
tttctagaag atgctttgca attgcgttat cttagacatca gttcaaataa aatccaggc	2460
attcagaaga cttagttccc agaaaatgtc ctcaacaatc tggagatgtt ggttttcat	2520
cacaatcgct ttcttgcaa ctgtgtatgct gtgtggtttg tctgggggt taaccataca	2580
gatgttacta ttccataacct ggccactgat gtgacttgtg taggtccagg agcacacaaa	2640
ggtcaaagtg tcataccct tgcgttat acgtgtgagt tagatctcac aaacctgatt	2700
ctgttctcag ttccatatac atcagtcctc ttcttatgg tagttatgac aacaagtcac	2760
ctcttttct gggatatgtg gtacatttat tattttggaa aagcaaagat aaaggggtat	2820
cagcatctgc aatccatggaa gtctgttat gatgtttta ttgtgtatga cactaaaaac	2880
tcagctgtga cagaatgggt tttgcaggag ctggggccaa aattggaaaga tccaaagagaa	2940
aaacacttca atttgcgtct agaagaaaaga gactggctac caggacagcc agttctagaa	3000
aaccttccc agagcataca gctcagcaaa aagacagtgt ttgtgtatgac acagaaat	3060
gctaagactg agagttttaa gatggcattt tatttgcgtct atcagaggct cctggatgaa	3120
aaagtggatg tgattatctt gatattctt gaaaaggccctc ttcagaagtc taagttctt	3180

cagctcagga agagactctg caggagctct gtccttgagt ggcctgcaaa tccacaggct 3240  
 cacccatact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtggcttat 3300  
 agtcaaatgt tcaaggaaac agtctagtc tctgaagaat gtcaccacctt aggacatgcc 3360  
 ttgg tacctg aagtttcat aaaggttcc ataaatgaag gtctgaattt ttcctaacag 3420  
 ttgtcatggc tcagatttgtt gggaaatca 3449

<210> 41  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 41

Met	Val	Phe	Ser	Met	Trp	Thr	Arg	Lys	Arg	Gln	Ile	Leu	Ile	Phe	Leu
1															15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys															
															30
20 25															
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile															
															45
35 40															
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro															
															50 55 60
65 70 75 80															
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu															
															85 90 95
100 105 110															
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys															
115 120 125															
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln															
															130 135 140
145 150 155 160															
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr															
															165 170 175
180 185 190															
Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val															
															195 200 205
Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro															
															210 215 220
Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile															

225                    230                    235                    240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245                    250                    255  
  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260                    265                    270  
  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275                    280                    285  
  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290                    295                    300  
  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305                    310                    315                    320  
  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325                    330                    335  
  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340                    345                    350  
  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355                    360                    365  
  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370                    375                    380  
  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385                    390                    395                    400  
  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405                    410                    415  
  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420                    425                    430  
  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435                    440                    445  
  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450                    455                    460  
  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465                    470                    475                    480  
  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485                    490                    495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500                    505                    510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515                    520                    525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530                    535                    540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                    550                    555                    560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser

565                    570                    575  
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
580                    585                    590  
  
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
595                    600                    605  
  
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
610                    615                    620  
  
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
625                    630                    640  
  
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
645                    650                    655  
  
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
660                    665                    670  
  
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
675                    680                    685  
  
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
690                    695                    700  
  
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
705                    710                    720  
  
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
725                    730                    735  
  
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
740                    745                    750  
  
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
755                    760                    765  
  
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
770                    775                    780  
  
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
785                    790                    800  
  
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
805                    810                    815  
  
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
820                    825                    830  
  
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
835                    840                    845  
  
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
850                    855                    860  
  
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
865                    870                    880  
  
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
885                    890                    895  
  
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu

900                    905                    910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915                    920                    925  
  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930                    935                    940  
  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                    950                    955                    960  
  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965                    970                    975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980                    985                    990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995                    1000                    1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010                    1015                    1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025                    1030                    1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040                    1045                    1050  
  
<210> 42  
<211> 1050  
<212> PRT  
<213> murine  
  
<400> 42  
  
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
1                        5                        10                        15  
  
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
20                      25                      30  
  
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
35                      40                      45  
  
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
50                      55                      60  
  
Thr Asn Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
65                      70                      75                      80  
  
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
85                      90                      95  
  
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
100                     105                     110  
  
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
115                     120                     125  
  
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130                     135                     140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
195 200 205

Leu Ser Ile Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys

465                    470                    475                    480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485                    490                    495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500                    505                    510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515                    520                    525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530                    535                    540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                    550                    555                    560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565                    570                    575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580                    585                    590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595                    600                    605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610                    615                    620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                    630                    635                    640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645                    650                    655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660                    665                    670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675                    680                    685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690                    695                    700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                    710                    715                    720  
  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725                    730                    735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740                    745                    750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755                    760                    765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770                    775                    780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                    790                    795                    800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val

	805	810	815	
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr				
	820	825	830	
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile				
	835	840	845	
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe				
	850	855	860	
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys				
	865	870	875	880
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile				
	885	890	895	
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu				
	900	905	910	
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys				
	915	920	925	
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu				
	930	935	940	
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln				
	945	950	955	960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His				
	965	970	975	
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu				
	980	985	990	
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu				
	995	1000	1005	
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His				
	1010	1015	1020	
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn				
	1025	1030	1035	
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val				
	1040	1045	1050	
<210> 43				
<211> 1050				
<212> PRT				
<213> murine				
<400> 43				
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu				
	1	5	10	15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys				
	20	25	30	
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile				
	35	40	45	

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370	375	380
Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys	Leu Pro Arg Leu Glu	
385	390	395
400		
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile		
405	410	415
Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys		
420	425	430
Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala		
435	440	445
Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His		
450	455	460
Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
465	470	475
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly		
485	490	495
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser		
500	505	510
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn		
515	520	525
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu		
530	535	540
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser		
545	550	555
560		
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser		
565	570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
580	585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
595	600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	635
640		
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		

705                    710                    715                    720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725                    730                    735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740                    745                    750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755                    760                    765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770                    775                    780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                    790                    795                    800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805                    810                    815  
  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820                    825                    830  
  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835                    840                    845  
  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850                    855                    860  
  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                    870                    875                    880  
  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885                    890                    895  
  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900                    905                    910  
  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915                    920                    925  
  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930                    935                    940  
  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                    950                    955                    960  
  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965                    970                    975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980                    985                    990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995                    1000                    1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010                    1015                    1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025                    1030                    1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val

1040                    1045                    1050  
<210> 44  
<211> 1050  
<212> PRT  
<213> murine  
  
<400> 44  
  
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
1                    5                            10                    15  
  
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
20                    25                            30  
  
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
35                    40                            45  
  
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
50                    55                            60  
  
Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile  
65                    70                            75                    80  
  
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
85                    90                            95  
  
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
100                    105                            110  
  
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
115                    120                            125  
  
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130                    135                            140  
  
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145                    150                            155                    160  
  
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
165                    170                            175  
  
Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
180                    185                            190  
  
Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
195                    200                            205  
  
Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
210                    215                            220  
  
Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
225                    230                            235                    240  
  
Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
245                    250                            255  
  
Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
260                    265                            270  
  
Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
275                    280                            285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
515 520 525

Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
530 535 540

Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
545 550 555 560

Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
565 570 575

Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
580 585 590

Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
595 600 605

Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610                    615                    620  
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
625                    630                    635                    640  
  
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
645                    650                    655  
  
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
660                    665                    670  
  
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
675                    680                    685  
  
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
690                    695                    700  
  
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
705                    710                    715                    720  
  
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
725                    730                    735  
  
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
740                    745                    750  
  
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
755                    760                    765  
  
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
770                    775                    780  
  
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
785                    790                    795                    800  
  
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
805                    810                    815  
  
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
820                    825                    830  
  
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
835                    840                    845  
  
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
850                    855                    860  
  
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
865                    870                    875                    880  
  
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
885                    890                    895  
  
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
900                    905                    910  
  
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
915                    920                    925  
  
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
930                    935                    940  
  
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln

945	950	955	960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
965		970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
980	985	990	
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
995	1000	1005	
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
1010	1015	1020	
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
1025	1030	1035	
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			
1040	1045	1050	
<210> 45			
<211> 1050			
<212> PRT			
<213> murine			
<400> 45			
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
1	5	10	15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
20	25	30	
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
35	40	45	
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro			
50	55	60	
Thr Asn Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile			
65	70	75	80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu			
85	90	95	
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys			
100	105	110	
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp			
115	120	125	
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln			
130	135	140	
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile			
145	150	155	160
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr			
165	170	175	
Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser			
180	185	190	

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn

515                    520                    525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530                    535                    540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                    550                    555                    560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565                    570                    575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580                    585                    590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595                    600                    605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610                    615                    620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                    630                    635                    640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645                    650                    655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660                    665                    670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675                    680                    685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690                    695                    700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                    710                    715                    720  
  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725                    730                    735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740                    745                    750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755                    760                    765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770                    775                    780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                    790                    795                    800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805                    810                    815  
  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820                    825                    830  
  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835                    840                    845  
  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe

850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys		
865	870	875
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile		
885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu		
900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys		
915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu		
930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln		
945	950	955
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His		
965	970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu		
980	985	990
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu		
995	1000	1005
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His		
1010	1015	1020
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn		
1025	1030	1035
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val		
1040	1045	1050

<210> 46  
 <211> 3311  
 <212> DNA  
 <213> Homo sapiens

<400> 46	
ttctgcgtcgt ctgcaaggta cggaaatgaaa aattagaaca acagaaaacat ggaaaacatg	60
ttccttcagt cgtcaatgct gacctgcatt ttcctgctaa tatctggttc ctgtgagttt	120
tgcgccgaag aaaatttttc tagaagctat cttgtgtatg agaaaaagca aaatgactca	180
gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacgggt gggcaaatat	240
gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcatttcaa	300
gggctgcaaa atctcaactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac	360
ggaaatcccc gtataacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta	420
aaaaaacctaa gggagttact gcttgaagac aaccagttac cccaaataacc ctctggtttgc	480
ccagagtctt tgacagaact tagtctaatt caaaacaata tatacaacat aactaaagag	540

ggcatttcaa gacttataaa cttaaaaat ctctattgg cctggaactg ctatTTAAC	600
aaagttgcg agaaaactaa catagaagat ggagtattt aaacgctgac aaatttggag	660
ttgctatcac tatctttcaa ttctcttca cacgtgccac ccaaactgcc aagctcccta	720
cgcAAacttt ttctgagcaa cacccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatttaagc gggaaactgtc cgaggtgctt caatgccccca	840
tttccatgcg tgcTTTgtga tggtgggtct tcaattaata tagatcgTT tgTTTCAA	900
aacttgaccc aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgct	960
gcctggTTTA aaaatatGCC tcATCTGAAG gtgctggatC ttGAATTCAA ctatTTAGTG	1020
ggagaaatAG cctctggggc atTTTAAACG atgctgcccc gcttagaaat acttgacttg	1080
tctTTTAact atataaAGGG gagttatCCA cagcatatta atattCCAG aaacttCTCT	1140
aaactTTTGT ctctacgggc attgcattta agaggTTATG tggTCCAGGA actcagagaa	1200
gatgatttcc agccccCTGAT gcagCTTCCA aacttATCGA ctatCAACTT ggTTATTAAT	1260
tttattaAGC aaatCGATT caaACTTTc caAAATTTCT ccaatCTGGA aattatTTAC	1320
ttgtcagAAA acagaatATC accgttggta aaagataccc ggcagAGTtA tgcaaatAGT	1380
tcctCTTTc aacgtcatat ccggAAACGA cgctcaacAG atTTTgAGTT tgaccCACAT	1440
tcgaACTTTT atcatttCAC ccgtcTTTA ataaAGCCAC aatgtgCTGC ttatggAAAA	1500
gccttagatt taagcctCAA cagtATTTc ttCATTTGGC caaACCAATT tgAAAATCTT	1560
cctgacATTG CCTGTTTAA tCTGTCtGCA aatAGCAATG ctcaAGTGTt aagtggAACT	1620
gaATTTCAg CCATTCCtCA tGTCAAATAT ttggATTtGA caaACAATAG actAGACTTT	1680
gataATGCTA gtGCTCTtAC tGAATTGTCC gACTTGGAAg ttCTAGATCT cAGCTATAAT	1740
tcacACTATT tcAGAAATAGC aggCGTAACA catCATCTAG aATTtATTCA aaATTTcaca	1800
aatCTAAAAG ttTTAAACtT gagCCACAAC AACATTATA CTTAACAGA taagtataAC	1860
ctggAAAGCA agtCCCTGGT agaATTAGTT ttCAgTGGCA atCGCCTtGA cATTtTGTGG	1920
aatGATGATG ACAACAGGTA tatCTCCATT ttCAAAGGTC tcaAGAAATCT gacACGTCTG	1980
gatttATCCC ttaATAGGt GAAGCACATC ccaaATGAAG cATTCCtAA ttGCCAGCG	2040
agtCTCACTG AACTACATAT AAATGATAAT ATGTTAAAGT ttTTTAactG gacATTACTC	2100
cagcAGTTCC CTCGTCTCGA gttGCTTGAC ttACGTGGAA acaaACTACT CTTTTAact	2160
gatAGCCTAT CTGACTTTAC atCTCCCTT CGGACACTGC tgCTGAGTCA taacAGGATT	2220
tcccACCTAC CCTCTGGCTT tCTTCTGAA gTCAGTAGTC tGAAGCACCT CGATTAAgT	2280
tccaATCTGC taaaaACAAT caACAAATCC GCACTTGAAA ctaAGACCAC cacCAAATTA	2340
tctatGTTGG aactACACGG aaACCCCTTt GAATGCACTt gtGACATTGG agATTTCCGA	2400
agatGGATGG atGAACATCT GAATGTCAAa ATTCCAGAC tggTAGATGT cATTGTGCC	2460

agtccctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca	2520
gatgtcaactg cagtgatatt attttcttc acgttctta tcaccaccat gtttatgttg	2580
gctgccctgg ctcaccattt gtttactgg gatgttttgtt ttatatataa tgtgtgttta	2640
gctaaggtaa aaggctacag gtctcttcc acatccccaa ctttctatga tgcttacatt	2700
tcttatgaca ccaaagatgc ctctgttaact gactgggtga taaatgagct ggcctaccac	2760
cttgaagaga gccgagacaa aaacgttctc ctttgtctag aggagaggga ttgggaccgg	2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt	2880
gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagctttta cttggctttg	2940
cagaggctaa tggatgagaa catggatgtg attatattta tcctgctgga gccagtgtta	3000
cagcattctc agtatttgag gctacggcag cgatctgtt agagctccat cttccagtgg	3060
cctgacaacc cgaaggcaga aggcttggg tggcaaactc tgagaaatgt ggtcttgact	3120
aaaaatgatt cacggtataa caaatgtat gtcgattcca ttaagcaata ctaactgacg	3180
ttaagtcatg atttcgcgecc ataataaaga tgcaaaggaa tgacatttct gtattgtta	3240
tctattgcta tgtaacaaat tatcccaaaa ctttagtggg taaaacaaca catttgctgg	3300
cccacagttt t	3311

<210> 47  
 <211> 3367  
 <212> DNA  
 <213> Homo spaiens

<400> 47	
ctcctgcata gagggtacca ttctgcgctg ctgcaagtta cgaaatgaaa aattagaaca	60
acagaaaacgt gtttcttttgc acacttcagt gtttagggAAC atcagcaaga cccatcccag	120
gagaccttga aggaagcctt tgaaaggag aatgaaggag tcatcttgc aaaatagctc	180
ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgtgac	240
ctgcatttc ctgctaataat ctggttcctg tgagttatgc gccgaagaaa attttctag	300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcatc acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacggg aatcccggtt tacaatcaaa	540
tggcttgaat atcacagacg gggcattcct caacctaaaa aacctaaggg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggtttggca gagtcttgc cagaacttag	660
tctaattcaa aacaatataat acaacataac taaagagggc atttcaagac ttataaactt	720

gaaaaatctc tatttggcct ggaactgcta tttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa ttggagttg ctatcactat ctttcaattc	840
tcttcacac gtgtcaccca aactgccaaag ctccctacgc aaacttttc tgagcaacac	900
ccagatcaa tacatttagt aagaagattt caagggattt ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatatacg atcggtttgc ttttcaaaac ttgaccacac ttgcataacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaagggtg ctggatctt aattcaacta ttttagtgggaa gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgtt tagaaatact tgacttgtct tttaactata taaaggggag	1260
ttatccacag catattaata ttccagaaa cttctctaaa cctttgtctc tacgggcatt	1320
gcatttaaga gtttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattatattt attaagcaaa tcgatttcaa	1440
actttccaa aatttctcca atctgaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggtaaaa gatacccgac agagttatgc aaatagttcc tctttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagttga cccacattcg aacttttac atttcaccccg	1620
tcctttaata aagccacaat gtgctgctt tgaaaagcc ttagatttaa gcctcaacag	1680
tatTTCTTC attggggccaa accaatttga aaatcttctt gacattgcct gtttaatct	1740
gtctgcaaat agcaatgctc aagtgttaag tggaaactgaa tttcagccca ttctctatgt	1800
caaataattt gatttgacaa acaatagact agactttgtt aatgcttagt ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactattca gaatagcagg	1920
cgtAACACAT catctagaat ttattcaaaa ttccacaaat ctAAAAGTTT taaacttgag	1980
ccacaacaac atttataactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040
attagtttca agtggcaatc gccttgacat ttgtggaaat gatgtgaca acaggtatat	2100
ctccattttc aaaggcttca agaattctgac acgtctggat ttatcccttta ataggctgaa	2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa	2220
tgataatatg ttaaagttt ttaactggac attactccag cagtttctc gtctcgagtt	2280
gtttgactta cgtggaaaca aactactt tttaactgtat agcctatctg actttacatc	2340
ttcccttcgg acactgctgc tgagtcttca caggatttcc cacctaccct ctggctttct	2400
ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa	2460
caaatccgca cttgaaaacta agaccaccac caaattatct atgttggAAC tacacggaaa	2520
cccctttggaa tgcacctgtg acattggaga ttccgaaga tggatggatg aacatctgaa	2580
tgtcaaaatt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa	2640

gagtattgtg agtctggagc taacaacttg tgttcagat gtcactgcag tgatattatt	2700
tttcttcacg ttctttatca ccaccatggt tatgttgct gccctggctc accatttgtt	2760
ttactggat gtttggttta tatataatgt gtgttagct aagataaaag gctacaggc	2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc	2880
tgttactgac tgggtgat'aa atgagctgcg ctaccacett gaagagagcc gagacaaaaaa	2940
cgttctcctt tgtcttagagg agagggattg ggacccggga ttggccatca tcgacaacct	3000
catgcagagc atcaacccaaa gcaagaaaac agtatttgtt ttaacccaaa aatatgc当地	3060
aagcttggAAC tttaaaacag cttttactt ggctttgcag aggctaattgg atgagaacat	3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct	3180
acggcagcgg atctgttaga gctccatcct ccagtggcct gacaacccga aggcagaagg	3240
cttgggggg caaaactctga gaaatgtggt cttgactgaa aatgatttac ggtataacaa	3300
tatgtatgtc gattccatta agcaataacta actgacgtta agtcatgatt tcgcgccata	3360
ataaaaga	3367

<210> 48  
<211> 4211  
<212> DNA  
<213> Homo spaiens

<400> 48	
ctcctgcata gagggtacca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca	60
acagaaaacat ggaaaacatg ttccctcagt cgtcaatgct gacctgcatt ttccctgctaa	120
tatctggttc ctgtgagtt tgcccgaaag aaaatttttc tagaagctat ccttggatg	180
agaaaaagca aatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc	240
cccaaacgggt gggcaaataat gtgacagaac tagacctgac tgataatttc atcacacaca	300
taacgaatga atcatttcaa gggctgcaaa atctcaactaa aataaatcta aaccacaacc	360
ccaatgtaca gcaccagaac ggaaatcccg gtatataatc aaatggctt aatatcacag	420
acggggcatt cctcaaccta aaaaacctaa gggagttact gcttgaagac aaccagttac	480
cccaaatacc ctctggttt ccagagtctt tgacagaact tagtctaatt caaaacaata	540
tatacaacat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctatttgg	600
cctgaaactg ctatTTAAC aaagttgcg agaaaaactaa catagaagat ggagtatttgc	660
aaacgctgac aaatttggag ttgctatcac tatctttcaa ttctcttca cacgtgccac	720
ccaaactgccc aagctcccta cgccaaacttt ttctgagcaa cacccagatc aaatacatta	780
gtgaagaaga tttcaaggga ttgataaatt taacattact agatTTAAGC gggactgtc	840

cgaggtgctt caatccccca tttccatgcg tgccctgtga tggtggtgct tcaattaata 900  
tagatgttt tgctttcaa aacttgaccc aacttcgata cctaaacctc tctagcactt 960  
ccctcaggaa gattaatgct gcctgggta aaaatatgcc tcatactgaag gtgctggatc 1020  
ttgaattcaa ctatttatgt ggagaaaatag cctctgggc attttaacg atgctgcccc 1080  
gcttagaaat acttgacttg tcttttaact atataaaggg gagttatcca cagcatatta 1140  
atatttccag aaacttctct aaactttgt ctctacgggc attgcattt agaggttatg 1200  
tgttccagga actcagagaa gatgattcc agcccctgat gcagcttcca aacttatcga 1260  
ctatcaactt gggatttaat ttattaaagc aaatcgattt caaacatttc caaaatttct 1320  
ccaatctgga aattatttac ttgtcagaaa acagaatatc accgttggta aaagataaccc 1380  
ggcagagtt tgcaaatagt tcccttttc aacgtcatat ccggaaacga cgctcaacag 1440  
atttttagtt tgacccacat tcgaactttt atcatttcac ccgtccttta ataaagccac 1500  
aatgtgctgc ttatggaaaa gccttagatt taagcctcaa cagtatttc ttcatgggc 1560  
caaaccattt taaaatctt cctgacattt cctgtttaaa tctgtctgca aatagcaatg 1620  
ctcaagtgtt aagtggaaact gaattttcag ccattcctca tgtcaaataat ttggatttga 1680  
caaacaatag actagacttt gataatgcta gtgctttac tgaattgtcc gacttggaaag 1740  
ttctagatct cagctataat tcacactatt tcagaatagc aggcgtaaca catcatctag 1800  
aatttattca aaatttcaca aatctaaaag ttttaactt gagccacaac aacatttata 1860  
ctttaacaga taagtataac ctggaaagca agtccctggt agaatttagtt ttcaagtggca 1920  
atgccttga cattttgtgg aatgatgatg acaacaggta tatctccatt ttcaaaggtc 1980  
tcaagaatct gacacgtctg gattttccc ttaataggct gaagcacatc ccaaataatg 2040  
cattccttaa tttgccagcg agtctcactg aactacatatt aatgataat atgttaaagt 2100  
tttttaactg gacattactc cagcaggttc ctgtctgca gttgcttgc ttacgtggaa 2160  
acaaaactact ctttttaact gatagccat ctgactttac atctccctt cggacactgc 2220  
tgctgagtca taacaggatt tcccacctac cctctggctt tctttctgaa gtcagtagtc 2280  
tgaaggcacct cgattnaagt tccaatctgc taaaaacaat caacaaatcc gcacttgaaa 2340  
ctaagaccac caccaaatta tctatgtgg aactacacgg aaaccccttt gaatgcacct 2400  
gtgacattgg agattnccga agatggatgg atgaacatct gaatgtcaaa attccagac 2460  
tggttagatgt catttgccttcc agtccctgggg atcaaagagg gaagagtatt gtgagttctgg 2520  
agctaacaac ttgtgtttca gatgtcactg cagtgtatatt attttcttc acgttcttta 2580  
tcaccaccat ggttatgttg gtcgcctgg ctcaccattt gtttactgg gatgtttgg 2640  
ttatataaa tgtgtgttta gctaaggtaa aaggctacag gtcttttcc acatcccaa 2700  
ctttctatga tgcttacatt tcttatgaca ccaaagatgc ctctgttact gactgggtga 2760

taaatgagct gcgcattaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag 2820  
 aggagaggga ttgggatccg ggattggcca tcatacgacaa cctcatgcag agcatcaacc 2880  
 aaagcaagaa aacagtattt gtttaacca aaaaatatgc aaaaagctgg aactttaaaa 2940  
 cagctttta ctggcttg cagaggctaa tggatgagaa catggatgtg attatattta 3000  
 tcctgctgga gccagtgta cagcattctc agtattttag gctacggcag cggatctgta 3060  
 agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttgc 3120  
 tgagaaatgt ggtcttgact gaaaatgatt cacggtataa caatatgtat gtgcattcca 3180  
 ttaagcaata ctaactgacg ttaagtcatg atttcgcgcc ataataaaaga tgcaaaggaa 3240  
 tgacatttct gtatttagtta tctattgcta tgtaacaaat tatcccaaaa cttagtggtt 3300  
 taaaacaaca catttgcggg cccacagttt ttgagggtca ggagtccagg cccagcataa 3360  
 ctgggtcctc tgctcagggt gtctcagagg ctgcaatgta ggtgttccacc agagacatag 3420  
 gcatcaactgg ggtcacactc atgtgggtgt tttctggatt caattcctcc tggcttattg 3480  
 gccaaaggct atactcatgt aagccatgctc agcctctccc acaaggcage ttgcttcattc 3540  
 agagcttagca aaaaagagag gttgcttagca agatgaagtc acaatctttt gtaatcgaat 3600  
 caaaaaagtg atatctcatc actttggcca tattctattt gttagaagta aaccacaggt 3660  
 cccaccagct ccatggagt gaccaccta gtccaggaa aacagctgaa gaccaagatg 3720  
 gtgagctctg attgcttcag ttggcatca actatccc cttgactgct gtccctggat 3780  
 ggcctgctat cttgatgata gattgtgaat atcaggaggc agggatcact gtggaccatc 3840  
 ttagcagttg acctaacaca tcttctttc aatatctaag aactttgcc actgtgacta 3900  
 atggcctaa tattaagctg ttgttatata ttatcatata tctatggcta catggttata 3960  
 ttatgctgtg gttgcgttcg gttttatata cagttgctt tacaaatatt tgctgttaaca 4020  
 tttgacttct aaggttttaga tgccattaa gaactgagat ggatagctt taaagcatct 4080  
 tttacttctt accatttttt aaaagtatgc agctaaattc gaagctttg gtctatattg 4140  
 ttaattgcca ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat tttacaaaaa 4200  
 aaaaaaaaaa a 4211

<210> 49  
 <211> 3468  
 <212> DNA  
 <213> Homo sapiens

<400> 49  
 ctccctgcata gagggtacca ttctgcgtcg ctgcaagttt cgaaatgaaa aattagaaca 60  
 acagaaacat gtttctttt acacttcagt gtttagggAAC atcagcaaga cccatcccag 120

gagaccttga aggaaggcctt tgaaaggtag aatgaaggag tcatcttgc aaaatagctc	180
ctgcagccctg gaaaaaggaga ctaaaaagga aaacatgttc cttagtcgt caatgctgac	240
ctgcattttc ctgctaataat ctggttcctg tgagttatgc gccgaagaaa attttcttag	300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacggtgaa caaatatgtg acagaactag acctgtctga	420
taatttcattt acacacataa cgaatgaatc atttcaaggg ctgaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa	540
tggcttgaat atcacagacg gggcatcctt caacctaaaa aacctaaggg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggttgcca gagttttga cagaacttag	660
tctaattcaa aacaatataat acaacataac taaagagggc atttcaagac ttataaactt	720
aaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa ttggagttt ctatcactat cttcaattc	840
tctttcacac gtgccacccca aactgccaag ctccctacgc aaacttttc tgagcaacac	900
ccagatcaaa tacatttagtg aagaagattt caagggattt ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtatgg	1020
tggtgtttca attaatataat atcggtttgc ttttcaaaac ttgacccaaac ttgcataacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggttaaaaa atatgcctca	1140
tctgaaggatg ctggatcttg aattcaacta ttttagtggg gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaataact tgacttgc ttttaactata taaaggggag	1260
ttatccacag catattaataa tttccagaaa cttctctaaa cttttgtctc tacgggcatt	1320
gcatttaaga gtttatgtgt tccaggaact cagagaagat gattccagc ccctgatgca	1380
gtttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa	1440
actttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggtaaaa gataccggc agagttatgc aaatagttcc tctttcaac gtcataatcg	1560
gaaacgacgc tcaacagatt ttgagttga cccacattcg aacttttatac atttcacccg	1620
tccttaata aagccacaat gtgctgctta tgaaaaagcc ttagatttaa gcctcaacag	1680
tattttcttc attggggccaa accaatttga aaatcttccct gacattgcct gtttaatct	1740
gtctgcaaattt agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttccctcatgt	1800
caaataattt gatttgacaa acaatagact agactttgat aatgcgtatgc ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactattca gaatagcagg	1920
cgttaacacat catctagaat ttattcaaaa tttcacaaat ctaaaagttt taaacttgag	1980
ccacaacaac atttataactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040

attagtttc agtggcaatc gccttgacat tttgtggaaat gatgatgaca acaggatat 2100  
 ctccattttc aaaggtctca agaatctgac acgtctggat ttatccctta ataggctgaa 2160  
 gcacatccca aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa 2220  
 tgataatatg ttaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt 2280  
 gcttgactta cgtggaaaca aactactctt tttactgtat agcctatctg actttacatc 2340  
 ttcccttcgg acactgctgc tgagtctaaa caggatttcc cacctaccct ctggcttct 2400  
 ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa 2460  
 caaatccgca cttgaaaacta agaccaccac caaattatct atgttggAAC tacacggaaa 2520  
 ccccttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa 2580  
 tgtcaaaatt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa 2640  
 gagtattgtg agtctggagc taacaacttg tgttttagat gtcactgcag tgatattatt 2700  
 tttcttcacg ttcttatca ccaccatggt tatgttggct gcccggctc accatttgg 2760  
 ttactggat gtttggttta tatataatgt gtgttagct aaggtaaaag gctacaggc 2820  
 tctttccaca tcccaaactt tctatgtgc ttacatttct tatgacacca aagatgcctc 2880  
 tgttactgac tgggtgataaa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940  
 cgttctcctt tgtcttagagg agagggattt ggatccggga ttggccatca tcgacaacct 3000  
 catgcagagc atcaacccaa gcaagaaaac agtatttgg ttaacccaaa aatatgcaaa 3060  
 aagctggAAC tttaaaacag ctttttactt ggctttgcag aggctaattgg atgagaacat 3120  
 ggtatgtgatt atatttatcc tgctggagcc agtggtagat cattctcagt atttggggct 3180  
 acggcagcgg atctgtaaaga gctccatcct ccagtggcct gacaaccgaa aggcagaagg 3240  
 cttgtttgg caaaactctga gaaatgtggt ctgactgaa aatgattcac ggtataacaa 3300  
 tatgtatgtc gattccattta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360  
 ataaagatgc aaaggaatga catttctgta ttagttatct attgctatgt aacaaattat 3420  
 cccaaaactt agtggtttaa aacaacacat ttgctggccc acagtttt 3468

<210> 50  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 50

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1 5 10 15

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
 20 25 30

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
35 40 45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

355                   360                   365  
Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
370                   375                   380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
385                   390                   395                   400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
405                   410                   415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
420                   425                   430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Phe Gln  
435                   440                   445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
450                   455                   460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
465                   470                   475                   480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile  
485                   490                   495

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu  
500                   505                   510

Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala  
515                   520                   525

Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe  
530                   535                   540

Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp  
545                   550                   555                   560

Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His  
565                   570                   575

Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser  
580                   585                   590

His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys  
595                   600                   605

Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp  
610                   615                   620

Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn  
625                   630                   635                   640

Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn  
645                   650                   655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn  
660                   665                   670

Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro  
675                   680                   685

Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr

690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser		
705	710	715
		720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser		
	725	730
		735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
	740	745
		750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu		
	755	760
		765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
	770	775
		780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
785	790	795
		800
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
	805	810
		815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
	820	825
		830
Phe Phe Thr Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
835	840	845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
850	855	860
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
865	870	875
		880
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
	885	890
		895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
	900	905
		910
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
915	920	925
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
930	935	940
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
945	950	955
		960
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
965	970	975
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
980	985	990
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
995	1000	1005
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
1010	1015	1020
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		

1025	1030	1035
Lys Gln Tyr		
1040		
<210> 51		
<211> 1059		
<212> PRT		
<213> Homo sapiens		
<400> 51		
Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu		
1	5	10
		15
Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile		
	20	25
		30
Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe		
	35	40
		45
Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile		
	50	55
		60
Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly		
	65	70
		75
		80
Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile		
	85	90
		95
Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu		
	100	105
		110
Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln		
	115	120
		125
Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn		
	130	135
		140
Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser		
	145	150
		155
		160
Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile		
	165	170
		175
Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn		
	180	185
		190
Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr		
	195	200
		205
Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu		
	210	215
		220
Ser Leu Ser Phe Asn Ser Leu Ser His Val Ser Pro Lys Leu Pro Ser		
	225	230
		235
		240
Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser		
	245	250
		255
Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser		
	260	265
		270

Gly Asn Cys Pro Arg,Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
290 295 300

Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
305 310 315 320

Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
325 330 335

Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
340 345 350

Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
355 360 365

Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro  
370 375 380

Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
385 390 395 400

Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
405 410 415

Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
420 425 430

Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
435 440 445

Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
450 455 460

Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
465 470 475 480

Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
485 490 495

Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
500 505 510

Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
515 520 525

Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
530 535 540

Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
545 550 555 560

Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
565 570 575

Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
580 585 590

His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595	600	605
Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu		
610	615	620
Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile		
625	630	635
Leu Trp Asn Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu		
645	650	655
Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile		
660	665	670
Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His		
675	680	685
Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln		
690	695	700
Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe		
705	710	715
Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu		
725	730	735
Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu		
740	745	750
Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr		
755	760	765
Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met		
770	775	780
Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp		
785	790	795
Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu		
805	810	815
Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile		
820	825	830
Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile		
835	840	845
Leu Phe Phe Phe Thr Phe Ile Thr Thr Met Val Met Leu Ala Ala		
850	855	860
Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val		
865	870	880
Cys Leu Ala Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr		
885	890	895
Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr		
900	905	910
Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp		
915	920	925
Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu		

930	935	940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		
945	950	955
955	960	
Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr		
965	970	975
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val		
980	985	990
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu		
995	1000	1005
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro		
1010	1015	1020
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn		
1025	1030	1035
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val		
1040	1045	1050
Asp Ser Ile Lys Gln Tyr		
1055		
<210> 52		
<211> 1041		
<212> PRT		
<213> Homo sapiens		
<400> 52		
Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu		
1	5	10
		15
Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu		
35	40	45
Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr		
50	55	60
Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn		
65	70	75
		80
Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His		
85	90	95
Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn		
100	105	110
Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg		
115	120	125
Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu		
130	135	140
Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn		
145	150	155
		160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
385 390 395 400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
405 410 415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
420 425 430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
435 440 445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
450 455 460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
465 470 475 480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu	485	490	495
	500	505	510
Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala	515	520	525
Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe	530	535	540
Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp	545	550	555
			560
Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His	565	570	575
Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser	580	585	590
His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys	595	600	605
Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp	610	615	620
Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn	625	630	635
			640
Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn	645	650	655
Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn	660	665	670
Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro	675	680	685
Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr	690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser	705	710	715
			720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser	725	730	735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn	740	745	750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu	755	760	765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg	770	775	780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp	785	790	795
			800
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser	805	810	815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe			

820	825	830
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
835	840	845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
850	855	860
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
865	870	875
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
885	890	895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
900	905	910
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
915	920	925
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
930	935	940
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
945	950	955
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
965	970	975
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
980	985	990
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
995	1000	1005
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
1010	1015	1020
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		
1025	1030	1035
Lys Gln Tyr		
1040		
<210> 53		
<211> 1041		
<212> PRT		
<213> Homo sapiens		
<400> 53		
Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu		
1	5	10
		15
Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Lys Gln Asn Asp Ser Val Ile Ala Glu		
35	40	45
Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr		
50	55	60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385	390	395	400												
Leu	Gly	Ile	Asn	Phe	Ile	Lys	Gln	Ile	Asp	Phe	Lys	Leu	Phe	Gln	Asn
405								410							415
420															430
425															
435															445
440															
445															
450															
455															460
465															
470															480
475															
485															495
490															
500															510
505															
515															525
520															
530															540
535															
545															560
550															
555															
565															575
570															
580															590
585															
595															605
600															
610															620
615															
625															640
630															
635															
645															655
650															
660															670
665															
675															685
680															
685															
690															700
695															
705															720
710															
715															
720															
725															
730															
735															
740															
745															
750															
755															
760															
765															
770															
775															
780															
785															
790															
795															
800															
805															
810															
815															
820															
825															
830															
835															
840															
845															
850															
855															
860															
865															
870															
875															
880															
885															

725                    730                    735  
 Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn  
 740                    745                    750  
  
 Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu  
 755                    760                    765  
  
 Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg  
 770                    775                    780  
  
 Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp  
 785                    790                    795                    800  
  
 Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser  
 805                    810                    815  
  
 Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe  
 820                    825                    830  
  
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala  
 835                    840                    845  
  
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu  
 850                    855                    860  
  
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr  
 865                    870                    875                    880  
  
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp  
 885                    890                    895  
  
 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn  
 900                    905                    910  
  
 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile  
 915                    920                    925  
  
 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe  
 930                    935                    940  
  
 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe  
 945                    950                    955                    960  
  
 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile  
 965                    970                    975  
  
 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu  
 980                    985                    990  
  
 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro  
 995                    1000                    1005  
  
 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu  
 1010                    1015                    1020  
  
 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile  
 1025                    1030                    1035  
  
 Lys Gln Tyr  
 1040

<210> 54  
<211> 1059  
<212> PRT  
<213> Homo sapiens

<400> 54

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu  
1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile  
20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe  
35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile  
50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly  
65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile  
85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu  
100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln  
115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn  
130 135 140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser  
145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile  
165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn  
180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr  
195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu  
210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser  
225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser  
245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser  
260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
290 295 300

Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
305 310 315 320

Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
325 330 335

Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
340 345 350

Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
355 360 365

Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu  
370 375 380

Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
385 390 395 400

Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
405 410 415

Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
420 425 430

Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
435 440 445

Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
450 455 460

Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
465 470 475 480

Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
485 490 495

Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
500 505 510

Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
515 520 525

Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
530 535 540

Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
545 550 555 560

Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
565 570 575

Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
580 585 590

His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn  
595 600 605

Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610                    615                    620  
 Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
 625                    630                    635                    640  
 Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
 645                    650                    655  
 Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
 660                    665                    670  
 Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
 675                    680                    685  
 Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
 690                    695                    700  
 Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
 705                    710                    715                    720  
 Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
 725                    730                    735  
 Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
 740                    745                    750  
 Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
 755                    760                    765  
 Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met  
 770                    775                    780  
 Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
 785                    790                    795                    800  
 Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
 805                    810                    815  
 Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
 820                    825                    830  
 Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
 835                    840                    845  
 Leu Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala  
 850                    855                    860  
 Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
 865                    870                    875                    880  
 Cys Leu Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
 885                    890                    895  
 Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
 900                    905                    910  
 Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
 915                    920                    925  
 Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu  
 930                    935                    940  
 Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr

945	950	955	960
Val Phe Val Leu Thr	Lys Lys Tyr Ala Lys	Ser Trp Asn Phe Lys	Thr
965	970	975	
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val			
980	985	990	
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu			
995	1000	1005	
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro			
1010	1015	1020	
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn			
1025	1030	1035	
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val			
1040	1045	1050	
Asp Ser Ile Lys Gln Tyr			
1055			

<210> 55  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 55	
attcagagtt gnatgttaag agagaaaacaa acgttttacc ttcccttgtc tatagaacat	60
ggaaaaacatg cccccctcagt catggattct gacgtgcatt tgcctgctgt cctctggAAC	120
cagtgcatttc ttccataaaag cgaactattc cagaagctat cttgtgacg agataaggca	180
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat	240
aggcaagtat gtgacaaaca tagacttgtc agacaatgcc attacacata taacgaaaga	300
gtccttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca	360
gcacccaaat gaaaataaaa atggatgaa tattacagaa ggggcacttc tcagcctaag	420
aaatctaaca gtttactgc tggaagacaa ccagtttatat actatacctg ctgggttgcc	480
tgagtctttg aaagaactta gcctaattca aaacaatata ttccaggtaa ctaaaaacaa	540
cactttggg ctttaggaact tgaaaagact ctatgggc tggaactgct attttaaatg	600
taatcaaacc tttaaggtag aagatgggc attaaaaat cttatacact tgaaggtact	660
ctcattatct ttcaataacc ttttctatgt gccccccaaa ctaccaagtt ctctaaggaa	720
actttttctg agtaatgccaa aaatcatgaa catcaactcag gaagacttca aaggactgga	780
aaattnaaca ttactagatc tgagtggaaa ctgtccaagg tggataatg ctccatttcc	840
ttgcacaccc tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaaatgt	900
cacccaaactt ctctatctaa acctttccag cactccctc aggacgattc cttctacctg	960
gtttgaaaat ctgtcaaatc tgaaggaact ccattttgaa ttcaactatt tagttcaaga	1020

aattgcctcg gggcatttt taacaaaact acccagttt caaatccttg atttgcctt 1080  
caacttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgtc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttggca ttaactttat 1260  
tgagaaaatt gattcaaaag ctttccagaa ttttccaaa ctcgacgtt tctatttatac 1320  
aggaaatcgc atagcatctg tattagatgg tacagattat tccttttgc gaaatcgct 1380  
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag 1440  
caccaaacct ttaataaaagc cacagtgtac tgcttatggc aaggccttgg atttaagtt 1500  
gaacaatatt ttcatatttgg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560  
aaatctgtcc ttcaatgcc aatactcaagt gtttaatggc acagaattct cctccatgcc 1620  
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgctt 1680  
cagtgatctt cacgatctag aagtgctgga cctgagccac aatgcacact atttcagtt 1740  
agcaggggta acgcacccgtc taggatttat ccagaactta ataaacctca ggggtttaaa 1800  
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860  
gaaagaattt gttttagtg gaaatcgct tgaccatttgg tggaatgcaa atgatggcaa 1920  
atactggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa 1980  
ccttcaacaa atcccaaatg gagcattcct caatttgcct cagagcctcc aagagttact 2040  
tatcagtggt aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct 2100  
tcacttgctg gatttatcga gaaatgagct gtatttcta cccatttgc tatctaagtt 2160  
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220  
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaaagat 2280  
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340  
tgggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa 2400  
tctgaatatc acaattccta aattggtaaa tgtttatatgt tccaatcctg gggatcaaaa 2460  
atcaaagagt atcatgagcc tagatctcac gacttgtgtt tcggataccca ctgcagctgt 2520  
cctgttttc ctacattcc ttaccaccc catggttatg ttggctgctc tggttcacca 2580  
cctgttttac tggatgttt ggttatcta tcacatgtgc tctgctaagt taaaaggcta 2640  
caggacttca tccacatccc aaactttcta tgatgcttatttcttatac acaccaaaga 2700  
tgcattgtt actgactggg taatcaatga actgcgtac cacattgaag agagtgaaga 2760  
caaaagtgtc ctcccttgc tagaggagag ggattggat ccaggattac ccatcattga 2820  
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata 2880

tgccaagagc tggaaacctt aaacagctt ctacttggcc ttgcagaggc taatggatga	2940
gaacatggat gtgattat ttcatccctt ggaaccagtg ttacagtact cacagtacct	3000
gagggttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atccccaaagc	3060
agaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta	3120
tgacgattt tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc	3180
atcataaaaa cacacagctt ctcccttacaa tgaaccgaat	3220

<210> 56  
<211> 3220  
<212> DNA  
<213> murine

<400> 56	
attcagagtt ggatgttaag agagaaaacaa acgttttacc ttcccttgtc tatagaacat	60
ggaaaacatg ccccctcagt catggattct gacgtgcttt tgtctgtctgt cctctggAAC	120
cagtgccttc ttccataaaag cgaactattc cagaagctat ccttgtgacg agataaggca	180
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat	240
aggcaagtat gtgacaaaca tagacttgtc agacaatgcc attacacata taacgaaaga	300
gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaacaa	360
gcacccaaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag	420
aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc	480
tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa	540
cactttggg ctttaggaact tgaaaagact ctatttgggc tggaactgct attttaaatg	600
taatcaaacc tttaaggtag aagatggggc attttaaaat cttatacact tgaaggtact	660
ctcattatct ttcaataacc ttttctatgt gccccccaaa ctaccaagtt ctctaaaggaa	720
actttttctg agtaatgcca aaatcatgaa catcaactcag gaagacttca aaggactgga	780
aaattnaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc	840
ttgcacaccc tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct	900
cacccaactt ctctatctaa acctttccag cacttccctc aggacgatcc ctctacctg	960
gtttgaaaat ctgtcaaattc tgaaggaact ccatcttcaa ttcaactatt tagttcaaga	1020
aattgcctcg gggcatttt taacaaaact acccagttt caaatccttg atttgcctt	1080
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaaagct	1140
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca	1200
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat	1260

tgagaaaatt gattcaaag ctttccagaa ttttccaaa ctcgacgtta tctatttac	1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgct	1380
tcggaaacct ctctcaacag acgatgatga gtttgcgttca cacgtgaatt tttaccatag	1440
caccaaacct ttaataaaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt	1500
gaacaatatt ttcattatttgg gaaaaagcca atttgaaggt tttcaggata tcgcctgctt	1560
aatctgtcc ttcaatgcca atactcaagt gtttaatggc acagaattct cctccatgcc	1620
ccacattaaa tatttggatt taaccaaaca cagactagac tttgatgata acaatgcttt	1680
cagtgtatctt cacgatcttag aagtgcgttgc cctgagccac aatgcacact atttcagtat	1740
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca gggtgttaaa	1800
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaaa gcatctcact	1860
gaaagaattt gttttcagtg gaaatcgctc tgaccatttg tggatgcaa atgatggcaa	1920
atactggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa	1980
ccttcaacaa atccccaaatg gaggcatttcc caatttgcct cagagcctcc aagagttact	2040
tatcagtggt aacaaatttac gtttctttaa ttggacatttca ctccagtatt ttccctcacct	2100
tcacttgctg gattttatcga gaaatgagct gtatttcta cccatttgc tatctaagtt	2160
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg	2220
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaaagat	2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctatttgc tggagctaca	2340
tgggaactat tttgactgca cgtgtgacat aagtgtttt cgaagctggc tagatgaaaa	2400
tctgaatatc acaatttccata aattggtaaa tgtttatatgt tccaatccctg gggatcaaaa	2460
atcaaagagt atcatgagcc tagatctcac gacttgcgttgc tcggataccca ctgcagctgt	2520
cctgttttcc ctcacattcc ttaccacccatc catggttatg ttggctgctc tggttccacca	2580
cctgttttac tggatgtttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta	2640
caggacttca tccacatccc aaactttcta tgatgcttatttcttatac accaaaaaga	2700
tgcacatgtt actgactggg taatcaatga actgcgttac cacattgaag agagtgaaga	2760
caaaaagtgtc ctccttgcgtt tagaggagag ggattggat ccaggattac ccatcattga	2820
taacccatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata	2880
tgccaaagagc tggaaacttta aaacagctttt ctacttggcc ttgcagagggc taatggatga	2940
gaacatggat gtgattttt tcacatccctt ggaaccaggatg ttacagtact cacagtaccc	3000
gaggcttcgg cagaggatct gtaagagctc catccatccag tggcccaaca atccccaaagc	3060
agaaaaacttg ttttggcaaa gtctgaaaaa tggatgttttgc actgaaaatg attcaccgtt	3120
tgacgatttgcgtt tacatttgcgtt ccatttgcgtt atactgttgcgtt tggatgttgcgtt	3180

atcataaaaa cacacagctt ctccttacaa tgaaccgaat 3220

<210> 57  
<211> 1032  
<212> PRT  
<213> murine

<400> 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu ~~Asp~~ Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
435 440 445

Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
450 455 460

Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
465 470 475 480

Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
485 490 495

Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
500 505 510

Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
515 520 525

Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
530 535 540

His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
545 550 555 560

Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
565 570 575

Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
580 585 590

Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly

595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
640		
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
720		
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
800		
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
880		
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		

930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
960		
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	
<210> 58		
<211> 1032		
<212> PRT		
<213> murine		
<400> 58		
Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu		
1	5	10
		15
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu		
35	40	45
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr		
50	55	60
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys		
65	70	75
		80
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His		
85	90	95
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile		
100	105	110
Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu		
115	120	125
Lys Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu		
130	135	140
Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn		
145	150	155
		160
Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn		
165	170	175
Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe		
180	185	190

Lys Asn Ile Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys His Phe Glu His  
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
435 440 445

Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
450 455 460

Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
465 470 475 480

Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
485 490 495

Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
500 505 510

Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515 520 525  
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
530 535 540

His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
545 550 555 560

Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
565 570 575

Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
580 585 590

Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
595 600 605

Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
610 615 620

Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
625 630 635 640

Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
645 650 655

Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
660 665 670

Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
675 680 685

Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
690 695 700

Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
705 710 715 720

Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
725 730 735

Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
740 745 750

Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
755 760 765

Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile  
770 775 780

Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln  
785 790 795 800

Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp  
805 810 815

Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met  
820 825 830

Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp  
835 840 845

Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser

850                    855                    860  
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
865                    870                    875                    880  
  
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
885                    890                    895  
  
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
900                    905                    910  
  
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
915                    920                    925  
  
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
930                    935                    940  
  
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
945                    950                    955                    960  
  
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
965                    970                    975  
  
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
980                    985                    990  
  
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
995                    1000                  1005  
  
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
1010                  1015                  1020  
  
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
1025                  1030

<210> 59  
<211> 1032  
<212> PRT  
<213> murine

<400> 59

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
1                    5                    10                    15  
  
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
20                  25                  30  
  
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
35                  40                  45  
  
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
50                  55                  60  
  
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
65                  70                  75                  80  
  
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
85                  90                  95  
  
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
100                105                110

Thr Glu Gly Ala Leu Leu Ser Ile Arg Asn Leu Thr Val Leu Leu Leu  
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys His Phe Glu His  
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp

435                    440                    445  
Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
450                    455                    460  
  
Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
465                    470                    475                    480  
  
Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
485                    490                    495  
  
Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
500                    505                    510  
  
Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
515                    520                    525  
  
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
530                    535                    540  
  
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
545                    550                    555                    560  
  
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
565                    570                    575  
  
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
580                    585                    590  
  
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
595                    600                    605  
  
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
610                    615                    620  
  
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
625                    630                    635                    640  
  
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
645                    650                    655  
  
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
660                    665                    670  
  
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
675                    680                    685  
  
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
690                    695                    700  
  
Leu Glu Thr Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
705                    710                    715                    720  
  
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
725                    730                    735  
  
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
740                    745                    750  
  
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
755                    760                    765  
  
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile

770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
800		
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
820	825	830
835	840	845
850	855	860
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
880		
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		
930	935	940
945	950	955
960		
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	
<210> 60		
<211> 3352		
<212> DNA		
<213> Homo sapiens		
<400> 60		
aggctggat aaaaatctta cttccttat tctctgagcc gctgctgcc ctgtggaaag		60
ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgcc gccagaccct		120
ctggagaagc ccctgcccc cagcatgggt ttctgcccga gcgcctgca cccgctgtct		180

ctcctggtgc aggccatcat gctggccatg accctggccc tgggtacett gcctgccttc	240
ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct	300
gtgccccact tctccatggc agcaccccggt ggcaatgtca ccagccttcc ttgtccctcc	360
aaccgcatcc accacacctca tgattctgac tttgcccacc tgcccagect gccgcatttc	420
aacctcaagt ggaactgccc gccgggttggc ctcagcccca tgcacttccc ctgccacatg	480
accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac	540
aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat	600
accaacatcc ttagtctaga ctctgccaggc ctcgcccggc tgcattgcctt gcgccttcata	660
ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcaactgga ggtggccccc	720
ggtgcctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcact	780
tggtgtccccc gcaacctgcc ttccagcctg gagtatctgc tggatgtccca caaccgcattc	840
gtcaaactgg cgccctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtgggc	900
ggaaattgcc gccgctgcga ccacgctccc aaccctgca tggagtgccc tcgtcacttc	960
ccccagctac atccccatac cttcagccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagttctc tctccctggct gaatgccagt tggttccgtg ggctggaaaa cctccgagtg	1080
ctggacctga gtgagaactt cctctacaaa tgcattacta aaaccaaggc cttccagg	1140
ctaacacagc tgcgcaagct taacctgtcc ttcaattacc aaaagagggt gtcctttgcc	1200
cacctgtctc tggcccttc ctccggagc ctggcgcccc tgaaggagct ggacatgcac	1260
ggcatcttct tccgctca cgtgagacc acgctccggc cactggcccc cctgcccattg	1320
ctccagactc tgcgtctgca gatgaacttc atcaaccagg cccagctcggt catcttcagg	1380
gccttccctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agttcggag	1440
ctgacagcca ccatggggga ggcagatgga ggggagaagg tctggctgca gcctggggac	1500
cttgctccgg ccccagtggc cactcccagc tctgaagact tcaggccaa ctgcagcacc	1560
ctcaacttca ctttggatct gtcacggAAC aacctggtga ccgtgcagcc ggagatgttt	1620
gcccagctct cgcacctgca gtgcctgcgc ctgagccaca actgcatttc gcaggcagtc	1680
aatggctccc agttcctgcc gctgaccggc ctgcagggtc tagacctgtc ccgcaataag	1740
ctggacctct accacgagca ctcattcacg gagctaccgc gactggaggc cctggaccc	1800
agctacaaca gccagccctt tggcatgcag ggcgtggcc acaacttcag cttcgtggct	1860
cacctgcgca ccctgcgcca cctcagcctg gcccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagtacgtc gctgcgggccc ctggacttca gggcaatgc actggccat	1980
atgtggggccg agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgatctgg	2040
ctggacttgt cccagaaccg cctgcacacc ctcctgcccc aaaccctgca caacctcccc	2100

aagagctac	aggtgctgog	tctccgtgac	aattacctgg	ccttcttaa	gtggtggagc	2160
ctccacttcc	tgcccaaact	ggaagtccctc	gacctggcag	gaaaccggct	gaaggccctg	2220
accaatggca	gcctgcctgc	tggcacccgg	ctccggaggc	tggatgtcag	ctgcaacagc	2280
atcagcttcg	tggccccccgg	cttctttcc	aaggccaagg	agctgcgaga	gctcaacctt	2340
agcgccaaacg	ccctcaagac	agtggaccac	tcctggtttgc	ggccccctggc	gagtgccctg	2400
caaatactag	atgtaagcgc	caaccctctg	cactgcgcct	gtggggcggc	ctttatggac	2460
ttcctgctgg	aggtgcagge	tgccgtgccc	ggctgtccca	gccgggtgaa	gtgtggcagt	2520
ccggggccagc	tccagggcct	cagcatctt	gcacaggacc	tgcgcctctg	cctggatgag	2580
gccctctcct	gggactgttt	cgcctctcg	ctgctggctg	tggctctggg	cctgggtgtg	2640
cccatgctgc	atcacctctg	tggctgggac	ctctggtaact	gcttccacct	gtgcctggcc	2700
tggcttccct	ggcgggggcg	gcaaagtggg	cgagatgagg	atgcctgoc	ctacgatgcc	2760
ttcgtggct	tcgacaaaac	gcagagcgc	gtggcagact	gggtgtacaa	cgagcttcgg	2820
gggcagctgg	aggagtgccc	tggcgctgg	gcactccgccc	tgtgcctgga	ggaacgcgcac	2880
tggctgcctg	gcaaaaccct	ctttgagaac	ctgtggccct	cggctatgg	cagccgcaag	2940
acgctgttttgc	tgctggccca	cacggaccgg	gtcagtggtc	tcttgcgcgc	cagttcctg	3000
ctggcccagc	aggcgcctgct	ggaggaccgc	aaggacgtcg	tggtgcgttgt	gatcctgagc	3060
cctgacggccc	gccgctcccg	ctacgtgcgg	ctgcgcgcage	gcctctggcg	ccagagtgtc	3120
ctcctctggc	cccaccagcc	cagtggtcag	cgcagcttct	gggcccagct	gggcatggcc	3180
ctgaccaggg	acaaccacca	cttctataac	cggaacttct	gccagggacc	cacggccgaa	3240
tagccgtgag	ccggaatccct	gcacggtgcc	acctccacac	tcacctcacc	tctgcctgcc	3300
tggtctgacc	ctccctgtct	cgccctccctc	accccacacc	tgacacagag	ca	3352

<210> 61  
<211> 3257  
<212> DNA  
<213> Homo sapiens

<400> 61	ccgctgctgc	ccctgtggga	agggacctcg	agtgtgaagc	atccctccct	gtagctgctg	60
	tccagtcgtc	cgcgcagacc	ctctggagaa	gccctgccc	cccagcatgg	gtttctgccc	120
	cagcgcctg	cacccgctgt	ctctcccttgt	gcaggccatc	atgctggcca	tgaccctggc	180
	cctgggtacc	ttgcctgcct	tcctaccctg	tgagctccag	ccccacggcc	tggtaactg	240
	caactggctg	ttcctgaagt	ctgtgcucca	cttctccatg	gcagcacccc	gtggcaatgt	300
	caccagcctt	tccttgcct	ccaaaccgc	ccaccacctc	catgattctg	actttgcucca	360

cctggccagc ctgcggcata tcaacctaa gtggaaactgc ccggccgttg gcctcagccc 420  
 catgacttc ccctgccaca tgaccatcg a gcccaggcacc ttcttgctg tgcccacccct 480  
 ggaagagcta aacctgagct acaacaacat catgactgtg cctgcgctgc ccaaattccct 540  
 catatccctg tccctcagcc ataccaacat cctgatgcta gactctgcca gcctegccgg 600  
 cctgcatgcc ctgcgcattcc tattcatgga cggcaactgt tattacaaga acccctgcag 660  
 gcaggcactg gaggtggccc cgggtgcctt cttggcctg ggcaacctca cccacctgtc 720  
 actcaagtac aacaacctca ctgtggtgcc ccgcaacctg cttccagcc tggagtatct 780  
 gctgttgtcc tacaaccgca tcgtcaaact ggcgcctgag gacctggcca atctgaccgc 840  
 cctgcgtgtg ctcgatgtgg gcgaaattt ccggccgtgc gaccacgctc ccaacccctg 900  
 catggagtgc ctcgtcaact tccccagct acatcccgtt accttccagcc acctgagccg 960  
 tcttgaaggc ctgggtttga aggacagttc totctcctgg ctgaatgcca gttgggtccg 1020  
 tgggctggga aaccccgag tgctggaccc gaggatggaa ttcctctaca aatgcacac 1080  
 taaaaccaag gccttcagg gcctaacaca gctgcgcag cttaacctgt cttcaatta 1140  
 cccaaagagg gtgtcctttt cccacctgtc tctggccctt tccttcggga gcctggctgc 1200  
 cctgaaggag ctggacatgc acggcatctt cttccgctca ctcgatgaga ccacgctccg 1260  
 gccactggcc cgccctgcccc tgctccagac tctgcgtctg cagatgaact tcatcaacca 1320  
 ggcccagctc ggcatttca gggccttccc tggcctgcgc tacgtggacc tgtcggacaa 1380  
 cccatcagc ggagcttcgg agctgacagc caccatgggg gaggcagatg gaggggagaa 1440  
 ggtctggctg cagcctgggg accttgcctt ggccccagtg gacactccca gctctgaaga 1500  
 cttcaggccc aactgcagca ccctcaactt caccttggat ctgtcacggg acaacctgg 1560  
 gaccgtgcag ccggagatgt ttgcccagct ctcgcacccctg cagtgcctgc gcctgagcca 1620  
 caactgcac tgcaggcag tcaatggctc ccagttccctg ccgctgaccg gtctgcaggt 1680  
 gctagacctg tcccacaata agctggaccc ctaccacgag cactcattca cggagctacc 1740  
 acgactggag gcccggacc tcagctacaa cagccagccc tttggcatgc agggcgtggg 1800  
 ccacaacttc agttcgtgg ctcacccgtcg caccctgcgc cacctcagcc tggcccacaa 1860  
 caacatccac agccaaatgtt cccagcagct ctgcagtgacg tcgctgcggg ccctggactt 1920  
 cagccggcaat gcaactggcc atatgtggc cgagggagac ctctatctgc acttcttcca 1980  
 aggccctgagc ggtttgcattt ggctggactt gtcccagaac cgcctgcaca ccctcctgcc 2040  
 ccaaaccctg cgcaacccctcc ccaagagccct acaggtgctg cgtctccgtg acaattacct 2100  
 ggccttcttt aagtggtgga gcctccactt cctgccccaaa ctggaaatccc tcgacccggc 2160  
 aggaaaccag ctgaaggccc tgaccaatgg cagccctgcct gctggcaccg ggctccggag 2220  
 gctggatgtc agctgcaaca gcatcagctt cgtggccccc ggcttctttt ccaaggccaa 2280

ggagctgcga gagctcaacc ttagcgccaa cgccctcaag acagtggacc actcctggtt	2340
tgggccccctg gcgagtgccccc tgcaaatact agatgttaagc gccaaccctc tgcactgcgc	2400
ctgtggggcg gccttatgg acttcctgct ggaggtgcag gctgccgtgc ccggctcgcc	2460
cagccgggtg aagtgtggca gtccgggcca gctccagggc ctcagcatct ttgcacagga	2520
cctgcgcctc tgccctggatg aggccctctc ctgggactgt ttgcacctct cgctgctggc	2580
tgtggctctg ggccctgggtg tgcccatgct gcatcacctc tgtggctggg acctctggta	2640
ctgcttccac ctgtgcctgg cctggcttcc ctggcgggggg cggcaaagtg ggcgagatga	2700
ggatgcctg ccctacgatg cttcgtggt cttcgacaaa acgcagagcg cagtggcaga	2760
ctgggtgtac aacgagcttc gggggcagct ggaggagtgc cgtggcgct gggcaactccg	2820
cctgtgcctg gaggaacgca actggctgcc tggcaaaaacc ctcttgaga acctgtggc	2880
ctcggcttat ggcagccgca agacgctgtt tgtgctggcc cacacggacc gggtcagtgg	2940
tctcttgcgc gccagcttcc tgctggccca gcagcgctg ctggaggacc gcaaggacgt	3000
cgtgggtctg gtgatcctga gcccgtacgg ccgcgcgtcc cgctacgtgc ggctgcgcca	3060
gcgcctctgc cgccagagtg tcctcctctg gccccaccag cccagtggtc agcgcagatt	3120
ctgggcccag ctgggcatgg ccctgaccag ggacaaccac cacttctata accggaactt	3180
ctgccaggga cccacggccg aatagccgtg agccggaatc ctgcacgggtg ccacctccac	3240
actcacctca cctctqc	3257

<210> 62  
<211> 1032  
<212> PRT  
<213> Homo sapiens

<400> 62

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
           35                  40                  45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
50 55 60

Val	Thr	Ser	Leu	Ser	Leu	Ser	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
65					70					75					80

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met

	100	105	110
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu		Glu Glu Leu	
115	120	125	
Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser			
130	135	140	
Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser			
145	150	155	160
Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly			
165	170	175	
Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro			
180	185	190	
Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr			
195	200	205	
Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr			
210	215	220	
Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu			
225	230	235	240
Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg			
245	250	255	
Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe			
260	265	270	
Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly			
275	280	285	
Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe			
290	295	300	
Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu			
305	310	315	320
Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu			
325	330	335	
Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala			
340	345	350	
His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu			
355	360	365	
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu			
370	375	380	
Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met			
385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly			
405	410	415	
Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu			
420	425	430	
Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu			

435	440	445
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu		
450	455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
485	490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
500	505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
515	520	525
Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
530	535	540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	555
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
565	570	575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
580	585	590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
595	600	605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
610	615	620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
645	650	655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
660	665	670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg		
675	680	685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		
690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		

770                    775                    780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser  
 785                    790                    795                    800  
  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
 805                    810                    815  
  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
 820                    825                    830  
  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
 835                    840                    845  
  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
 850                    855                    860  
  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865                    870                    875                    880  
  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
 885                    890                    895  
  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
 900                    905                    910  
  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
 915                    920                    925  
  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930                    935                    940  
  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945                    950                    955                    960  
  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
 965                    970                    975  
  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980                    985                    990  
  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
 995                    1000                    1005  
  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
 1010                    1015                    1020  
  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu  
 1025                    1030  
  
 <210> 63  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 63  
  
 Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
 1                    5                    10                    15  
  
 Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20                    25                    30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu

355                   360                   365  
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
370                   375                   380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
385                   390                   395                   400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
405                   410                   415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
420                   425                   430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
435                   440                   445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
450                   455                   460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
465                   470                   475                   480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
485                   490                   495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
500                   505                   510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
515                   520                   525

Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
530                   535                   540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
545                   550                   555                   560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
565                   570                   575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
580                   585                   590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
595                   600                   605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
610                   615                   620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
625                   630                   635                   640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
645                   650                   655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
660                   665                   670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
675                   680                   685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690                         695                         700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705                         710                         715                         720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725                         730                         735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740                         745                         750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755                         760                         765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
 770                         775                         780  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser  
 785                         790                         795                         800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
 805                         810                         815  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
 820                         825                         830  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
 835                         840                         845  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
 850                         855                         860  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
 865                         870                         875                         880  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
 885                         890                         895  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
 900                         905                         910  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
 915                         920                         925  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
 930                         935                         940  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
 945                         950                         955                         960  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
 965                         970                         975  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
 980                         985                         990  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
 995                         1000                         1005  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
 1010                         1015                         1020  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu

1025                    1030  
<210> 64  
<211> 333  
<212> PRT  
<213> Homo sapiens  
  
<400> 64  
  
Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr  
1                        5                        10                        15  
  
His Thr Ala Leu Pro Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His  
20                      25                        30  
  
Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala  
35                      40                        45  
  
Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly  
50                      55                        60  
  
Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser  
65                      70                        75                        80  
  
Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn  
85                      90                        95  
  
Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu  
100                    105                        110  
  
Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro  
115                    120                        125  
  
Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala  
130                    135                        140  
  
Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr  
145                    150                        155                        160  
  
Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr  
165                    170                        175  
  
Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu  
180                    185                        190  
  
Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg  
195                    200                        205  
  
Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu  
210                    215                        220  
  
Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn  
225                    230                        235                        240  
  
Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val  
245                    250                        255  
  
Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu  
260                    265                        270  
  
Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys  
275                    280                        285

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser  
290 295 300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser  
305 310 315 320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu  
325 330

<210> 65

<211> 216

<212> PRT

<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln  
1 5 10 15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu  
20 25 30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu  
35 40 45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His  
50 55 60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe  
65 70 75 80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser  
85 90 95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser  
100 105 110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser  
115 120 125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu  
130 135 140

Ala Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met  
145 150 155 160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His  
165 170 175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala  
180 185 190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys  
195 200 205

Arg Gln Ala Leu Glu Val Ala Pro  
210 215

<211> 117  
<212> PRT  
<213> Homo sapiens

<400> 66

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala  
1 5 10 15

Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp  
20 25 30

Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly  
35 40 45

Asn Val Thr Ser Leu Ser Leu Ser Asn Arg Ile His His Leu His  
50 55 60

Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys  
65 70 75 80

Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His  
85 90 95

Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu  
100 105 110

Leu Asn Leu Ser Tyr  
115

<210> 67  
<211> 1032  
<212> PRT  
<213> Homo sapiens

<400> 67

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu

450                    455                    460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465                    470                    475                    480  
  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485                    490                    495  
  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500                    505                    510  
  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515                    520                    525  
  
 Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530                    535                    540  
  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545                    550                    555                    560  
  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565                    570                    575  
  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580                    585                    590  
  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595                    600                    605  
  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610                    615                    620  
  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625                    630                    635                    640  
  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645                    650                    655  
  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660                    665                    670  
  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
 675                    680                    685  
  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
 690                    695                    700  
  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705                    710                    715                    720  
  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725                    730                    735  
  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740                    745                    750  
  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755                    760                    765  
  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
 770                    775                    780  
  
 Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser

785	790	795	800
Ile Phe Ala Gln Asp Leu Arg Leu Cys Ieu Asp Glu Ala Leu Ser Trp			
805	810	815	
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val			
820	825	830	
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His			
835	840	845	
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp			
850	855	860	
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln			
865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu			
885	890	895	
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp			
900	905	910	
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr			
915	920	925	
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser			
930	935	940	
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu			
945	950	955	960
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg			
965	970	975	
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val			
980	985	990	
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln			
995	1000	1005	
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg			
1010	1015	1020	
Asn Phe Cys Gln Gly Pro Thr Ala Glu			
1025	1030		

<210> 68  
 <211> 3200  
 <212> DNA  
 <213> murine

<400> 68		
tgtcagaggg agcctcgaaa gaatcccca tctcccaaca tggttctccg tcgaaggact	60	
ctgcacccct tgccctcct ggtacaggct gcagtgcgtt ctgagactct ggccctgggt	120	
accctgcctg ctttcctacc ctgtgagctg aagcctcatg gcctgggtga ctgcaattgg	180	
ctgttcctga agtctgtacc ccgtttctct gcggcagcat cctgctccaa catcacccgc	240	
ctctccttga tctccaaaccg tatccaccac ctgcacaact ccgacttcgt ccacccgttcc	300	

aacctgcggc agctgaacct caagtggAAC tgtccaccca ctggccTTAG ccccCTGcac	360
ttctCTTgCC acatgaccat tgagCCCAGA acctTCCTGG CTATGCGTAC actggaggAG	420
ctgAACCTGA gCTATAATGG tatCACCACT gtGCCCGAC tgCCCAgCTC CCTGGTGAAT	480
ctgAGGCCTGA GCCACACCAA catCCTGGTT CTAGATGCTA acAGCCTCGC CGGCCTATAAC	540
agCCTGCgCG ttCTCTTcat ggACGGGAAC tgCTACTACA agAACCCCTG cacAGGAGCG	600
gtGAAGGTGA CCCAGGCGC CCTCCTGGC CTGAGCAATC tcACCCATCT gtCTCTGAAG	660
tataacaACC tcacAAAGGT gCCCCCcaa CTGCCCCCC GACTGGAGTA CCTCCTGGTG	720
tcCTATAACC tcATTGTCAA GCTGGGGCCT gaAGACCTGG CCAATCTGAC CTCCCTTCGA	780
gtACTTgATG tgggtgggaa ttGCCGTCGc TGCGACCAtG CCCCAATCC CTGTATAGAA	840
tgtggccAAA agtCCCTCCA CCTGACCCT gagACCTTC ATCACCTGAG CCATCTGGAA	900
ggCCTGGTGC TGAAGGACAG CTCTCTCCAT ACACTGAACT CCTCCTGGTT CCAAGGTCTG	960
gtCAACCTCT CGGTGCTGGA CCTAAGCGAG AACTTTCTCT atGAAAGCAT CAACCACACC	1020
aatGCCTTTC AGAACCTAAAC CGCCTGCGC AAGCTCAACC TGTCTTCAA TTACCGCAAG	1080
aaggTATCCT ttGCCCGCCT CCACCTGGCA AGTTCCTTCA AGAACCTGGT GTCACTGCAg	1140
gagCTGAACA TGAACGGCAT CTTCCTCCGC TCgCTCAACA AGTACACGCT CAGATGGCTG	1200
gccgATCTGC CCAAACtCCA CACTCTGCAT CTTCaaaATGA ACTTCATCAA CCAGGCAcAG	1260
CTCAGCATCT ttggTACCTT CGAGCCCTT CGTTTGTGG ACTTGTcAGA CAATCGCAtC	1320
AGTGGGCCTT CAAcGCTGTC AGAACCCACC CCTGAAGAGG CAGATGATGC AGAGCAGGAG	1380
gagCTGTTGT CTGCGGATCC TAACCCAGCT COACTGAGCA CCCCTGCTTC TAAGAACtTC	1440
ATGGACAGGT GtaAGAACtT CAAGTTCAcc ATGGACCTGT CTCGGAAACAA CCTGGTgACT	1500
ATCAAGCCAG AGATGTTGT CAATCTCTCA CGCCTCCAGT GTCTTAGCCT GAGCCACAAc	1560
TCCATTGcAC AGGCTGTCAA TGGCTCTAG TTCCtGCCGC TGACTAATCT GCAGGTGCTG	1620
GACCTGTCCC ATAACAAACT GGACTTGTAC CACTGGAAAT CGTTCAgTGA GCTACCACAG	1680
ttgcAGGCCC TGGACCTGAG CtACAACAGC CAGCCCTTA GCAcTAAGGG TATAGGCCAC	1740
AATTTCAGTT ttgtggCCCA tCTGTCCATG CTACACAGCC TTAGCCTGGC ACACAAATGAC	1800
ATTCATAACCC GtGTGTCCtC ACATCTCAAC AGCAACTCAg TGAGGTTCT TGACTTCAGC	1860
GGCAACGGTA tggggccat gtgggatgag gggggcCTTT AtCTCCATTt CTtCCAAAGGC	1920
CTGAGTGGCC TGCTGAAGCT GGACCTGTCT CAAAATAACC TGCAATATCTT CGGGCCCCAG	1980
AACCTTGACA ACCTCCCCAA GAGCCTGAAG CTGCTGAGCC TCCGAGACAA CTACCTATCT	2040
ttctttaact ggaccAGTCT GTCCTTCCTG CCCAACCTGG aAGTCCTAGA CCTGGCAGGC	2100
aaccAGCTAA AGGCCCTGAC CAATGGCACC CTGCTTAATG GCACCCtCCT CCAGAAACTG	2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgctct ggccggcgag	2220
ctgaaagagg tcaaccttag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg	2280
cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgttagactt actgttggag gtgcagacca aggtgcctgg cctggctaata	2400
gttgtgaagt gtggcagccc cggccagctg cagggccgta gcacatcttcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctcttttg gactgcttg gcctttcaact cttggctgtg	2520
gccgtggca tgggtgtgcc tataactgcac catctctgca gctgggacgt ctggtaactgt	2580
tttcatctgt gcctggcatg gctaccttg ctggccgcga gccgacgcag cgcccaagct	2640
ctccccatgt atgccttcgt ggtgttcgt aaggcacaga ggcgcagttgc ggactgggtg	2700
tataacgagc tgccgggtgcg gctggaggag cggcgccggtc gccgagccct acgcttgcgt	2760
ctggaggacc gagattggct gcctggccag acgctttcg agaacctctg ggcttccatc	2820
tatggagcc gcaagactct atttgtgctg gcccacacgg accgcgtcag tggcctcctg	2880
cgcaccagct tcctgtggc tcagcagcgc ctgttggaaag accgcaagga cgtgggtgg	2940
ttgggtatcc tgctccgga tgcccaccgc tcccgctatg tgctgactgcg ccagcgtctc	3000
tgccgccaga gtgtgtctt ctggcccccag cagcccaacg ggcaggggggg cttctggcc	3060
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcattt catgcctgg	3180
tcccgagttg ctctgcctgc	3200

<210> 69  
<211> 3471  
<212> DNA  
<213> murine

<400> 69	
tgaaaagtgtc acttcctcaa ttctctgaga gaccctggtg tgaaacatca ttctctgccg	60
cccagttgt cagagggagc ctcggagaa tcctccatct cccaaacatgg ttctccgtcg	120
aaggactctg caccccttgc cccatctgtt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tggggactg	240
caattggctg ttctgttgtt ctgtaccccg tttctctgcg gcagcatctt gctccaacat	300
cacccgcctc tccttgatct ccaaccgtat ccaccacatcg cacaactccg acttcgtccca	360
cctgtccaaac ctgcggcagc tgaacctcaa gtggaaactgt ccacccactg gccttagccc	420
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttccctggcta tgcgtacact	480
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct	540

ggtaatctg agcctgagcc acaccaacat cctggttcta gatgctaaaca gcctgcgg  
cctatacagc ctgcgcgttc tttcatgga cgaaaactgc tactacaaga acccctgcac 600  
660  
aggagcggtg aaggtagcccc caggcgccct cctgggcctg agcaatctca cccatctgtc  
tctgaagtat aacaacctca caaagggtgcc cggccaactg ccccccagcc tggagtacct 720  
780  
cctgggtgcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc  
ccttcgagta cttgtatgtgg gtggaaattt ccgtcgctgc gaccatgccc ccaatccctg 840  
900  
tatagaatgt gccaaaaagt ccctccaccc gcaccctgag accttccatc acctgagcca  
tctggaaggc ctgggtctga aggacagctc tctccatata ctgaactctt cctggttcca 960  
1020  
aggctggtc aacctctcggt tgctggacct aagcgagaac tttctctatg aaagcatcaa  
ccacaccaat gcctttcaga acctaaccgg cctgcgcaga ctcaacccgt ccttcaatta 1080  
1140  
ccgcaagaag gtatcctttt cccgcctcca cctggcaagt tccttcaaga acctgggtgc  
actgcaggag ctgaacatgaa acggcatctt ctccgctcg ctcaacaagt acacgctcag 1200  
1260  
atggctggcc gatctgcccc aactccacac tctgcacatctt caaatgaact tcatcaacca  
ggcacagctc agcatctttt gtaccttcgg agcccttcgc tttgtggact tgtcagacaa 1320  
1380  
tcgcacatcgt gggccttcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga  
gcaggaggag ctgttgtctg cggatccatca cccagctcca ctgagcacccc ctgcttctaa  
gaacttcatg gacaggtgta agaacttcaa gttcaccatg gacctgtctc ggaacaacct 1440  
1560  
ggtgactatc aagccagaga tgttgtcaa tctctcacgc ctccagtgatc tttagcctgag  
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgcccgtga ctaatctgca 1620  
1680  
ggtgctggac ctgtcccata acaaactgga ctgttaccac tggaaatcgat tcagttagct  
accacagttt cagggccctgg acctgagcta caacagccag cccttttagca tgaagggtat 1800  
1860  
aggccacaat ttcatgtttt tgaccatct gtccatgcta cagagcctta gcctggcaca  
caatgacatt catacccggt tgccatcaca tctcaacagc aactcagtga ggtttcttga  
cttcagcggc aacggtatgg gcccgtatgtt ggatgagggg ggcctttatc tccatttctt 1920  
1980  
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg  
gccccagaac ctgtacaacc tccccaaagag cctgaagctg ctgagcctcc gagacaacta 2040  
2100  
cctatcttc tttaactgga ccagtctgtc ctccatcccc aacctggaag tcctagaccc  
ggcaggcaac cagctaaagg ccctgaccaaa tggcaccctg cctaatggca ccctccatca  
gaaactcgat gtcagtagca acagtatcgat ctctgtggc ccagccttct tcgtctggc 2220  
2280  
ggtcgagctg aaagaggtca acctcagccaa caacattctc aagacggtgg atcgctcctg  
gtttggccccc attgtatgaa acctgacagt tctagacgtg agaagcaacc ctctgcactg  
tgcctgtggg gcagccttcg tagacttact gttggaggtg cagaccaagg tgcctggcc 2340  
2400  
2460

ggctaatggt gtgaagtgtg gcagccccgg ccagctgcag ggccgttagca tttcgcgca	2520
ggacctgcgg ctgtgcctgg atgaggtcct ctcttggac tgctttggcc tttcactctt	2580
ggctgtggcc gtgggcatgg tggtgccatat actgcaccat ctctgcggct gggacgtctg	2640
gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgcagcc gacgcagcgc	2700
ccaaactctc ccttatgatg ctttcgtggt gttcgataag gcacagagcg cagttgccga	2760
ctgggtgtat aacgagctgc gggtgcggct ggaggagcgg cgccgtcgcc gagccctacg	2820
cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc	2880
ttccatctat gggagccgca agactctatt tgtgtggcc cacacggacc gcgtcagtgg	2940
cctcctgcgc accagcttcc tgctggctca gcagcgcctg ttggaagacc gcaaggacgt	3000
ggtgtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgc当地	3060
gcgtctctgc cgccagagtg tgctcttctg gcccagcag cccaacgggc aggggggctt	3120
ctggcccag ctgagttacag ccctgactag ggacaaccgc cacttctata accagaactt	3180
ctgcggggga cctacagcag aatagcttag agcaacagct ggaaacagct gcatcttcat	3240
gcctggttcc cgagttgctc tgccctgcctt gctctgtctt actacaccgc tatttggcaa	3300
gtgcgaata tatgctacca agccaccagg cccacggagc aaaggttggc agtaaagggt	3360
agtttcttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca	3420
ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgtat	3471

<210> 70  
 <211> 3340  
 <212> DNA  
 <213> murine

<400> 70	
tctctgagag accctgggtt ggaacatcat tctctgcgc ccagttgtc agagggagcc	60
tcggagaat cttccatctc ccaacatggt tctccgtcga aggactctgc accccttgc	120
cctccctgta caggctgcag tgctggctga gactctggcc ctgggtaccc tgccctgcctt	180
cctaccctgt gagctgaagc ctcatggct ggtggactgc aattggctgt tcctgaagtc	240
tgtacccctgt ttctctgcgg cagcatctg ctccaaacatc accccgcctct ctgtatctc	300
caaccgtatc caccacctgc acaactccga ctgcgtccac ctgtccaaacc tgccggcagct	360
gaacctcaag tggaaactgtc cacccactgg ccttagcccc ctgcacttct cttgccacat	420
gaccatttag cccagaacct tcctggctat gcgtacactg gaggagctga acctgagcta	480
taatggtatac accactgtgc cccgactgcc cagctccctg gtgaatctga gcctgagcca	540
caccaacatc ctgggtcttag atgctaacag cctcgccggc ctatacagcc tgccgcgttct	600

cttcatggac gggaaactgct actacaagaa cccctgcaca ggagcggta aggtgacccc	660
aggcccccctc ctgggcctga gcaatctcac ccacatctgtct ctgaagtata acaacctcac	720
aaagggtgccc cgccaaactgc cccccagcct ggagtacctc ctgggtgcct ataacctcat	780
tgtcaagctg gggcctgaag acctggccaa tctgacctcc cttcgagttac ttgatgtggg	840
tgggaattgc cgtcgctgctg accatgcccc caatccctgt atagaatgtg gccaaaagtc	900
cctccacctg caccctgaga cttccatca cctgagccat ctggaaaggcc tggtgctgaa	960
ggacagctct ctccatacac tgaactcttc ctggttccaa ggtctggtca acctctcggt	1020
gctggaccta agcgagaact ttetctatga aagcatcaac cacaccaatg ctttcagaa	1080
cctaaccgcg ctgcgcaagc tcaacctgtc cttcaattac cgcaagaagg tatcctttgc	1140
ccgcctccac ctggcaagtt cttcaagaa cctgggtgtca ctgcaggagc tgaacatgaa	1200
cggcatcttc ttccgctcgc tcaacaagta cacgctcaga tggctggccg atctgcccaa	1260
actccacact ctgcacatcttc aaatgaactt catcaaccag gcacagctca gcatctttgg	1320
taccttcgaa gcccctcgct ttgtggactt gtcaagacaat cgcatcagtg ggccttcaac	1380
gctgtcagaa gccacccctg aagaggcaga tggatgcagag caggaggagc tggtgtctgc	1440
ggatcctcac ccagctccac tgagcacccc tgcttctaag aacttcatgg acaggtgtaa	1500
gaacttcaag ttcaccatgg acctgtctcg gaacaacctg gtgactatca agccagagat	1560
ttttgtcaat ctctcagcgc tccagtgctc tagcctgagc cacaactcca ttgcacaggc	1620
tgtcaatggc tctcagttcc tgccgctgac taatctgcag gtgctggacc tgcccataa	1680
caaactggac ttgttaccact ggaaatcggtt cagttagctt ccacagttgc aggccctgga	1740
cctgggctac aacagccagc ctttagcat aaagggtata ggccacaatt tcagtttgt	1800
ggcccatctg tccatgctac acagccttag cctggcacac aatgacattc ataccgtgt	1860
gtcctcacat ctcaacagca actcagttagt gtttcttgac ttcaaggcggca acgttatggg	1920
ccgcatgtgg gatgaggggg gcctttatct ccatttcttc caaggcctga gtggcctgct	1980
gaagctggac ctgtctcaaa ataacctgca tattcctccgg ccccagaacc ttgacaacct	2040
ccccaaagac ctgaagctgc tgagcctccg agacaactac ctatcttct ttaactggac	2100
cagtctgtcc ttccctgccc acctggaaatg cctagacctg gcaggcaacc agctaaaggc	2160
cctgaccaat ggcaccctgc ctaatggcac cttccctccag aaactggatg tcagcagcaa	2220
cagtatcgac tctgtggtcc cagccttctt cgctctggcg gtcgagctga aagaggtcaa	2280
cctcagccac aacattctca agacggtgga tcgctctgg tttggccca ttgtgatgaa	2340
cctgacagtt cttagacgtga gaagcaaccc tctgcactgt gcctgtgggg cagccttcgt	2400
agacttactg ttggaggtgc agaccaaggt gcctggcctg gctaattggg tgaagtgtgg	2460
cagccccggc cagctgcagg gcccgtacat ctgcacag gacctgcggc tgcctggaa	2520

tgaggccctc tcttggact gctttggcct ttcaactcttg gctgtggccg tgggcattgt 2580  
 ggtgcctata ctgcaccatc tctgcggctg ggacgtctgg tactgttttc atctgtgcct 2640  
 ggcatggcta cctttgctgg cccgcagccg acgcagcgcc caagctctcc cctatgatgc 2700  
 cttcggtgt ttcgataagg cacagagcgc agttgcggac tgggtgtata acgagctgcg 2760  
 ggtgcggctg gagggggccgc gcgggtcgccg agccctacgc ttgtgtctgg aggaccgaga 2820  
 ttggctgcct ggccagacgc tcttcgagaa cctctggct tccatctatg ggagccgcaa 2880  
 gactctatcc gtgttgtggccc acacggaccc cgtaatgtggc ctcctgcgc ccaatccct 2940  
 gctggctcag cagcgccgt tggaagaccc caaggacgtg gtgggtttgg tgatcctgcg 3000  
 tccggatgcc caccgcctcc gctatgtgcg actgcgcag cgtctctgcc gccagagtgt 3060  
 gctctttgg ccccagcagc ccaacgggc ggggggcttc tgggcccagc tgagtacagc 3120  
 cctgactagg gacaaccgc acttctataa ccagaacttc tgccggggac ctacagcaga 3180  
 atagctcaga gcaacagctg gaaacagctg catcttcatg cctgggtcccc gagttgtct 3240  
 gcctgccttg ctctgtctta ctacaccgct atttggcaag tgcgcaatat atgctaccaa 3300  
 gccaccgggc ccacggagca aagggtggct gtaaagggtta 3340

<210> 71  
 <211> 3471  
 <212> DNA  
 <213> murine

<400> 71  
 tgaaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggaacatca ttctctgcgg 60  
 cccagtttgt cagagggagc ctcggagaa tcctccatct cccaacatgg ttctccgtcg 120  
 aaggactctg cacccttgcgtt ccctcctggt acaggctgca gtgctggctg agactctggc 180  
 cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg 240  
 caattggctg ttctctgaatg ctgtaccccg tttctctgcg gcagcatctt gctccaacat 300  
 caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca 360  
 cctgtccaac ctgcggcagc tgaacctcaa gtggaaactgt ccacccactg gccttagccc 420  
 cctgcacttc tcttgccaca tgaccattga gcccagaacc ttctggctt tggtacact 480  
 ggaggagctg aacctgagct ataatggat caccactgtg ccccgactgc ccagctccct 540  
 ggtaatctg agcctgagcc acaccaacat cctgggttcta gatgctaaca gcctcgccgg 600  
 cctatacagc ctgcgcgttc tcttcatgga cggaaactgc tactacaaga accccctgcac 660  
 aggagcggtg aaggtgaccc caggcccccct cctggggctg agcaatctca cccatctgtc 720  
 tctgaagtat aacaacctca caaagggtgcc ccgcctaactg ccccccagcc tggagtacct 780

cctgggtgtcc tataacacctca ttgtcaagct ggggcctgaa gaccctggcca atctgaccc 840  
ccttcgagta cttgtatgtgg gtgggaaatttgc cctgtcgctgc gaccatgccc ccaatccctg 900  
tatagaatgt gccaaaagt ccctccaccc gcaccctgag accttccatc acctgagcca 960  
tctggaaaggc ctgggtgtga aggacagctc tctccataca ctgaacttctt cctgggttcca 1020  
aggctggtc aacctctcg tgctggacct aagcgagaac tttctctatg aaagcatcaa 1080  
ccacaccaat gccttcaga acctaaccgg cctgcgcag ctcaacctgt ccttcattaa 1140  
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaga acctgggtgc 1200  
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag 1260  
atggctggcc gatctgccc aactccacac tctgcacatctt caaatgaact tcatcaacca 1320  
ggcacagctc agcatctttg gtacccctcg agcccttcgc tttgtggact tgtcagacaa 1380  
tcgcacatcgt gggccttcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga 1440  
gcaggaggag ctgttgcctg cggatccca cccagctcca ctgaggcaccc ctgcttctaa 1500  
gaacttcatg gacaggtgtaa agaacttcaa gttcaccatg gacctgtctc ggaacaacct 1560  
ggtgactatc aagccagaga tgtttgccttacgc ctccagtgac tttagcctgag 1620  
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgcccgtga ctaatctgca 1680  
ggtgctggac ctgtcccata acaaacttggaa cttgtaccac tggaaatcgat tcagtggact 1740  
accacagtttgc caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat 1800  
aggccacaat ttccatggat tgacccatct gtccatgcta cagaggctta gcctggcaca 1860  
caatgacatt catacccgat tgccttcaca tctcaacagc aactcagtgtaa ggtttcttgc 1920  
cttcagccggc aacggtatgg gcccgcgttg ggatgaggggg ggcctttatc tccatttctt 1980  
ccaaggccctg agtggcctgc tgaagcttggaa cctgtctcaa aataacctgc atatcctccg 2040  
gccccagaac cttgacaacc tccccaaagag cctgaagctg ctgaggccctc gagacaacta 2100  
cctatcttcc tttaacttggaa ccagtctgtc ctccctaccc aacctggaaag tcctagaccc 2160  
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaatggca ccctccctcc 2220  
gaaactcgat gtcagtagca acagtatcgat ctctgtggc ccagccttct tcgtctggc 2280  
ggtcgagctg aaagaggtca acctcagccaa caacattctc aagacgggtgg atcgctccctg 2340  
gtttggggccc attgtatgtaa acctgacagt tctagacgtg agaagcaacc ctctgcactg 2400  
tgcctgtggg gcagccctcg tagacttact gttggaggtg cagaccaagg tgcctggcc 2460  
ggctaatgggt gtgaagttgtg gcagccccgg ccagctgcag ggccgttagca tcttcgcgc 2520  
ggacctgcgg ctgtgcctgg atgaggtctt ctcttggac tgctttggcc tttcaacttctt 2580  
ggctgtggcc gtgggcattgg tgggcctat actgcaccat ctctgcggct gggacgtctg 2640  
gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgcagcc gacgcagcgc 2700

ccaaactctc ctttatgtat ctttcgtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggtgccgct ggaggagcgg cgccgtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctctgcgc accagcttcc tgctggctca gcagcgcctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgcctc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgctcttcg gccccagcag cccaaacgggc aggggggctt 3120  
 ctgggcccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagcttag agcaacagct ggaaacagct gcatttcat 3240  
 gcctggttcc cgagttgctc tgccctgcctt gctctgtctt actacaccgc tatttggcaa 3300  
 gtgcgcaata tatgctacca agccaccagg cccacgggc aaaggttggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgtat 3471

<210> 72  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

465	470	475	480
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu			
485		490	495
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala			
500	505	510	
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp			
515	520	525	
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu			
530	535	540	
Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe			
545	550	555	560
Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser			
565	570	575	
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val			
580	585	590	
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595	600	605	
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610	615	620	
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625	630	635	640
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645	650	655	
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660	665	670	
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675	680	685	
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690	695	700	
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705	710	715	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			
725	730	735	
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn			
740	745	750	
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly			
755	760	765	
Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly			
770	775	780	
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg			
785	790	795	800
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser			

385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala			
405		410	415
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr			
420		425	430
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu			
435		440	445
Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser			
450		455	460
Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu			
465		470	475
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu			
485		490	495
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala			
500		505	510
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp			
515		520	525
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu			
530		535	540
Leu Pro Gln Leu Gln Ala Leu Asp Leu Gly Tyr Asn Ser Gln Pro Phe			
545		550	555
Ser Ile Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser			
565		570	575
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val			
580		585	590
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595		600	605
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610		615	620
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625		630	635
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645		650	655
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660		665	670
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675		680	685
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690		695	700
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705		710	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			

	725	730	735	
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn				
	740	745	750	
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly				
	755	760	765	
Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly				
	770	775	780	
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg				
	785	790	795	800
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser				
	805	810	815	
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val				
	820	825	830	
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe				
	835	840	845	
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser				
	850	855	860	
Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln				
	865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu				
	885	890	895	
Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp				
	900	905	910	
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr				
	915	920	925	
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser				
	930	935	940	
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu				
	945	950	955	960
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His				
	965	970	975	
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val				
	980	985	990	
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln				
	995	1000	1005	
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln				
	1010	1015	1020	
Asn Phe Cys Arg Gly Pro Thr Ala Glu				
	1025	1030		

<210> 74  
<211> 1032  
<212> PRT

&lt;213&gt; murine

&lt;400&gt; 74

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser  
565 570 575

Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu

	645	650	655													
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr	
	660	665												670		
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn	
								675	680					685		
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu	
								690	695					700		
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala	
									705	710					720	
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn	
									725	730					735	
Ile	Leu	Lys	Thr	Val	Asp	Arg	Ser	Trp	Phe	Gly	Pro	Ile	Val	Met	Asn	
								740	745					750		
Leu	Thr	Val	Leu	Asp	Val	Arg	Ser	Asn	Pro	Leu	His	Cys	Ala	Cys	Gly	
								755	760					765		
Ala	Ala	Phe	Val	Asp	Leu	Leu	Glu	Val	Gln	Thr	Lys	Val	Pro	Gly		
									770	775					780	
Leu	Ala	Asn	Gly	Val	Lys	Cys	Gly	Ser	Pro	Gly	Gln	Leu	Gln	Gly	Arg	
								785	790					800		
Ser	Ile	Phe	Ala	Gln	Asp	Leu	Arg	Leu	Cys	Leu	Asp	Glu	Val	Leu	Ser	
								805		810				815		
Trp	Asp	Cys	Phe	Gly	Leu	Ser	Leu	Leu	Ala	Val	Ala	Val	Gly	Met	Val	
								820		825				830		
Val	Pro	Ile	Leu	His	His	Leu	Cys	Gly	Trp	Asp	Val	Trp	Tyr	Cys	Phe	
								835		840				845		
His	Leu	Cys	Leu	Ala	Trp	Leu	Pro	Leu	Leu	Ala	Arg	Ser	Arg	Arg	Ser	
								850		855				860		
Ala	Gln	Thr	Leu	Pro	Tyr	Asp	Ala	Phe	Val	Val	Phe	Asp	Lys	Ala	Gln	
								865	870		875			880		
Ser	Ala	Val	Ala	Asp	Trp	Val	Tyr	Asn	Glu	Leu	Arg	Val	Arg	Leu	Glu	
								885		890				895		
Glu	Arg	Arg	Gly	Arg	Arg	Ala	Leu	Arg	Leu	Cys	Leu	Glu	Asp	Arg	Asp	
								900		905				910		
Trp	Leu	Pro	Gly	Gln	Thr	Leu	Phe	Glu	Asn	Leu	Trp	Ala	Ser	Ile	Tyr	
								915		920				925		
Gly	Ser	Arg	Lys	Thr	Leu	Phe	Val	Leu	Ala	His	Thr	Asp	Arg	Val	Ser	
								930		935				940		
Gly	Leu	Leu	Arg	Thr	Ser	Phe	Leu	Leu	Ala	Gln	Gln	Arg	Leu	Leu	Glu	
								945	950		955			960		
Asp	Arg	Lys	Asp	Val	Val	Val	Leu	Val	Ile	Leu	Arg	Pro	Asp	Ala	His	
								965		970				975		
Arg	Ser	Arg	Tyr	Val	Arg	Leu	Arg	Gln	Arg	Leu	Cys	Arg	Gln	Ser	Val	

980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln		
995	1000	1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 75  
<211> 1032  
<212> PRT  
<213> murine

<400> 75

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln		
1	5	10
		15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe		
20	25	30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu		
35	40	45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn		
50	55	60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His His Leu His Asn		
65	70	75
		80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp		
85	90	95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met		
100	105	110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu		
115	120	125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser		
130	135	140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala		
145	150	155
		160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly		
165	170	175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro		
180	185	190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr		
195	200	205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr		
210	215	220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu		
225	230	235
		240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

565	570	575
Met Leu Gln Ser	Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val	
580	585	590
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly		
595	600	605
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe		
610	615	620
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn		
625	630	635
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu		
645	650	655
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr		
660	665	670
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn		
675	680	685
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu		
690	695	700
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala		
705	710	715
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn		
725	730	735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn		
740	745	750
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly		
755	760	765
Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly		
770	775	780
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg		
785	790	795
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser		
805	810	815
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val		
820	825	830
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe		
835	840	845
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser		
850	855	860
Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln		
865	870	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu		
885	890	895
Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp		

900	905	910
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln		
995	1000	1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 76  
 <211> 3002  
 <212> DNA  
 <213> Homo sapiens

<400> 76	60
gtggcttggc attcaactggc aggtttcaga cattttagatc tttcttttaa tgactaacac	60
catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta	120
atactattat ttggcagtaa tccagattgc ttttgccacc aacctgaaga catatagagg	180
cagaaggaca ggaataattc tatttgttc ctgtttgaa acttccatct gtaaggctat	240
caaaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaaccaaa	300
ggtcattat gcttctcc tcgtgaaatc ctgacttacc tcaacaacgg agacatggca	360
cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gacccaatat	420
acagggtttt gagtcatct tcatttcata tatgaggaaa taagtggtaa aatccttggaa	480
aatacaatga gactcatcag aaacatttac atatttgta gtattgttat gacagcagag	540
ggtgatgctc cagagctgcc agaagaaagg gaactgatga ccaactgctc caacatgtct	600
ctaagaaaagg ttccccgcaga cttgacccca gccacaacga cactggattt atcctataac	660
ctcctttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt	720
ctatgccata acagaattca acagctggat ctcaaaacct ttgaattcaa caaggagttt	780
agatatttag atttgtctaa taacagactg aagagtgtta cttggatattt actggcaggt	840
ctcaggttatt tagatcttcc tttaatgac tttgacacca tgcctatctg tgaggaagct	900

ggcaacatgt cacacctgga aatcctagg ttagtgggg caaaaataca aaaatcgat	960
ttccagaaaa ttgctcatct gcatctaaat actgtttct taggatttag aacttttcct	1020
cattatgaag aaggttagcct gcccatctta aacacaacaa aactgcacat tgttttacca	1080
atggacacaa atttctgggt tctttgcgt gatggaatca agacttcaa aatattagaa	1140
atgacaaata tagatggcaa aagccaattt gtaagttatg aaatgcaacg aaatcttagt	1200
ttagaaaatg ctaagacatc ggttcttattt cttaataaaag ttgatttact ctgggacgac	1260
cttttcctta tcttacaatt tgtttggcat acatcagtgg aacactttca gatccgaaat	1320
tgacttttg gtggtaaggg ttatcttgac cacaattcat ttgactactc aaatactgta	1380
atgagaacta taaaattgga gcatgtacat ttcagagtgt tttacattca acaggataaa	1440
atctatttgc ttttgaccaa aatggacata gaaaacctga caatatcaa tgcacaaatg	1500
ccacacatgc ttttcccga ttatcctacg aaattccaaat atttaaattt tgccaataat	1560
atcttaacag acgagttgtt taaaagaact atccaaactgc ctcacttga aactctcatt	1620
ttgaatggca ataaaactgga gacactttct ttagtaagtt gctttgctaa caacacaccc	1680
ttggAACACT tggatcttag tcaaaatcta ttacaacata aaaatgatga aaattgctca	1740
tggccagaaa ctgtggtcaa tatgaatctg tcatacata aattgtctga ttctgtcttc	1800
aggtgcttgc ccaaaagtat tcaaatactt gacctaaata ataaccaaata ccaaactgta	1860
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgaac	1980
ttcattctca gccccatctct ggattttgtt cagagctgcc aggaagttaa aactctaaat	2040
gggggaagaa atccattccg gtgtacctgt gaattaaaaaa atttcatca gcttgaacaca	2100
tattcagagg tcatgatgg tggatggtca gattcataca cctgtgaata ccctttaaac	2160
ctaagggaa ttaggtaaa agacgttcat ctccacgaat tatcttgc当地 cacagctctg	2220
ttgattgtca ccattgtgg tattatgcta gttctgggt tggctgtggc cttctgctgt	2280
ctccactttg atctgccctg gatatcagg atgcttaggtc aatgcacaca aacatggcac	2340
agggttagga aaacaaccca agaacaactc aagagaaaatg tccgattcca cgcatttatt	2400
tcatacagtg aacatgattc tctgtgggtg aagaatgaat tgatccccaa tctagagaag	2460
gaagatggtt ctatottgat ttgcctttat gaaagctact ttgaccctgg caaaaaggatt	2520
agtgaaaata ttgtaagctt cattgagaaa agctataagt ccatctttgt tttgtctccc	2580
aactttgtcc agaatgagtg gtgccattat gaattttact ttgcccacca caatctcttc	2640
catgaaaatt ctgatcatat aattcttatac ttactggAACAC ccattccatt ctattgcatt	2700
cccaccaggt atcataaaact gaaagcttc ctggaaaaaa aagcataactt ggaatggccc	2760
aaggataggc gtaaatgtgg gctttctgg gcaaacccttc gagctgctat taatgttaat	2820

gtatttagcca ccagagaaaat gtagactg cagacattca cagagtaaa tgaagagtct	2880
cgagggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg	2940
aagttgggga ccacatacac tggatg tacattgata caaccttat gatggcaatt	3000
<b>tg</b>	<b>3002</b>

<210> 77.  
<211> 811  
<212> PRT  
<213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr  
1                       5                       10                       15

Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr  
20                      25                      30

Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro  
35                      40                      45

Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln  
50                      55                      60

Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys  
65                      70                      75                      80

His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys  
85                      90                      95

Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr  
100                    105                      110

Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp  
115                    120                      125

Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu  
130                    135                      140

Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln  
145                    150                      155                      160

Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr  
165                    170                      175

Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys  
180                    185                      190

Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg  
195                    200                      205

Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly  
210                    215                      220

Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu  
225                    230                      235                      240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp  
 245 250 255  
 Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu  
 260 265 270  
 His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp  
 275 280 285  
 His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu  
 290 295 300  
 Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr  
 305 310 315 320  
 Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala  
 325 330 335  
 Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr  
 340 345 350  
 Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr  
 355 360 365  
 Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu  
 370 375 380  
 Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu  
 385 390 395 400  
 His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn  
 405 410 415  
 Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys  
 420 425 430  
 Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu  
 435 440 445  
 Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His  
 450 455 460  
 Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp  
 465 470 475 480  
 Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu  
 485 490 495  
 Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln  
 500 505 510  
 Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys  
 515 520 525  
 Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met  
 530 535 540  
 Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg  
 545 550 555 560  
 Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr

	565	570	575	
Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu				
	580	585	590	
Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg				
	595	600	605	
Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr				
	610	615	620	
Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr				
	625	630	635	640
Ser Glu His Asp Ser Ile Trp Val Lys Asn Glu Leu Ile Pro Asn Leu				
	645	650	655	
Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe				
	660	665	670	
Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys				
	675	680	685	
Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu				
	690	695	700	
Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu				
	705	710	715	720
Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr				
	725	730	735	
Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys				
	740	745	750	
Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp				
	755	760	765	
Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu				
	770	775	780	
Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly				
	785	790	795	800
Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu				
	805	810		

<210> 78  
<211> 2760  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (2529)..(2529)  
<223> n is a, c, g, or t

<400> 78  
aagaatttgg actcatatca agatgctctg aagaagaaca accctttagg atagccactg 60  
caacatcatg accaaagaca aagaacctat tggtaaaagc ttccattttg tttgccttat 120

gatcataata gttggaacca gaatccagtt ctccgacgga aatgaatttg cagtagacaa	180
gtcaaaaaga ggtcttatttc atgttccaaa agacctaccg ctgaaaacca aagtcttaga	240
tatgtctcag aactacatcg ctgagcttca ggtctctgac atgagcttc tattcagagtt	300
gacagtttg agactttccc ataacagaat ccagctactt gatttaagtg ttttcaagtt	360
caaccaggat ttagaatatt tggatttatac tcataatcag ttgcaaaaga tattcctgccaa	420
tcctattgtg agttcaggc atttagatct ctcattcaat gatttcaagg ccctgccccat	480
ctgtaaggaa tttggcaact tattcacaact gaatttcttg ggattgagtg ctatgaagct	540
gcaaaaatta gatttgcgc caattgctca cttgcatactt agttatatcc ttctggattt	600
aagaaattat tatataaaag aaaatgagac agaaagtcta caaattctga atgcaaaaac	660
ccttcacccctt gttttcacc caactagttt attcgctatac caagtgaaca tatcagttaa	720
tacttttaggg tgcttacaac tgactaatat taaattgaat gatgacaact gtcaagttt	780
cattaaattt ttatcagaac tcaccagagg tccaacctta ctgaatttttta ccctcaacca	840
catagaaacg acttggaaat gcctggtcag agtcttcaa tttcttggc ccaaacctgt	900
ggaatatctc aatatttaca atttaacaat aattgaaagc attcgtgaag aagattttac	960
ttattctaaa acgacattga aagcattgac aatagaacat atcacgaacc aagttttct	1020
gttttcacag acagctttgtt acaccgtgtt ttctgagatg aacattatga tgttaaccat	1080
ttcagataca cctttatac acatgctgtg tcctcatgca ccaagcacat tcaagtttt	1140
gaactttacc cagaacgttt tcacagatag tattttgaa aaatgttcca cgtagttaa	1200
attggagaca cttatcttac aaaagaatgg attaaaagac cttttcaaag taggtctcat	1260
gacgaaggat atgccttctt tggaaatact ggatgttagc tggaaattctt tggaaatctgg	1320
tagacataaa gaaaactgca cttgggttga gagtatagtg gtgttaaatt tgtcttcaa	1380
tatgcttact gactctgttt tcagatgttt acctcccagg atcaaggtac ttgatctca	1440
cagcaataaa ataaagagcg ttccctaaaca agtcgtaaaa ctggaagct tgcaagaact	1500
caatgttgc ttcaattctt taactgacct tcctggatgt ggcagcttta gcagccttca	1560
tgtattgatc attgatcaca attcagtttc ccacccatcg gctgatttct tccagagctg	1620
ccagaagatg aggtcaataa aagcagggga caatccattc caatgtacct gtgagctaa	1680
agaatttgc aaaaatatac accaagtatac aagtgaagtg ttagagggtt ggcctgattc	1740
ttataagtgt gactacccag aaagttatag aggaagccca ctaaaggact ttcacatgtc	1800
tgaattatcc tgcaacataa ctctgctgat cgtcaccatc ggtgccacca tgctgggttt	1860
ggctgtgact gtgacccccc tctgcatactt cttggatctg ccctggatctc tcaggatgg	1920
gtgccagtgg acccagactc ggcgcaggc caggaacata cccttagaag aactccaaag	1980
aaacccctccag tttcatgctt ttatttcata tagtgaacat gattctgcct gggtgaaaag	2040

tgaattggta ccttacctag	aaaaagaaga tatacagatt	tgtcttcatg agaggaactt	2100
tgtccctggc aagagcattg	tggaaaatat catcaactgc	attgagaaga gttacaagtc	2160
catcttggtt ttgtctccca	actttgtcca gagtgagtgg	tgccattacg aactctat	2220
tgcccatcac aatcttttc	atgaaggatc taataactta	atcctcatct tactggaacc	2280
cattccacag aacagcattc	ccaaacaagta ccacaagctg	aaggctctca tgacgcagcg	2340
gacttatttg cagtggccca	aggagaaaaag caaacgtggg	ctctttggg ctaacattag	2400
agccgcgttt aatatgaaat	taacactagt cactgaaaac	aatgatgtga aatctaaaaa	2460
aaatttagga aattcaactt	aagaaccat tatttacttg	gatgatggtg aatagtacag	2520
tcgtaagtna ctgtctggag	gtgcctccat tattcctcatg	ccttcaggaa agacttaaca	2580
aaaacaatgt ttcatctggg	gaactgagct aggccgtgag	gttagcctgc cagttagaga	2640
cagcccagtc tcttctgggtt	taatcattat gtttcaaatt	gaaacagtct cttttgagta	2700
aatgctcagt ttttcagctc	ctctccactc tgctttccca	aatggattct gttgggtgaag	2760

<210> 79  
<211> 2753  
<212> DNA  
<213> Homo sapiens

<400> 79			
agaatttgga ctcatatcaa	gatgctctga agaagaacaa	cccttagga tagccactgc	60
aacatcatga ccaaagacaa	agaacctatt	gtaaaagct tccattttgt ttgccttat	120
atcataatag ttggaaccag	aatccagttc	tccgacggaa atgaatttgc	180
tcaaaaagag gtcttattca	tgttcaaaa	gacctaccgc tgaaaaccaa agtcttagat	240
atgtctcaga actacatcgc	tgagcttcag	gtctctgaca tgagcttct atcagagttg	300
acagtttga gactttccca	taacagaatc	cagctacttg atttaagtgt tttcaagttc	360
aaccaggatt tagaatattt	ggatttatct	cataatcagt tgcaaaagat atcctgccat	420
cctattgtga gtttcaggca	tttagatctc	tcattcaatg atttcaaggc cctgccccatc	480
tgtaaggaat ttggcaactt	atcacaactg	aatttcttgg gattgagtgc tatgaagctg	540
caaaaattag atttgctgcc	aattgctcac	ttgcatctaa gttatatcct tctggattta	600
agaaattatt atataaaaga	aatgagaca	gaaagtctac aaattctgaa tgcaaaaaacc	660
cttacaccc ttttcaccc	aactagttt	ttcgctatcc aagtgaacat atcagttat	720
acttttagggt gcttacaact	gactaatatt	aaattgaatg atgacaactg tcaagtttc	780
attaaatttt tatcagaact	caccagaggt	tcaaccttac tgaattttac cctcaaccac	840
atagaaacga cttggaaatg	cctggcaga	gtctttcaat ttcttggcc caaacctgtg	900

gaatatctca atatttacaa tttaacaata attgaaaagca ttcgtgaaga agattttact	960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agttttctg	1020
ttttcacaga cagcttgta cacggtgtt tctgagatga acattatgat gttaccatt	1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagttttg	1140
aactttaccc agaacgtttt cacagatgt attttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc tttcaaagt aggtctcatg	1260
acgaaggata tgccctctt ggaaatactg gatgttagct ggaattctt ggaatctggt	1320
agacataaag aaaactgcac ttgggttag agtatagtgg tgtaaattt gtctcaaatt	1380
atgcttactg actctgtttt cagatgtta cctcccagga tcaaggtact tgatcttcac	1440
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaaac tggaaagctt gcaagaactc	1500
aatgttgctt tcaattctt aactgacctt cctggatgtg gcagctttag cagcctttct	1560
gtattgatca ttgatcacaa ttcaagttcc caccatcggt ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga	1680
gaatttgtca aaaatataga ccaagtatca agtgaagtgt tagagggctg gcctgattct	1740
tataagtgtg actacccaga aagttataga ggaagcccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgctgatc gtcaccatcg gtgccaccat gctgggttg	1860
gctgtgactg tgacccctt ctgcatttac ttggatctgc cctggtatct caggatggtg	1920
tgccagtggaa cccagactcg ggcaggggcc aggaacatac ccttagaaga actccaaaga	1980
aacctccagt ttcatgcttt tatttcatat agtgaacatg attctgcctg ggtaaaaagt	2040
gaatttggtagt cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt ggaaaatatc atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgcctccaa ctttgcctag agtgagtggt gccattacga actctatttt	2220
gcccatcaca atctcttca tgaaggatct aataacttaa tcctcattt actggAACCC	2280
attccacaga acagcattcc caacaagttac cacaagctga aggctctcat gacgcagcgg	2340
acttatttgc agtggcccaa ggagaaaaagc aaacgtgggc tctttgggc taacattttaga	2400
gccgcctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atctaaaaaa	2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggta atagtagcgt	2520
cgtaagtaac tgcctggagg tgcctccatt atcctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggcgggtgagg ttagcctgcc agtttagagac	2640
agcccaagtct cttctgggtt aatcattatg tttcaaattt aaacagtctc tttttagttaa	2700
atgctcagtt ttccagctcc tctccactct gctttcccaa atggattctg ttg	2753

<210> 80  
<211> 796  
<212> PRT  
<213> Homo sapiens

<400> 80

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
1 5 10 15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
20 25 30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
35 40 45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
50 55 60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
85 90 95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
595 600 605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr

610                    615                    620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625                    630                    635                    640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645                    650                    655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660                    665                    670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675                    680                    685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690                    695                    700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705                    710                    715                    720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725                    730                    735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740                    745                    750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755                    760                    765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770                    775                    780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                    790                    795  
  
 <210> 81  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 81  
 Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1                    5                    10                    15  
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20                    25                    30  
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35                    40                    45  
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50                    55                    60  
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65                    70                    75                    80  
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85                    90                    95  
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100                    105                    110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu  
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu

435                    440                    445  
Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450                    455                    460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465                    470                    475                    480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485                    490                    495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500                    505                    510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515                    520                    525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530                    535                    540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545                    550                    555                    560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565                    570                    575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580                    585                    590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
595                    600                    605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
610                    615                    620

Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
625                    630                    635                    640

Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
645                    650                    655

Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
660                    665                    670

Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
675                    680                    685

Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
690                    695                    700

Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705                    710                    715                    720

His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu  
725                    730                    735

Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
740                    745                    750

Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
755                    760                    765

Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys

770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 82  
<211> 796  
<212> PRT  
<213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
1                       5                       10                       15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
20                      25                      30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
35                      40                      45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
50                      55                      60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
65                      70                      75                      80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
85                      90                      95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
100                    105                      110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115                    120                      125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130                    135                      140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145                    150                      155                      160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165                    170                      175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180                    185                      190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195                    200                      205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210                    215                      220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225                    230                      235                      240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
245                    250                      255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260                    265                      270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595	600	605
Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr		
610	615	620
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro		
690	695	700
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
705	710	715
720		
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu		
725	730	735
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys		
740	745	750
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser		
755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys		
770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 83  
 <211> 2604  
 <212> DNA  
 <213> murine

<400> 83	
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc	60
aagacagaaa acccatcgta gggagtttcc actttgtttg cggccctggcc ttaatagtcg	120
gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc	180
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact	240
ctatatctga gcttcggatg cctgatataca gctttctgtc agagctgaga gttctgagac	300
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag	360
aataacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcct atggcgagcc	420
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg	480
gcaacctgac gaagctgact ttcttggat taagtgtgc caagttccga caactggatc	540

tgctccagt tgctcaacttgcatctaagct gcattttctggacttagtg agtcatacata	600
taaaaggcgggaaacacagaa agtcttcaga ttcccaatac caccgttctc catttggct	660
ttcatccaaa tagttgttc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt	720
tacaactgag taatattaaa ttgaatgtatg aaaactgtca aaggtaatg acattttat	780
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct	840
ggaagtgcgtt ggttaaactt ttccaattct tttggccccg accgggtggag tacctaata	900
tttacaactt aacgataact gagagaatcg acagggaaaga atttacttac tcggagacag	960
cactgaagtc actgtatgata gagcacgtca aaaaccaagt gttcctctt tcaaaggagg	1020
cgctataactc ggtgtttgtct gagatgaaca tcaagatgtctctatctca gacacccctt	1080
tcatccacat ggtgtgccccg ccattcccaa gtcattttac atttctgaac tttaccaga	1140
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta	1200
tcttacaaag gaatggtttgaagaactttt ttaaagttagc tctcatgact aagaatatgt	1260
cctctctgaa aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga	1320
catgcgcctg ggctgagagc atattgggt tgaatttgc ttcgaatatg cttacaggct	1380
ctgtcttcag atgcttaccccccaccaagggtca aggtccttga ctttcacaac aacaggataa	1440
tgagcatccc taaagatgtc acccaccgtc aggcttgca ggaactcaat gtagcatcca	1500
actccttaac tgaccttcctt ggggtgtgggg ctttcagcag ctttctgtg ctggcatcg	1560
accataactc agtttccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacaac gggaaacaac ccattccaat gcacatgtga gctgaggac tttgtcaaga	1680
acataggctg ggttagcaaga gaagtgggtgg aggctggcc tgactttac aggtgtgact	1740
acccagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgt	1800
atactgttct gctgactgtc accatgggg ccactatgtct ggtgctggct gtcactgggg	1860
ctttcctctg tctctacttt gacctggccct ggtatgtgag gatgctgtgt cagtgacac	1920
agaccaggca cagggccagg cacatccccct tagaggaact ccagagaaac ctccagttcc	1980
atgctttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactaccca	2040
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcattgtgga gaacatcatc aatttcatttga agaagagtta caaggccatc tttgtgtgt	2160
ctccccactt catccagagt gagtggtgcc attatgaact ctatttgcc catcataatc	2220
tcttcctcatga aggctctgat aacttaatcc tcattttgtct ggaacccatt ctacagaaca	2280
acattccac tagataccac aagctgcggg ctctcatggc acagcggact tacttggaat	2340
ggcctactga gaagggcaaa cgtgggtgt tttggccaa ctttagagct tcatttatta	2400
tgaagtttagc ctttgtcaat gaggatgtatg tgaaaacttg aaacttgggt ttctaaactta	2460

ataaaactgtc aacctggct ctcataaca ctgtggttt cagttcctac ctggaggtag 2520  
ttctgttgtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagttagt 2580  
ttatgaaggt gctaagttca ttaa 2604

<210> 84  
<211> 2604  
<212> DNA  
<213> murine

<400> 84  
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
aagacagaaa acccatcgta gggagttcc actttgtttg cgccctggcc ttaatagtcg 120  
gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc 180  
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
ctatatctga gcttcggatg cctgatatac gcttctgtc agagctgaga gttctgagac 300  
tctccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
aataacctgga tgtctcacac aatcggtgc aaaacatctc ttgctgcct atggcgagcc 420  
tgaggcatct agacotctca ttcaatgact ttgatgtact gcctgtgtt aaggaatttg 480  
gcaacactgac gaagctgact ttccctggat taagtgtgc caagttccga caactggatc 540  
tgctcccagt tgctcaacttgc catctaagct gcattcttgc ggacttagtg agtcatcata 600  
taaaaggcgg gaaaaacagaa agtcttcaga ttcccaatac caccgttctc catttggct 660  
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt 720  
tacaactgag taatattaaa ttgaatgatg aaaactgtca aaggtaatg acattttat 780  
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct 840  
ggaagtgtc gtttaaactt ttccaaattct tttggccccg accgggtggag tacctcaata 900  
tttacaactt aacgataact gagagaatcg acagggaaaga atttacttac tcggagacag 960  
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctctt tcaaaggagg 1020  
cgctataactc ggtgtttgtc gagatgaaca tcaagatgtc ctctatctca gacacccctt 1080  
tcatccacat ggtgtgccccg ccattcccaa gtcatttac atttctgaac tttacccaga 1140  
atgttttac tgacagtgtt tttcaaggct gttccacctt aaagagattt cagacactta 1200  
tcttacaaag gaatggttt aagaactttt ttaaagtagc tctcatgact aagaatatgt 1260  
cctctctgga aactttggat gtttagttga attctttgaa ctctcatgca tatgacagga 1320  
catgcgcctg ggctgagagc atattgggtt tgaatttgc ttcgaatatg cttacaggct 1380  
ctgtcttcag atgcttaccc cccaaagggtca aggtccttga ctttcacaac aacaggataa 1440

tgagcatccc taaagatgtc acccacctgc aggctttgca ggaactcaat gtacgtatcca 1500  
 actccctaac tgaccttcot ggggtgtggg ccttcagcag cctttctgtg ctggtcatcg 1560  
 accataactc agtttcccat ccctctgagg atttcttcca gagctgtcag aatatttagat 1620  
 ccctaacaac gggaaacaac ccattccaat gcacatgtga gctgaggac ttgtcaaga 1680  
 acataggctg gtagcaaga gaagtggtgg agggctggcc tgactcttac aggtgtgact 1740  
 acccagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg 1800  
 atactgttct gctgactgtc accatccccg coactatgct ggtgctggct gtcactgggg 1860  
 ctttcctctg tctctacttt gacctgccc ggtatgtgag gatgctgtgt cagtggacac 1920  
 agaccaggca cagggccagg cacatcccc tagaggaact ccagagaaac ctccagttcc 1980  
 atgctttgt ctcatacagt gacatgatt ctgcctgggt gaagaacgaa ttactaccca 2040  
 acctagagaa agatgacatc cgggttgcc tccatgagag gaactttgtc cctggcaaga 2100  
 gcattgtgga gaacatcatc aatttcattt agaagagtta caaggccatc tttgtctgt 2160  
 ctccccactt catccagagt gagtgggcc attatgaact ctatttgcc catcataatc 2220  
 tttccatga aggctctgat aacttaatcc tcatcttgc ggaaccatt ctacagaaca 2280  
 acattccccag tagataaccac aagctgcggg ctctcatggc acagcggact tacttggaaat 2340  
 ggcctactga gaagggcaaa cgtggctgt tttggccaa ccttagagct tcatttatta 2400  
 tgaagttagc ctttgtcaat gaggatgatg taaaaacttg aaacttgggt ttcttaactta 2460  
 ataaaactgtc aacctgggt ctcataaca ctgtggttt cagttcctac ctggaggtac 2520  
 ttctgttggc gtgtcttagt ttgctctgtc cttatgataa ataacatgtt tagaagtagt 2580  
 ttatgaaggt gctaagttca ttaa 2604

<210> 85  
 <211> 2421  
 <212> DNA  
 <213> murine

<400> 85  
 atggtaaagt ccctctggga tagcctctgc aacatgagcc aagacagaaa acccategtg 60  
 gggagtttcc actttgttg cgccctggcc ttaatagtcg gaagcatgac cccgttctct 120  
 aatgaacttg agtctatggt agactattca aacaggaacc ttactcatgt ccccaaagac 180  
 ctgccaccaa gaacaaaagc cctgagtctg tctaaaaact ctatatctga gcttcggatg 240  
 cctgatatca gtttctgtc agagctgaga gttctgagac tctccacaa caggatacgg 300  
 agccttgatt tccatgtatt cttgttcaat caggacttag aataacctgga tgtctcacac 360  
 aatcggttgc aaaacatctc ttgctgccc atggcgagcc tgaggcatct agacactctca 420  
 ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg gcaacctgac gaagctgact ... 480

ttcctggat taagtgtgc aaagttccga caactggatc tgctcccagt tgctcaacttgc	540
catctaagct gcattttct ggacttagtg agttatcata taaaaggcg ggaaacagaa	600
agtcttcaga ttcccaatac caccgttctc catttggtct ttcatccaaa tagttgttc	660
tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt tacaactgag taatattaaa	720
ttgaatgtatg aaaactgtca aaggtaatg acatttttat cagaactcac cagaggcaca	780
accttattga atgtgaccct ccagcacata gaaacaacct ggaagtgctc ggttaaactt	840
ttccaattct tttggccccg accggtggag tacctaata tttacaactt aacgataact	900
gagagaatcg acagggaaaga atttacttac tcggagacag cactgaagtc actgtatgata	960
gagcacgtca aaaaccaagt gttcctctt tcaaaggagg cgctatactc ggtgtttgct	1020
gagatgaaca tcaagatgct ctctatctca gacacccctt tcatccacat ggtgtgccccg	1080
ccatccccaa gtcatttac atttctgaac tttacccaga atgtttttac tgacagtgtt	1140
tttcaaggct gttccacctt aaagagattt cagacactta ttttacaaag gaatggtttgc	1200
aagaactttt ttaaagttagc tctcatgact aagaatatgt cctctctggaa aactttggat	1260
gttagtttga atttcttgcatttgcata tatgacagga catgcgcctg ggctgagagc	1320
atattggtgt tgaatttgcatttgcata ttacaggct ctgttttgcata atgcttacat	1380
cccaagggtca aggtccttgcata ctttcacaaac aacaggataa tgacatccc taaagatgtc	1440
accacactgc aggttttgcata ggaactcaat gtacatccc actccttgcata tgaccttgcata	1500
gggtgtgggg ctttcagcag ctttcgttgcata ctggcgttgcata accataactc agttttccat	1560
ccctctgagg atttcttgcata gagctgttgcata aatatttagat ccctaacagc gggaaacaac	1620
ccattccaat gcacatgtca gctgagggac tttgtcaaga acataggctg ggttagcaaga	1680
gaagtgggtgg agggctggcc tgacttgcata aggtgttgcata acccagaaag ctctaaggga	1740
actgcactgc aggttttgcata catgtcttgcata ctgttttgcata atactgttgcata gctgactgtc	1800
accatcgccccctt ccactatgtc ggtgttgcata gtcactgggg ctttccttgcata tctctacttt	1860
gacctggccctt ggtatgttgcata gatgttgcata cagtgacac agaccaggca cagggccagg	1920
cacatccccctt tagaggaact ccagagaaac ctccagttgcata atgcttttgcata ctcatacagt	1980
gagcatgattt ctgcctgggtt gaagaacgaa ttactacccaa accttagagaa agatgacatc	2040
cggttttgcata tccatgagag gaacttttgcata cctggcaaga gcattgtggaa gaacatcatc	2100
aatttcatttgcata agaagagtttcaaggccatc tttgttgcata ctccccactt catccagagt	2160
gagtgggttgcata attatgttgcata ctatgttgcata catcataatc tttccatgttgcata aggctgttgcata	2220
aacttaatcc tcatcttgcata ggaaccatc ctacagaaca acattccatc tagataccac	2280
aagctgcgggg ctctcatggc acagcggact tacttggaaat ggcctactgttgcata gaaggcataa	2340
cgtgggttgcata tttggccaa ctttagagtttgcata tcatttttgcata tgaagtttgcata cttagtcaat	2400

gaggatgtatg tgaaaacttg a

2421

<210> 86  
<211> 806  
<212> PRT  
<213> murine

&lt;400&gt; 86

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
1 5 10 15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
20 25 30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
35 40 45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
50 55 60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
545 550 555 560

Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
565 570 575

Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
580 585 590

Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val

595                    600                    605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610                    615                    620  
  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625                    630                    635                    640  
  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645                    650                    655  
  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660                    665                    670  
  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675                    680                    685  
  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690                    695                    700  
  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705                    710                    715                    720  
  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725                    730                    735  
  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Glu Pro Ile Leu Gln  
 740                    745                    750  
  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755                    760                    765  
  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770                    775                    780  
  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785                    790                    795                    800  
  
 Glu Asp Asp Val Lys Thr  
 805

<210> 87  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1                    5                    10                    15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20                    25                    30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35                    40                    45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50                    55                    60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65                    70                    75                    80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Ile Ser His  
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr  
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

	405	410	415												
Glu	Thr	Leu	Asp	Val	Ser	Leu	Asn	Ser	Leu	Asn	Ser	His	Ala	Tyr	Asp
				420				425						430	
Arg	Thr	Cys	Ala	Trp	Ala	Glu	Ser	Ile	Leu	Val	Leu	Asn	Leu	Ser	Ser
						435			440					445	
Asn	Met	Leu	Thr	Gly	Ser	Val	Phe	Arg	Cys	Leu	Pro	Pro	Lys	Val	Lys
						450			455				460		
Val	Leu	Asp	Leu	His	Asn	Asn	Arg	Ile	Met	Ser	Ile	Pro	Lys	Asp	Val
								465	470		475			480	
Thr	His	Leu	Gln	Ala	Leu	Gln	Glu	Leu	Asn	Val	Ala	Ser	Asn	Ser	Leu
								485		490				495	
Thr	Asp	Leu	Pro	Gly	Cys	Gly	Ala	Phe	Ser	Ser	Leu	Ser	Val	Leu	Val
								500		505				510	
Ile	Asp	His	Asn	Ser	Val	Ser	His	Pro	Ser	Glu	Asp	Phe	Phe	Gln	Ser
								515		520				525	
Cys	Gln	Asn	Ile	Arg	Ser	Leu	Thr	Ala	Gly	Asn	Asn	Pro	Phe	Gln	Cys
						530			535				540		
Thr	Cys	Glu	Leu	Arg	Asp	Phe	Val	Lys	Asn	Ile	Gly	Trp	Val	Ala	Arg
						545			550			555			560
Glu	Val	Val	Glu	Gly	Trp	Pro	Asp	Ser	Tyr	Arg	Cys	Asp	Tyr	Pro	Glu
						565			570				575		
Ser	Ser	Lys	Gly	Thr	Ala	Leu	Arg	Asp	Phe	His	Met	Ser	Pro	Leu	Ser
						580			585				590		
Cys	Asp	Thr	Val	Leu	Leu	Thr	Val	Thr	Ile	Gly	Ala	Thr	Met	Leu	Val
						595			600				605		
Leu	Ala	Val	Thr	Gly	Ala	Phe	Leu	Cys	Leu	Tyr	Phe	Asp	Leu	Pro	Trp
						610			615				620		
Tyr	Val	Arg	Met	Leu	Cys	Gln	Trp	Thr	Gln	Thr	Arg	His	Arg	Ala	Arg
						625			630			635			640
His	Ile	Pro	Leu	Glu	Glu	Leu	Gln	Arg	Asn	Leu	Gln	Phe	His	Ala	Phe
						645			650				655		
Val	Ser	Tyr	Ser	Glu	His	Asp	Ser	Ala	Trp	Val	Lys	Asn	Glu	Leu	Leu
						660			665				670		
Pro	Asn	Leu	Glu	Lys	Asp	Asp	Ile	Arg	Val	Cys	Leu	His	Glu	Arg	Asn
						675			680				685		
Phe	Val	Pro	Gly	Lys	Ser	Ile	Val	Glu	Asn	Ile	Ile	Asn	Phe	Ile	Glu
						690			695				700		
Lys	Ser	Tyr	Lys	Ala	Ile	Phe	Val	Leu	Ser	Pro	His	Phe	Ile	Gln	Ser
						705			710			715			720
Glu	Trp	Cys	His	Tyr	Glu	Leu	Tyr	Phe	Ala	His	His	Asn	Leu	Phe	His
						725			730				735		
Glu	Gly	Ser	Asp	Asn	Leu	Ile	Leu	Ile	Leu	Glu	Pro	Ile	Leu	Gln	

740	745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln		
755	760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe		
770	775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn		
785	790	795
Glu Asp Asp Val Lys Thr		
805		

<210> 88  
<211> 806  
<212> PRT  
<213> murine  
  
<400> 88

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg		
1	5	10
		15
Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile		
20	25	30
Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp		
35	40	45
Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg		
50	55	60
Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met		
65	70	75
80		
Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His		
85	90	95
Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp		
100	105	110
Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys		
115	120	125
Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe		
130	135	140
Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr		
145	150	155
160		
Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro		
165	170	175
Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His		
180	185	190
His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr		
195	200	205
Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val		
210	215	220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg

545	550	555	560
Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu			
565		570	575
Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser			
580		585	590
Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val			
595		600	605
Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp			
610		615	620
Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg			
625		630	635
His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe			
645		650	655
Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu			
660		665	670
Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn			
675		680	685
Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu			
690		695	700
Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser			
705		710	715
Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His			
725		730	735
Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Glu Pro Ile Leu Gln			
740		745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln			
755		760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe			
770		775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn			
785		790	795
Glu Asp Asp Val Lys Thr			
805			

<210> 89  
<211> 795  
<212> PRT  
<213> murine

<400> 89

Met Ser Gln Asp Arg Lys Pro Ile Val Gly Ser Phe His Phe Val Cys			
1	5	10	15
Ala Leu Ala Leu Ile Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu			
20		25	30

Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys  
35 40 45

Asp Ieu Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile  
50 55 60

Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val  
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe  
85 90 95

Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu  
100 105 110

Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln  
145 150 155 160

Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu Leu  
165 170 175

Asp Leu Val Ser Tyr His Ile Lys Gly Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu  
195 200 205

Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln  
210 215 220

Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu  
245 250 255

Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe  
260 265 270

Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu  
290 295 300

Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu  
325 330 335

Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro  
340 345 350

Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

355	360	365
Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu		
370	375	380
Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys		
385	390	395
Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn		
405	410	415
Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val		
420	425	430
Leu Asn Leu Ser Ser Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu		
435	440	445
Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser		
450	455	460
Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val		
465	470	475
Ala Ser Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser		
485	490	495
Leu Ser Val Leu Val Ile Asp His Asn Ser Val Ser His Pro Ser Glu		
500	505	510
Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn		
515	520	525
Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile		
530	535	540
Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg		
545	550	555
Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His		
565	570	575
Met Ser Pro Leu Ser Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly		
580	585	590
Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr		
595	600	605
Phe Asp Leu Pro Trp Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr		
610	615	620
Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro		

690                695                700  
His Phe Ile Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705                710                715                720  
  
His Asn Leu Phe His Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu  
725                730                735  
  
Glu Pro Ile Leu Gln Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg  
740                745                750  
  
Ala Leu Met Ala Gln Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly  
755                760                765  
  
Lys Arg Gly Leu Phe Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys  
770                775                780  
  
Leu Ala Leu Val Asn Glu Asp Asp Val Lys Thr  
785                790                795

<210> 90  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus p50 subunit

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = c or t

<400> 90  
ggggatnccc

10

<210> 91  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus p65 subunit

<220>  
<221> misc\_feature  
<222> (4)..(4)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = a, c, g, or t

<400> 91  
gggnnttcc

10

<210> 92

<211> 22  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; consensus subunit

<400> 92  
agttgagggg actttcccag gc

22

<210> 93  
<211> 27  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; CREB binding site

<400> 93  
agagattgcc tgacgtcaga gagctag

27

<210> 94  
<211> 21  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; AP-1 binding site

<400> 94  
cgcttgatga gtcagccgga a

21

<210> 95  
<211> 15  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; AP-1 binding site

<400> 95  
cgcatgagtc agaca

15

<210> 96  
<211> 19  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

&lt;400&gt; 96

tgcagaagtg aaactgagg 19  
<210> 97  
<211> 11  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 97  
agaacgaaac a 11

<210> 98  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 98  
gagaagtcaa agtgg 15

<210> 99  
<211> 18  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 99  
taagaacatg aaactgaa 18

<210> 100  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 100  
atgaaactga aagta 15

<210> 101  
<211> 16  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 101  
tgaaaaaccgaa aagcgc 16

<210> 102  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 102  
agaaaatggaa agt 13

<210> 103  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 103  
tcaccccac 9

<210> 104  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 104  
ctcaccccac 10

<210> 105  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 105  
gccaccctac 10

<210> 106  
<211> 17  
<212> DNA  
<213> artificial sequence

<220>  
<223> NFAT

<400> 106  
tatgaaacag ttttcc

17

<210> 107  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<400> 107  
aggaaactc

9

<210> 108  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = a or g

<400> 108  
anganattcc

10

<210> 109  
<211> 16  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<400> 109  
ccagttgagc cagaga

16

<210> 110  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>

<223> GAS

<400> 110 30  
cttcagttt catattactc taaatccatt

<210> 111  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<220>  
<221> misc\_feature  
<222> (1)..(3)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(6)  
<223> N = a or t

<220>  
<221> misc\_feature  
<222> (8)..(10)  
<223> N = c or t

<400> 111 10  
nnncnngnnn

<210> 112  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112 10  
aggcatgcct

<210> 113  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113 10  
gggcttgcct

<210> 114

<211> 10  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 114  
gggccttgctt 10  
  
<210> 115  
<211> 13  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 115  
gcctggactt gcc 13  
  
<210> 116  
<211> 20  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 116  
ggacatgccc gggcatgtcc 20  
  
<210> 117  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 117  
gtagcattag cccagacatg tcc 23  
  
<210> 118  
<211> 36  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> TARE  
  
<400> 118  
gaggatgca gacaagagtc agagttccc cttgaa 36

<210> 119  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<220>  
<221> misc\_feature  
<222> (3)..(8)  
<223> N = a or t

<400> 119  
ccnnnnnnngg 10

<210> 120  
<211> 11  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<400> 120  
ccaaataagg c 11

<210> 121  
<211> 670  
<212> DNA  
<213> Homo sapiens

<400> 121  
agaaaaattt taaaaaatta ttcattcata tttttaggag ttttgaatga ttggatatgt 60  
aattatatttc atattattaa tgtgtatcta tatagatttt tattttgcattt atgtactttg 120  
atacaaaaatt tacatgaaca aattacacta aaagttatttc cacaaatata cttatcaaatt 180  
taagttaaat gtcaatagct tttaaactta aatttttagtt taactttctt gtcattcttt 240  
actttgaata aaaagagcaa actttgttgtt ttttatctgtt gaagtagagg tatacgtaat 300  
atacataaaat agatatgccaa aatctgtgtt attaaaattt catgaagatt tcaatttagaa 360  
aaaaatacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaaatgaa 420  
aaaactttttt aaacacatgtt agagagtgcgt taaagaaaagc aaaaacagag atagaaaagta 480  
caacttaggaa atttagaaaaa tggaaattttatgatgttacttatttaagacc tatgcacaga 540  
gcaaagtctt cagaaaaacctt agaggccgaa gttcaagggtt atccatctca agtagccttag 600  
caatatttgc aacateccaa tggccctgtc cttttcttta ctgatggccg tgctggtgct 660  
cagctacaaa 670

<210> 122  
<211> 207  
<212> DNA  
<213> Homo sapiens

<400> 122  
aggttctctg aaggccttgc ttccctgcaga tgccttaaat agggAACATA ctgatttcca 60  
ctttcttaat gtttctggac catttcatt tctgtttttt ctttccttct taactctta 120  
catgagtttga gagccgtgtt tctcaaatga tgggcttagca cgcgtaagag. ctcggcac 180  
atcgatAGAG aaatgttctg gcacctg 207

<210> 123  
<211> 161  
<212> DNA  
<213> Homo sapiens

<400> 123  
aggttctctg aaggccttgc ttccctgcaga tgccttaaat agggAACATA ctgatttcca 60  
ctttcttaat gtttctggac cacttcatt ttctgtttttt gcttccttc ttgaactctt 120  
tacatgagtt tagagccgtg tttctcaacc attttgtttt t 161

<210> 124  
<211> 300  
<212> DNA  
<213> Homo sapiens

<400> 124  
ttctcaggTC gtttgctttc ctttgctttc tcccaagtct tgTTTACAA tttgctttAG 60  
tcattcactg aaACTTTAAA aaACATTAGA aaACCTCACA gtttgtaaat ctTTTCCCT 120  
attatatata tcataagata ggagCTTTAA taaAGAGTTT tagAAACTAC taaaATGTA 180  
atgacatagg AAAACTGAAA gggAGAAGTG AAAGTGGAA attcctctGA atAGAGAG 240  
gaccatctca tataAAATAGG ccataccccAC ggAGAAAGGA cattctaact gcaACCTTC 300

<210> 125  
<211> 401  
<212> DNA  
<213> Homo sapiens

<400> 125  
gatctgtat gaataAGCAG gaACTTTGAA gACTCAGTGA CTCAGTGAAGT aataAAAGACT 60  
cAGTGACTTC tgatcctGTC CTAACtGCCA CTCCTGTTG TCCCAAGAAA GCGGCTTCCT 120  
gCTCTGTAG gaggACCCCT TCCCTGGAAG GTAAAACtAA GGATGTCAGC AGAGAAATT 180  
ttccaccatt ggtgcttGgt caaAGAGGAA ACTGATGAGC TCACTCTAGA TGAGAGAGCA 240  
gtgaggGGAGA gacAGAGACT CGAATTCCG gagCTATTc agTTTCTTT TCCGTTTGT 300

gcaatttcac ttatgatacc ggccaatgtctggttgctat tttggaaact ccccttaggg 360  
 gatgccctc aactggccct ataaaggccc agcctgagct g 401

<210> 126  
<211> 781  
<212> DNA  
<213> Homo sapiens

<400> 126  
 ggttgtctgt atgcctccct gagggtatTT cacttctgc tcccatccgc ccctatgagc 60  
 gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagtt 120.  
 tatcatctcc ccaggtctgt gtctgtatga aatgtgcatt ggtgtgtgtg tgacacgcgtg 180  
 tgttccact cgggaaatgt ggggagaggt gcatggagcc aagatgggtg gtAAatagta 240  
 tgTTTCTGAA attaaaggac taatgtggag gaaggcgccc cagatgtact aaacccttg 300  
 ctttcatctc atcctctctg acttgggaag aaccaggatt ttgtttttaa gcccttggc 360  
 atacagttgt tccatcccgaa catgaactca gcctcccgTC tgacccggcc ttggccttcc 420  
 ttcttcctcg atctgtggaa cccagggaaat ctgcctagtg ctgtctccaa gcaccttggc 480  
 catgatgtaa acccagagaa attagcatct ccatctccctt ctttattccc cacccaaaag 540  
 tcatttcctc tttagttcatt acctgggatt ttgatgtcta tgTTCCCTCC tcgttattga 600  
 tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattcccccc agaaggTTT 660  
 gagagttgtt ttcaatgttg caacaagtca gtttctagtt taagttcca tcagaaagga 720  
 gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgtttcagg 780  
 g 781

<210> 127  
<211> 277  
<212> DNA  
<213> Homo sapiens

<400> 127  
 gcatctccat ctccctccctt attccccacc caaaagtcat ttccctttag ttcattacct 60  
 gggattttga tgtctatgtt ccctctcgT tattgatACA cacacagaga gagacaaaca 120  
 aaaaaggaac ttcttgaat tccccccagaa ggtttgaga gttgtttca atgttgcaac 180  
 aagtcagttt ctatgttaag ttccatcg aaaggagtag agtatataag ttccagtacc 240  
 agcaacagca gcagaagaaa caacatctgt ttccaggg 277

<210> 128  
<211> 305  
<212> DNA  
<213> Homo sapiens

<400> 128

caagacatgc caagtgctga gtcactaata aagaaaaaaag aagtaaagga agagtggttc	60
tgcttcttag cgctagccctc aatgacgacc taagctgcac ttttccccct agttgtgtct	120
tgcgatgcta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag ccccacccgc	180
tctggccca ccotcaccct ccaacaaaga tttatcaaata gtgggatttt cccatgagtc	240
tcaatattag agtctcaacc cccaataaaat ataggactgg agatgtctct gaggctcatt	300
ctgcc	305

<210> 129  
<211> 1181  
<212> DNA  
<213> Homo sapiens

<400> 129	
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaataaga	60
aattcttggg tgccgacggg gacagcagat tcagagccta gagccgtgcc tgcgtccgta	120
gtttccttct agtttcttt tgatttcaaa tcaagactta cagggagagg gagcgataaa	180
cacaaactct gcaagatgcc acaaggtcct ctttgacat ccccaacaaa gaaggtgagt	240
agtaatctcc ccctttctgc cctgaaccaa gtggcttcag taagttcag ggctccagga	300
gacctggca tgcaggtgcc gatgaaacag tggtaagag actcagtggc agtggcagtg	360
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtccct cactggagga	420
ttcccaaggg tcaactggga gagggcaggc agcagccaac ctccctctaag tgggctgaag	480
caggtgaaga aatggcagaa gacgcggtgg tggcaaaaag gagtcacaca ctccacctgg	540
agacgccttg aagtaactgc acgaaatttg agggtggcca ggcagttcta caacagccgc	600
ctcacagggc gagccagaac acagcaagaa ctcagatgac tggtagtatt accttcttca	660
taatcccagg ctggggggc tgcgatggag tcagaggaaa ctcagttcag aacatctttg	720
gtttttacaa tacaaattaa ctggaacgct aaattctagc ctgttaatct ggtcactgaa	780
aaaaaaaaaaa ttttttttt ttcaaaaaac atagctttag cttatttttt ttttctcttt	840
gtaaaaacttc gtgcatgact tcagctttac tcttgtcaag acatgccaag tgctgagtca	900
ctaataaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg	960
acgacctaag ctgcacttt cccccctagtt gtgtcttgcg atgctaaagg acgtcattgc	1020
acaatcttaa taaggttcc aatcagcccc acccgctctg gccccaccct caccctccaa	1080
caaagattta tcaaatgtgg gatttccca tgagtctcaa tattagagtc tcaaccccca	1140
ataaaatata tag gactggagat gtctctgagg ctcattctgc c	1181

<210> 130  
<211> 778  
<212> DNA

<213> Homo sapiens  
<400> 130  
ctaccacttg tctattctgc tatatagtca gtccttacat tgctttttc ttctgataga 60  
ccaaactctt taaggacaag tacctagtct tatctatttc tagatcccc acattactca 120  
gaaagttact ccataaatgt ttgtggaact gatttctatg tgaagacatg tgccccc 180  
ctctgttaac tagcattaga aaaacaaaatc ttttggaaag ttgttagtgc cccctaagag 240  
cagtaacagt tcctagaaac tctctaaaat gcttagaaaa agattttattt taaattacct 300  
ccccaaataaa atgattggct ggcttatctt caccatcatg atagcatctg taattaactg 360  
aaaaaaaaata attatgccat taaaagaaaa tcattccatga tcttggctca acacctgcca 420  
ctcttagtact atatctgtca catggcttat gataaagtta tctagaaata aaaaagcata 480  
caattgataa ttccaccaaattt tgtggagttt cagtttttta aatgtatatt aaaattaaat 540  
tattttaaag atcaaagaaa actttcgatca tactccgtat ttgataagga acaaatacgaa 600  
agtgtgatga ctccagggttg ccctgagggg atggccatc agttgcaaat cgtggattt 660  
cctctgacat aatgaaaaga tgagggtgca taagttctt agtaggggtga tgatataaaa 720  
agccaccgga gcactccata aggcacaaac tttcagagac agcagagcac acaagctt 778

<210> 131  
<211> 207  
<212> DNA  
<213> Homo sapiens  
<400> 131  
actccgtatt tgataaggaa caaataggaa gtgtgatgac tcagggttgc cctgagggga 60  
tgggccatca gttgcaaatc gtggaaatttc ctctgacata atgaaaagat gaggggtgcatt 120  
aagttctcta gttaggggtat gatataaaaa gccaccggag cactccataa ggcacaaact 180  
ttcagagaca gcagagcaca caagctt 207

<210> 132  
<211> 645  
<212> DNA  
<213> Homo sapiens  
<400> 132  
gggggtgatt tcactccccg gggctgtccc aggcttgtcc ctgctacccg caccggcct 60  
ttcctgagggc ctcaaggctg ccaccaagcc cccagctcct tctccccgca gggcccaaacc 120  
acaggcctca ggactcaaca cagttttcc ctccaacccc gttttctctc cctcaacggaa 180  
ctcagcttc tgaagccctt cccagttctt gttctatctt tttcctgcat cctgtctggaa 240  
agttagaagg aaacagacca cagacgttggt ccccaaaaaga aatggaggca ataggttttgg 300  
agggggcatgg ggacgggggtt cagcctccag ggtcctacac acaaattcagt cagtggccca 360

gaagaccccc ctcggaatcg gagcagggag gatggggagt gtgaggggta tccttgatgc	420
ttgtgtgtcc ccaacttcc aaatccccgc ccccgcgatg gagaagaaac cgagacagaa	480
ggtcagggc ccactaccgc ttccctccaga tgagctcatg ggtttctcca ccaaggaagt	540
tttccgctgg ttgaatgatt ctttccccgc ctcctctcg ccccagggac atataaaggc	600
agttgttggc acacccagcc agcagacgct ccctcagcaa ggaca	645

<210> 133  
<211> 457  
<212> DNA  
<213> Homo sapiens

<400> 133	
gcctgtactc agccaagggt gcagagatgt tatatatgtat tgctcttcag ggaaccgggc	60
ctccagctca caccccaagct gctcaaccac ctccctctcg aattgactgt cccttccttg	120
gaactctagg cctgaccccc ca ctcctggcc ctcccagccc acgatcccc tgacccgact	180
cccttccca gaactcagtc gcctgaaccc ccagcctgtg gttctctcct aggcctcagc	240
ctttcctgcc tttgactgaa acagcagtat cttctaagcc ctgggggctt ccccgggccc	300
cagccccgac ctagaacccg cccgctgcct gccacgctgc cactgccgt tcctctataaa	360
agggacctga gcgtccgggc ccaggggctc cgcacagcag gtgaggctat cctgccccat	420
ctccttggc tgcccggtct tcgtgtttt gactacc	457

<210> 134  
<211> 973  
<212> DNA  
<213> Homo sapiens

<400> 134	
gcagcaaatac agaatggcag tttgattcat ggtgctgaga ctggaggttc ctctgctgta	60
ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgcca	120
tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttt	180
acttagcaaa acctgctggc tgttcctggg gaagtcccat gttgcagact cgaaggtatt	240
atttattgtt gcctccaagt tacgaaattt ccctctgctc ctctttttt ggtaatagtg	300
aatttagttt cacttccaa aacatgaact gtttctgaa aaaaagaact tcattgcata	360
tagaaaaaaaaa caaaggttgc aatccattct aactataatg cttttctca acacttaaac	420
ttttacagtt actttcagag gttattttc aaaatatccc cagtaataga aatttttcat	480
cctttatagg taaacctaatttttggtaa cagcaagttg tgcctgatta tttagaacagt	540
gatttacctg gacagtcctc cttgatcaaa tactataaag taataggact ggcctgctt	600
gacagggtca aagatctgga actggcaagt tttaaataat tcaataaatg ctttgatcat	660
tcataacacc attagattaa gtaaatagcc tccaacataa ctatttgag ggaaaacatt	720

gctcatttgg gtatctgatt ttttgtgtgt taaaacaagt ttcacgtctt atagcagtcc	780
ctgaatgaaa acatcataag atggtatcta gaatgggtgtg agaaaaggat tcatagctat	840
cctagggtta ttgtaaaaaa caaagggtgc ttttgagga aatgaattta aaagccccgg	900
ggcacgcata gagacagacc ttggaaagt agcttgagac agaaggaaa caggttgatt	960
tacgatgggg ttc	973

<210> 135  
<211> 333  
<212> DNA  
<213> Homo sapiens

<400> 135	
gctaccttaa gaaggctgg taccatctgg gtttcacag tgcttcaca ttcttatcac	60
tttcaacact actgcaaata ggaaggaca gtaacattta gaagagaaca aaacagaaaac	120
tcttggaaagc agggaaaggatg catgactcaa agaggaaat tcctgtgcca taaaaggatt	180
gctggtgtat aaaatgctct atatatgccca attatcaatt tccttcatg ttcagcattt	240
ctactccttc caagaagagc agcaaagctg aagtttagcag cagcagcacc agcagcaaca	300
gcaaaaaaca aacatgagtg tgaaggcat ggc	333

<210> 136  
<211> 1048  
<212> DNA  
<213> Homo sapiens

<400> 136	
ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgctga ccaaacagca	60
ctaaatttgt gtggacatg atcccagagg tgtgtggctt caccctcaa cgagtggcgt	120
ggcatggagt tactgaatct ccaaggtcaa acaggccctc aaattcatca agaaaagggt	180
agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg	240
aggaaagcag ctgccaagaa ggactgagcc cctgccatct gcctataatg aaagcttgc	300
aaaataaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaataaa	360
gcaaaaacaaa ataaaatata taaagtaaaa attgttaaaa tgcaaaacaa tatggacata	420
aatacagaaa cacagggaaa cttctttagg cactcattta caggtaaaaa tatgaaattg	480
aataaaggtc atctgggtgc aaataatata ggccttatct attataagag tttggactga	540
aaagcaaaag tgagataaca aaaaaaagct tttcagaata ttatggta tagatatgtg	600
aaggatgaag ggtgggtgaa aggaccaaaa acagaaacac agtcttcctg aatgaatgac	660
aatcagaatt ccgctgccc aagtagtccg acaattaaat ggatttctag gaaaagctac	720
cttaagaagg ctggttacca tctgggtttt cacagtgc ttacattctt atcacttca	780

acactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg	840
gaagcagggaa aggtgcatga ctcaaagagg gaaattcctg tgccataaaa ggattgctgg	900
tgtataaaat gctcttatata tgccaattat caatttcctt tcatgttcag catttctact	960
ccttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaa	1020
aaacaaacat gagtgtgaag ggcattgc	1048

<210> 137  
<211> 504  
<212> DNA  
<213> Homo sapiens

<400> 137 agggggcccc gcagcagccc cttggcttcc cttctccctt gcctcccttc cggggctccg	60
gttcagaggc actctggcg cctgctacag cttccaaact ggcgcgttcc cttttcgcc	120
agaaaaaggac tttcagatgc ggccggcg gggccggcg ctcaggacag cgccccctcc	180
cctaacggcc gcctctccct ctccccctcg cccgccccgg ctccccccacc tctgggaagg	240
cgctgggggt gtggccaggg accggtataa agtccggggg agccggtccc gggcagccgc	300
tcagccccct gcccctcgcc gcccggcgcc tgccctggcc gggccgagga tgccggcgag	360
cgccctcgccg gccaggcttgc ctccctccgg cacgcctgtc aacttccccc gctacgtccc	420
cgttcgccccg ccggggccgccc ccgtctcccc ggcgcctccg ggtcgggtcc tccaggagcg	480
ccaggcgctg ccgcgtgtg ccct	504

<210> 138  
<211> 1042  
<212> DNA  
<213> Homo sapiens

<400> 138 gatcacaaca gctctacaaa tacacaatga ttacaaggaa tggtgccca ctggagttgt	60
tcaacgcaaa acttgcacat tgcaagtggc aatctccag gcctgcctcc ctccacgagt	120
gggtctgaat gggcctgaga ggcaaacatc caagaaggag gaagaggctc ggcggcacct	180
ccctccccgg gagttctgtc gattccatct tggggaaagca gggtgacca gggcccaaata	240
gccccttggg gagattgcgg gggcgggaga gtttgcagg ggcaagtggc aagagcctgt	300
taacgtctta gggcctccag gcctttctgt gcccctagct gtgcctgtac gctttacc	360
acctcaggag gcttggtctc cagcggttga ggctggaaagc accgggggtgc ggtggaaagg	420
gctctgtcca ggaagaccgg atccgcagag ccgggagtc gggcttaggaa gtccctttat	480
cggtggaga ctgaggccgc cttggcgaaa cgggacgaga ctcctccgag gtcggaaag	540
ggggccccgc agcagccccct tggcttccct tctcccttgc ctccccccgg gggctccgg	600

tcagaggcac tctgggcgcc tgctacaget tccaaactgc gccgcttcct tcttcggcag 660  
aaaaggactt tcagatgcgg cggcgccggc ggccggcact caggacagcg cccccctcccc 720  
taacggccgc ctctccctct cccccctcgcc cgccccggct ccccccacctc tgggaaggcg 780  
ctgggggtgt ggccaggac cggtataaaag tccggggag ccggtcccg gcagccgctc 840  
agccccctgc ccctcgccgc cccggcctg cctggccgg gccgaggatg cggcgcagcg 900  
cctcggccgc caggcttgct ccctccggca cgcctgctaa cttcccccgc tacgtccccg 960  
ttcgcggcc gggccggccc gtctcccgcc gccctccggg tcgggtccctc caggagcgcc 1020  
aggcgctgcc gccgtgtgcc ct 1042

<210> 139  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 139  
tcgtcgaaaa gacgttttgt cgtt

24

<210> 140  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 140  
tcgtcgaaaa gtcgttttt tcga

24

<210> 141  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 141  
tcgtcgaaaa gtcgtttcggt cgtt

24

<210> 142  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 142  
tcgtcgtttc gtcgttttgcgtt cgtt 24

<210> 143  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 143  
tcgtcgtttt tcggtcgttt t 21

<210> 144  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 144  
tcgtcgtttt tcgtgcgttt tt 22

<210> 145  
<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 145  
tcgtcgtttt cggcggccgc cg 22

<210> 146  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 146  
tcgtcgtttt acggcggccgt gccg 24

<210> 147  
<211> 24  
<212> DNA

<213> artificial sequence  
<220>  
  
<223> Immunostimulatory nucleic acid  
  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (21)..(21)  
<223> N = 5-methylcytosine  
  
<400> 147  
tngtngttt gtngtttgt ngtt

24

<210> 148  
<211> 27  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> Immunostimulatory nucleic acid  
  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (11)..(11)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (13)..(14)  
<223> N = 5-methylcytosine

```
<220>
<221> misc_feature
<222> (16)..(16)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (26)..(27)
<223> N = 5-methylcytosine

<400> 148
tngtngntgt nttnngntnt ntntggnn
```

27

```
<210> 149
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> Immunostimulatory nucleic acid

<220>
<221> misc_feature
<222> (2)..(2)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> N = 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
```

<223> N = 5-methylcytosine  
<400> 149  
gngtttgntn ttnttnttgn g

21

<210> 150  
<211> 20  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(4)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (12)..(12)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (15)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<400> 150  
gnnnnaagntg gnatnnngtna

20

<210> 151  
<211> 15  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 151  
tcctggcgaaat

15

<210> 152  
<211> 42  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<400> 152  
gaaactcgag ccaccatgag acagactttg ccttgtatct ac 42

<210> 153  
<211> 37  
<212> DNA  
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153  
gaaagaattc ttaatgtaca gagttttgg atccaaag 37

<210> 154  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154  
tgctgctttt gtgcttttgt gctt 24

<210> 155  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155  
tccatgacgt tcctgatgct 20

<210> 156  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156  
tccatgagct tcctgatgct 20

<210> 157  
<211> 20  
<212> DNA  
<213> artificial sequence

WO 2004/094671

PCT/US2004/012788

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (8)..(8)

<223> N = 5-methylcytosine

<400> 157

tccatgangt tcctgatgct

20

<210> 158

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158

tcgtcgaaaa cggcgccgcg cg

22

<210> 159

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159

ggggacgacg tcgtgggggg g

21

<210> 160

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160

tgctgctttt cggcgccgcg cg

22

<210> 161

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161

ggggagcagc tgctgggggg g

21